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With the rise of antiviral and anticancer drug resistance, a new approach must be taken to 
overcome this burden. The APOBEC3 (A3) family of cytosine deaminases hypermutate 
cytosines to uracils in single-stranded DNA (ssDNA). These enzymes act as double-
edged swords: on one side they protect humans against a range of retroviruses and other 
pathogens, but several A3s are exploited by viruses and cancer cells to increase their rate 
of evolution using the enzyme’s mutagenic actions. This latter mode permits escape of 
cancer cells from the adaptive immune response and leads to the development of drug 
resistance. In particular, APOBEC3B (A3B) is considered to be a main driving source of 
genomic mutations in cancer cells. Inhibition of A3B, while retaining the beneficial 
actions of the other A3 in the immune system, may be used to augment existing anticancer 
therapies. 
In this study, we showed for the first time that short ssDNAs containing cytosine analogue 
nucleosides, 2'-deoxyzebularine (dZ) or 5-fluoro-2'-deoxyzebularine (5FdZ) in place of 
the substrate 2'-deoxycytidine (dC) in the preferred 5'-TC motif, inhibit the catalytic 
activity of A3B. However, as most A3 enzymes (except A3G) prefer to deaminate ssDNA 
with a 5'-TC motif, selective A3B inhibition was uncertain. We noted that nucleotides 
adjacent to the 5'-CCC motif influence the dC deamination preference of A3A, A3B, and 
A3G’s. Replacement of the A3B’s preferred dC in the 5'-CCC motif with dZ (5'-dZCC) 
led to the first selective inhibitor of A3B, in preference to A3A and A3G. Furthermore, 
using small-angle X-ray scattering (SAXS) we obtained the first model of a full-length 
two-domain A3 in complex with a dZ-ssDNA inhibitor. Our model showed that the 
ssDNA was largely bound to the C-terminal domain (CTD) with limited contact to the N-
terminal domain in solution, due to the high affinity of the dZ for the CTD active-site. 
Our work provides a new platform for use of ssDNA-based inhibitors in targeting the 
mutagenic action of the A3B. Further developments using more potent inhibitors will 
help to achieve inhibition in cellular studies, with the ultimate goal to complement anti-
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°C Degrees Celsius  
× g Multiples of gravitational force 
ΔG Gibbs free energy 
ΔH Enthalpy 
ΔS  Entropy 
ΔTm Change in melting temperature 
λ Wavelength 
1H-NMR Proton NMR 
1/V0 Inverse of initial rate of a reaction 
1/[S] Inverse of the substrate concentration 
1/[I] Inverse of the inhibitor concentration 
298 K 298 Kelvin 
5FdZ 5-Fluoro-2'-deoxyzebularine  
Å Angstrom (10-10 m) 
A260 Absorbance at 260 nm 
A280 Absorbance at 280 nm 
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AID Activation-induced cytosine deaminase 
Amp Ampicillin 
APOBEC Apolipoprotein B mRNA-editing enzyme-catalytic polypeptide 
aq. Aqueous 
Au Absorbance units 
bp Base pair 
β-ME β-mercaptoethanol 
cDNA Complementary DNA 
CDA Cytosine deaminase 
Chi2 (or 2)  Chi-squared distribution 
CTD Carboxyl terminal domain 
C-terminal Carboxyl terminal 











DNA 2'-Deoxyribonucleic acid 
dsDNA Double-stranded DNA 
DSS 4,4-Dimethyl-4-silapentane-1-sulfonic acid 
DTT Dithiothreitol 
[E] Enzyme concentration 
E. coli Escherichia coli 
EDTA Ethylenediaminetetraacetic acid 




His6 Hexa-histidine tag 
HMW High molecular weight 
HSQC Heteronuclear single quantum coherence 
I Scattering intensity 
[I] Inhibitor concentration 
I(0) Forward scattering intensity 
Ig Immunoglobulin 
IMAC Immobilized metal affinity chromatography 
IPTG Isopropyl-β-D-thiogalactoside 
ITC Isothermal titration calorimetry 
Ka Equilibrium binding association constant 
kb Kilobase pairs (of DNA) 
kcat Catalytic rate constant 
kcat/Km Specificity constant (catalytic efficiency) 
Kd Equilibrium dissociation binding constant 
kDa KiloDalton 
Ki Inhibition constant 
Km Michaelis constant (apparent binding) 
LB Luria Bertani media 
LMW Low molecular weight 
M9 media M9 minimal media 
mAU Milli absorbance units 
min Minute 
mM Millimolar 
mRNA Messenger RNA 
MW Molecular weight 
n Sample size 
NES Nuclear export signal 
NLS Nuclear localisation signal 
NMR Nuclear magnetic resonance 




N-terminal Amino terminal 
NTD N-terminal domain 
OD Optical density at 600 nm 
Oligo Oligonucleotide 
PAGE Polyacrylamide gel electrophoresis 
PCR Polymerase chain reaction 
PDB Protein data bank 
pH Negative decadal logarithm of proton activity (concentration) 
PIPES 1,4-Piperazinediethanesulfonic acid 
P(r) Pair distribution plot 
p.s.i. Pounds per square inch 
q Scattering vector 
qmin Minimum scattering vector 
RNA Ribonucleic acid 
RNP Ribonucleoprotein 
Rg Radius of gyration 
RT Reverse transcriptase 
[S] Substrate concentration 
SAXS Small angle X-ray scattering 
sec Seconds 
SEC Size exclusion chromatography 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
ssDNA Single-stranded DNA 
SVD Singular value decomposition 
TB Transformation buffer 
TEMED Tetramethylethylenediamine 
Tm Melting temperature 
Tris Trisaminomethane 




V Porod volume 
V0 Initial rate of a reaction 













































Amino acid 3-letter abbreviation 1-letter abbreviation 
Alanine Ala A 
Arginine Arg R 
Asparagine Asn N 
Aspartic acid Asp D 
Cysteine Cys C 
Glutamic acid Glu E 
Glutamine Gln Q 
Glycine Gly G 
Histidine His H 
Isoleucine Ile I 
Leucine Leu L 
Lysine Lys K 
Methionine Met M 
Phenylalanine Phe F 
Proline Pro P 
Serine Ser S 
Threonine Thr T 
Tryptophan Trp W 
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This chapter provides a brief background on the human APOBEC family, focusing on the 
APOBEC3 subfamily structure, functions, and pathological consequences. I also 
delineate the aims of this study and rationale of investigation. 
1.1 Preface 
Over the last millennium, exponential advancements have been made in the treatment of 
various cancers. From ancient Egyptian civilisation until the 18th century, surface tumour 
masses were removed by radical surgical and burning procedures, but this led to poor 
prognosis and life expectancy due to poor hygiene practices 30, 254. By the 19th century, 
surgical practices improved and led to better survival rates 72. The discovery of X-rays in 
the late 19th century lead to the development of novel non-surgical radiation therapy to 
treat tumours 66, 173. A major breakthrough came in 1956 when the first chemotherapy 
drug was discovered capable of targeting a large array of cancers 44; then by the 1980s 
specific anticancer drugs targeting particular tumours were developed 130. These 
therapeutic treatments provided improved patient outcomes but also led to toxicity of 
normal cells. However, it became apparent that tumours could develop resistance to these 
standard therapies 44. Tumour cells can undergo changes through a number of clonal 
expansion, genetic diversification, and selective pressures leading to the evolution of 
cancer and evasion of therapy 85-86, 288.  
Over the last two decades, immunotherapeutic and monoclonal antibody drugs have been 
utilised in conjunction with standard therapies against the advancement of tumours and 
metastasis, obtaining better treatment outcomes 229, 263. Eliminating the driving factors in 
cancer evolution would be essential to prevent the development of drug resistance and in 
turn may enhance the efficacy of standard therapies. Recent studies, indicated that a major 
driving force behind somatic mutations in various cancers was by the action of the 
APOBEC3B (A3B) enzyme, found in the nucleus 12, 34, 137-138, 147, 253. The A3B belongs to 
a family of cytosine deaminases (APOBEC3), which mutate cytosines to uracils in single-
stranded DNA (ssDNA). In normal cells, the A3 enzymes defend the humans against a 
range of retroviruses and pathogenic viruses. However, in cancer cells A3B is 
upregulated, enabling the accumulation of somatic mutations and progression of tumours 
in line with resistance against anticancer drugs. Selective inhibition of A3B, which has 
not been investigated previously, would provide a method in preventing cancer evolution 
and the development of drug resistances, while maintaining the beneficial actions of the 




Substrate 2'-deoxycytidine (dC) within specific deamination sequences in ssDNA binds 
into the active site of the A3 enzyme, where it is deaminated to 2'-deoxyuridine (dU). As 
the A3 enzymes prefer to interact with ssDNA 15, 26, 48, we aimed to design and evaluate 
substrate-like ssDNAs incorporated with cytosine analogue nucleosides in place of dC in 
the preferred A3B deamination sequence motifs (5’-TC, and 5’-CCC, underlined is target 
dC). By placing these cytosine analogue nucleosides in these ssDNA sequences, the 
ssDNA would rationally deliver these nucleosides into the active site of the enzyme. 
These cytosine analogues are anticipated to mimic the transition state of deamination and 
would remain bound in the active site, thereby inhibiting the mutagenic action of A3B. 
The development of these potential inhibitors offers a promising new approach to 
complement existing anticancer therapies.  
1.2 Zinc-dependent cytosine deaminases  
APOBEC enzymes are zinc-dependent cytosine deaminases that catalyse the conversion 
of cytosines to uracils (C-to-U) through a hydrolytic reaction as shown in Figure 1.1 100, 
113, 210. A closely related ancestral enzyme cytosine deaminase (CDA) functions through 
the pyrimidine salvage pathway by deaminating free cytosines to recover uracils 296.  
Like the ancestral CDA, all the APOBEC members contain a conserved cytosine 
deaminase motif within the active site that facilitates the deamination of the target 
cytosines 63, 100, 142, 276 (discussed further 1.6.2). The evolutionary conservation of this 
motif implies that the general method of cytosine deamination by APOBEC enzymes is 
tentatively analogous to that of the reported mechanism of CDA 14, 120. However, due to 
structural differences the APOBEC family members tend to deaminate cytosines within 
polynucleotides such as single-stranded DNA (ssDNA) or RNA over single cytosine 
Figure 1.1 APOBEC catalysed cytosine deamination of polynucleotides.  














nucleosides or nucleotides, as further discussed in section 1.6.3.1 and 1.6.3.2) (Figure 
1.1). 
1.3 The human APOBEC family 
In humans, the APOBEC family consists of eleven distinct members that are grouped 
together based on sequence homology. Members of this family include the activation 
induced deaminase (AID), APOBEC1 (A1), APOBEC2 (A2), APOBEC4 (A4), and seven 
APOBEC3 (A3A-H) enzymes, which are encoded as single- or double-domain entities 
on various chromosomes 100, 113 (Figure 1.2).  
The members derive their name from the founding member, the apolipoprotein B (apoB) 
mRNA-editing catalytic enzyme 1 (A1), which is the only enzyme that has the ability to 
deaminate cytosines within the apolipoprotein B (apoB) pre-mRNA for the regulation of 
lipid metabolism 60, 95, 142, 186, 262. Other APOBEC members, such as AID and A3 
subfamily, have been characterised to act in various roles within the immune system, 
largely by deaminating ssDNA 41, 95, 122-123, 207, 210, 252. The catalytic action of these 
enzymes must be tightly regulated to prevent detrimental effects on the host. 
1.3.1 APOBEC1 (A1)  
The first APOBEC family member identified, A1, is mainly responsible for regulating 
the secretion of lipoproteins by editing the apoB pre-mRNA 186, 262. Recent in vitro studies 
have implied that A1 can also target various RNAs 19, 215, while its overexpression 
encompasses DNA deaminase activity with no known substrates, but maybe related to 
Figure 1.2 APOBEC family members chromosomal arrangement. 





the other APOBEC members 17, 95, 106, 202-203. A1 is encoded by a gene on chromosome 12, 
separated by nearly 1 megabase from the AID gene (Figure 1.2) and is expressed in the 
gastrointestinal tissues and testis 182.  
The A1 enzyme specifically deaminates cytosine 6666 (C6666) of the apolipoprotein B 
(apoB100) pre-mRNA, which changes a glutamine codon into a stop codon, leading to a 
truncated form of apoB (apoB48). The generated apoB48 form is the main component of 
the lipoprotein chylomicron, which is necessary for lipid transport 2, 204, 262. This enzyme 
was described to have an intrinsic dinucleotide binding preference of 5'-TC 113, but it also 
binds to RNA with low affinity 2, 184-185. Therefore, RNA binding proteins, APOBEC1 
complementation factor (A1CF) and an RNA‐binding motif protein 47 (RBM47), binds 
upstream of the target C6666 to recruit A1 to the target mRNA achieving recruitment of 
A1 and providing specific deamination 73, 81  
It was noted that the overexpression of A1 in vitro was linked to oncogenesis 285. 
Therefore, to prevent this potential A1’s catalytic activity appears to be tightly controlled 
through a number of mechanisms. First, the presence of the RNA binding proteins, 
described above, regulate the binding of A1 to the target substrate (Figure 1.3). Second, 
the A1 enzyme functions in the nucleus, but it is shuttled out to the cytoplasm by a 
carboxy-terminal nuclear export signal (NES) when not required and back into the 
nucleus by an amino-terminal nuclear localisation signal (NLS) when required 144, 287. 
Finally, the expression of A1 is modulated to specific tissues 249.   
Figure 1.3 A1 deamination of apoB100 pre-mRNA aided by the RNA binding proteins A1CF 
and RBM47.  





1.3.2 Activation-induced cytosine deaminase (AID) 
AID is also encoded by a gene on chromosome 12 and is capable of nucleotide editing 
(Figure 1.2) 113. Initially, it was thought that AID was an RNA-editing enzyme as it has 
the closest sequence homology to A1. However, unlike A1 it was discovered to largely 
act as a DNA mutator 201. This enzyme is specifically expressed in germinal centres of 
activated B cells and mainly functions in the adaptive immune system through antibody 
diversification against a range of pathogens 28, 176-177. Antibody maturation is 
accomplished when AID deaminates the complementary DNA (cDNA) of the 
immunoglobulin (Ig) locus variable regions leading to the accumulation of mutations 
(changes C:G pairs into U:G mispairs). As shown in Figure 1.4, this initiates the base-
repair mechanism where uracil DNA glycosylase (UDG) cleaves uracil leaving abasic 
sites, triggering somatic hypermutation, class-switch recombination, or gene conversion, 
which modifies the antibodies’ affinity and isotypes 4, 95, 104, 175-176, 188.  
Regulation is crucial to avoid genomic mutations arising due to the enzyme having DNA 
editing activity 192. AID is acutely expressed in the activated B cell tissues, but, similar to 
A1, its deaminase activity is controlled through multiple mechanisms. First, AID is 
preferentially cytoplasmic and localises to the nucleus only when required 28, 109. Second, 
the nuclear lifespan of AID is dictated by ubiquitination-dependent degradation 3. Finally, 
AID is thought to selectively target its preferred dinucleotide in ssDNA when a cytosine 
is preceded by a purine (A/G) 41, 123 by binding to cis-acting element in the Ig loci or other 
cofactors 199, 260. Lately, it has also been reported that AID is involved in the innate 
Figure 1.4 AID deaminase and antibody diversification.  





immune system. AID binds directly to the mRNA of some retroelements, to prevent these 
elements from inserting their DNA into the host genome, but the mechanism remains 
unclear 160, 169. 
1.3.3 APOBEC2 (A2)  
A less known APOBEC enzyme, A2 is encoded by a gene on chromosome 6 100 (Figure 
1.2). A2 was observed to be expressed in cardiac and skeletal muscles 153, noted to be 
essential for the maintenance and development of muscles 222, 271. Earlier studies implied 
that this enzyme was unable to target single-stranded polynucleotides 95, 153. Through its 
close sequence homology and similar crystal structure to APOBEC members it can be 
assumed that A2 is capable of binding polynucleotides 134, 205. Currently, an experimental 
study has depicted that A2 targets specific tumour suppressor genes by editing RNA 193. 
However, the mechanism and significance of A2 remain to be unearthed.  
1.3.4 APOBEC4 (A4) 
A4 was found to have the lowest sequence homology to the APOBEC family members 
62, 214. It is encoded by a gene on chromosome 1 and expressed in the human testis, 
suggesting that it may be involved in spermatogenesis 163. Lately, in vitro experiments 
indicated that A4 may enhance the expression of HIV-1 by mediating the activity of the 
promotor 163. Several studies found that A4 lacked mutagenic activity 171, 210 and the 
APOBEC signature motif portrayed in section 1.6.2, suggesting that it may function 
through an alternative mechanism that is yet to be discovered. 
1.3.5 APOBEC3 subfamily  
Unlike other species, humans contain seven A3 enzymes (A3A-A3H) that share similar 
sequence homologies and are encoded by genes clustered in tandem on chromosome 22 
100, 113, 143. These enzymes play significant roles in the innate immune system, and it is 
believed that in humans they diverged and expanded from a single enzyme to permit the 
protection against a range of exogenous viruses and endogenous retroelements, as shown 




The A3 enzymes are regulated through a number of mechanisms (refer to section 1.5) and 
accomplish their functions largely by modifying viral ssDNA 49, 95, 113, 230 (discussed in 
section 1.6.3.2). A3A and A3G have recently been identified to be capable of editing 
RNA 234-236, but with less efficiency than ssDNA targets (unpublished raw data, Dr. Stefan 
Harjes). However, misregulation of A3 activity is linked to pathological consequences, 
such as viral and cancer evolution further discussed in section 1.7 34-35, 138, 140, 255 (Figure 
1.5).  
1.4 The A3 immune system defence mechanisms  
1.4.1 Restriction of retroviruses 
Typically, upon infection of a host cell with the retrovirus, the hosts’ reverse transcriptase 
(RT) generates a cDNA intermediate from the retroviral RNA in the cytoplasm. The 
cDNA is then reverse transcribed using the same enzyme eventually forming a double-
stranded DNA (dsDNA) which then migrates into the nucleus as displayed in Figure 1.6. 
In the nucleus the dsDNA is integrated into the host cell’s DNA where it can replicate 
using the host cell’s machinery and the cycle of infection can repeat. Several A3 enzymes 
have been identified to restrict numerous retroviruses, such as simian immunodeficiency 
viruses (SIVs), murine leukaemia virus (MLV), human T-cell lymphotropic virus 
(HTLV), by deaminating cytosines within the nascent retroviral cDNA intermediate. The 
pathogenic lentivirus human immunodeficiency virus type-1 (HIV-1) has been 
Figure 1.5 Roles of A3 deamination activity. 





extensively studied and was one of the first discovered retroviruses to be inhibited by 
A3G 98, 148, 237. In addition to A3G, three other APOBECS, A3D, A3F, and A3H, were 
also identified to be capable of restricting the replication of HIV-1 211, 274. Several assays 
noted that A3G and A3F were co-expressed and were the most potent inhibitors of HIV-
1, suggesting their mutual role, while A3D and A3H inhibited HIV-1 modestly 17, 141, 278.  
In infected T lymphocytes lacking the counter restrictive virion infectivity factor (Vif) 
(discussed further in next paragraphs), the A3G/A3D/A3F/A3H present in the cytoplasm 
interact with the virus group-specific antigen (Gag) ribonucleoprotein complex allowing 
for its encapsulation along with the HIV genomic RNA into a budding virion 20, 88, 110, 165, 
258. Once the virion attaches to its target cell, its components are released and the viral 
genomic RNA undergoes reverse transcription producing the nascent viral cDNA, which 
is quickly deaminated by the A3 enzyme resulting in C-to-U hypermutations 98, 290-291. 
The mutated cDNA is then either targeted for degradation or is used as a template for the 
synthesis of the second DNA strand, which compromises the virus’ viability to 
subsequently replicate due to potentially lethal non-functional mutations (second strand 
contains G-to-A hypermutations). as shown in Figure 1.6 98, 148, 237. Alternatively, HIV-1 
replication can also be prevented through a deaminase-independent method, where the 
A3s bind to the viral RNA and block the path of reverse transcriptase (RT) 16, 18, 110-111, 
189.  
Figure 1.6 A3 inhibition of HIV-1 replication mechanism. 




However, retroviruses have developed several mechanisms to overcome this immune 
response or indeed to utilise the A3 action for viral diversification, which is further 
elaborated in section 1.7.1. One well-known mechanism to override the restriction of the 
HIV-1 retrovirus by the A3 enzymes is by the presence of a small protein termed the 
virion infectivity factor (Vif). Vif mediates ubiquitination by the E3 ligase and subsequent 
proteasomal degradation of the A3 enzymes, allowing the HIV-1 virus to infect and 
propagate in susceptible cells 61, 100, 162, 237 (Figure 1.6). Furthermore, Vif was noted to 
also be capable of stopping the action of A3s by preventing its encapsulation into the HIV 
virion and blocking its catalytic activity by means that are not well understood 42, 87, 238.     
1.4.2 Targeting endogenous retrotransposons  
Endogenous retrotransposons are mobile DNA elements that make up a large fraction of 
the human genome 139. As displayed in Figure 1.7, these retroelements are first transcribed 
in the nucleus forming an RNA intermediate that is transferred into the cytoplasm. In the 
cytoplasm, proteins, such as ORF1 and ORF2, attach to the retroelement RNA forming a 
ribonucleoprotein (RNP) complex. This complex is translocated into the nucleus where it 
is reverse transcribed forming cDNA, which is inserted into a new site in the genome 198.  
Many studies have indicated that these transposable elements play a key role in the 
evolution of the genome, genetic diversity, and regulation of gene expression. However, 
the ability of retrotransposons to reorganise genetic elements also comes at a cost, causing 
genetic instabilities that lead to detrimental effects such as various genetic disorders and 
Figure 1.7 Replication of the retrotransposon LINE-1 and its inhibition by A3 enzymes.  






cancers 52, 64, 126, 139, 170. Overtime, mechanisms have arisen to maintain the integrity of the 
genome by shaping the action of these elements. The expansion of the human A3 family 
has not only been prompted to target exogenous viruses, but it is now thought to have 
arisen to restrict or diversify the retroelements to benefit the host 221, 223, 292. Several A3 
members, including A3A, A3B, A3C, A3F, and A3G, have been implicated in the 
inhibition of endogenous retrotransposons, such as long terminal repeats (LTR), and non-
LTR (such as long interspersed nuclear elements, LINE, and short interspersed nuclear 
elements, SINE) 54, 69-71, 141, 210. A3 enzymes deaminate the reverse transcribed cDNA 
causing significant mutations in the retrotransposon. This can either inactivate further 
cycles of retrotransposition or decrease the number of transposed cDNA copies 71. 
Inhibition of the retrotransposons can also be achieved through the mutation of the minus 
DNA strand by A3 or through deamination-independent mechanisms by directly binding 
to the intermediate RNA transcript and redirecting the complex to p-bodies for 
degradation (see Figure 1.7). However, the overall system remains unclear 54, 124. 
1.4.3 Inhibition of DNA-based viruses 
Aside from retroviruses, the A3 family has been implicated to restrict a large subset of 
DNA-based viruses. The cancer-associated viruses, hepatitis B virus (HBV), which 
replicates in the liver and human papillomavirus (HPV), which replicates in keratinocytes 
of the skin, are key targets of several A3 members. Unlike retroviruses (refer to 1.4.1), 
the viral DNA parasite is first transcribed into an intermediate pre-genomic RNA in the 
nucleus by the hosts machinery. In the cytoplasm, the pre-genomic RNA is reverse 
transcribed to an intermediate cDNA (minus strand) then to partially dsDNA, as shown 
in Figure 1.8.  
In vitro assays noted that both DNA strands of HBV and HPV are deaminated by A3 
enzymes during transcription or replication of dsDNA resulting in either C-to-T 
hypermutations (positive strand) or G-to-A hypermutations (negative strand) which 
together compromise the virus replication cycle 10, 121, 257, 266-267 (Figure 1.8). Furthermore, 




mechanisms by targeting the pre-genomic RNA, causing interference with reverse 
transcription 216, 265. 
Several A3 members, A3B, A3C, A3G, and A3H, were found to cause low levels of HBV 
hypermutations in response to increased levels of cytokines released in the inflammatory 
response, leading to restriction of acute and chronic HBV infection 267. Moreover, A3A, 
A3C, and A3H were shown in vitro to be involved in the hypermutations of the HPV 
genome 266, 275 to restrict HPV’s wide range of diseases from warts to invasive cancers 29, 
38. However, studies noted a strong link between these DNA-based viruses and cancer 
progression, whereby the catalytic action of the A3s in cancer cells is hijacked 101, 191, 269, 
275, 284 (described further in section 1.7.2). 
1.5 Regulation of the A3 deamination activity 
The capacity to control the A3s’ functions relies on a number of mechanisms, including 
gene expression, post-transitional modifications, cofactors, tissue-specific expression, 
and subcellular distribution (Table 1.1) 125, 212. Importantly, during mitosis all the A3 
enzymes are excluded from the genomic DNA 137-138, but following mitosis A3B co-
localises with the DNA in the nucleus, A3D, A3F, and A3G appear in the cytoplasm, 
while A3A, A3C, and A3H are widely distributed in both the cytoplasm and nucleus 12, 
21, 137-138, 253 (Table 1.1). Subcellular regulation maybe a way to sequester the action of 
these enzymes away from the genomic DNA. However, A3 enzymes that are in contact 
Figure 1.8 HBV DNA-based virus replication mechanism and inhibition by A3 enzymes. 






with the nucleus may have additional mechanisms to prevent a genotoxic effect on the 
cell.  
Table 1.1 APOBEC family localisation and function. 










AID 12 1 Activated B 
cells, testis 
Cytoplasmic





A1 12 1 Small intestine Cytoplasmic





















A3B 22 2 Peripheral-




Nuclear DNA  Retroviruses, 
DNA-viruses, 
retrotransposons 







A3DE 22 2 Thyroid, 
spleen, blood 
Cytoplasmic DNA Retroviruses  
A3F 22 2 Multiple 
tissues 
Cytoplasmic DNA  Retroviruses, 
DNA-viruses, 
retrotransposons 








A3H 22 2 Blood, 
thyroid, 
placenta 
Unknown DNA DNA-viruses 





Multiple studies have also implied the potential of oligomerisation for some A3 proteins 
(A3B, A3D, A3F-H), which may occur through protein self-association or an RNA-
dependent manner 48, 65, 80, 103, 145, 150, 167, 205-206, 220, 250, 276, 293, although the necessity for 
multimerisation remains unresolved. Several studies have suggested that the action of 
multimerisation through surface interactions may regulate the A3s’ catalytic activity by 
forming inactive conformations 22-23, 27, 79, 118, 233. Therefore, to better understand the role 
of A3 oligomerisation solution-state structures would be useful.   
1.6 Structural and biochemical insight of the A3 family  
1.6.1 Organisation of the A3 domains   
The A3 members are expressed as either a single or double domain. A3A, A3C, and A3H 
are characterised as single-domain enzymes, whereas A3B, A3G, A3D, and A3F are 
made up of two tandem domains believed to be linked by a short flexible linker 60, 142-143 
(see linker in black connecting domains in Figure 1.9). In double domain A3 enzymes, 
the carboxy-terminal domain (referred to as the C-terminal domain or CTD) demonstrates 
catalytic activity, whereas the amino-terminal domain (referred to as the N-terminal 
domain or NTD) is said to be pseudo-catalytic but is believed to be important in binding 
substrates, which may regulate catalytic activity, consistent with observations that 
double-domain (referred to as full-length, fl) A3s are more active than the CTD alone 24, 
78, 88, 91, 187, 189, 247.   
Figure 1.9 Organisation of the domains of the A3 family.  






In contrast to the zinc-dependent deaminase domain (ZDD) of the ancestral CDA and 
other cytosine deaminases, the domains of the A3 members can be further classified into 
subtypes (Z1, Z2, and Z3) based on specific amino acids found in the ZDD, highlighted 
(green, red, and blue) in Figure 1.9. These subclasses may explain the variation in 
substrate preference and function. The single-domain A3 enzymes are defined by a 
different Z-domain subtype (A3A-Z1, A3C-Z2, A3H-Z3), whereas the double-domain 
A3B and A3G are composed of Z2-Z1 domains, and the A3D and A3F consist of Z2-Z2 
domains. 
1.6.2 Structure of the A3 domain 
Before 2015, there were no structures of the A3 enzymes so they were modelled using 
closely related zinc-dependent deaminases 14, 120, 158, 205. Several single A3 domain 
structures have in the last few years been reported including A3A 36, 239, A3BCTD 
37, 240, 
A3BNTD 
282, A3C 118, A3FCTD 
22, 232, A3GCTD 
53, 79, 92, 103, 233, A3GNTD 
128, and A3H 108, 231. 
These all showed an overall similar domain structural fold despite differences in amino 
acid sequences. However, at the time this thesis research was conducted, structures of 
two-domain A3s were yet unknown.  
Each domain shares a conserved globular fold, consisting of a hydrophobic core formed 
by five β-strands flanked by six α-helices that are connected through flexible loops 
(Figure 1.10A) 22, 53, 120. The majority of differences between the A3 domain structures 
are predominantly found in loops 1, 3, and 7, which are near the active-site, as displayed 
in Figure 1.10B. This may reflect the observed differences in the intrinsic sequence 
preference (refer to 1.6.3.3 and 1.6.4), regulation of catalytic activity (refer to 1.5 and 
1.6.4), physiological roles (refer to 1.4), and potential to oligomerise (refer to 1.5) 41, 122-
123, 273.  
The active-site is highly conserved between the A3s and related zinc-dependent 
deaminases, implying that the mechanism of cytosine deamination is conserved. The core 
of the active-site comprises a single zinc (Zn2+) ion and a hallmark ZDD-motif: His-x-
Glu-x23–28-Pro-Cys-x2-Cys (where x is any amino acid residue) localised at the N-terminal 
ends of the α2 and α3 helices. Important residues within the ZDD-motif, histidine (His) 
and two cysteines (Cys), coordinate Zn2+ ion into the active-site and the catalytic glutamic 





1.6.3 Biochemical insights of the A3 family  
1.6.3.1 Cytosine deaminase mechanism 
The cytosine deamination mechanism is based on early structural studies of bacterial and 
yeast CDAs 14, 120. Initially, an active-site water molecule is deprotonated by Glu, 
resulting in a stabilised Zn2+-hydroxide ion (OH-). Deamination of the cytosine 
pyrimidine ring begins through the protonation of nitrogen 3 (N3) by Glu (coordinated 
by Zn2+-OH-), which permits the nucleophilic attack of carbon 4 (C4) of the cytosine by 
the hydroxide ion. This yields an unstable tetrahedral intermediate, which is followed by 
the successive protonation of the amino group (NH2) and the release of ammonia (NH3) 
forming uracil as the product 100, 188 (Figure 1.11).  
Figure 1.10 Crystal structures of the catalytic C-terminal domain of A3B. 
(A) Crystal structure of A3BCTD PDB 5CQI (A3BCTD-QM-ΔL3), (B) Comparisons between the 
A3BCTD (magenta, PDB; 5CQI), A3A (green, PDB; 4XXO), A3GCTD (cyan, PDB; 3IQS) structures. 
Cited from 240. 
(A) 















As the ZDD-motif is conserved across the zinc-dependent cytosine deaminases, it is 
presumed that the mechanism described in Figure 1.11 is preserved for the A3 enzymes. 
This is consistent with this notion, upon mutagenesis of the residues (Glu, His or Cys) 
directly involved in the hydrolytic deamination mechanism the catalytic activity of the 
A3 enzymes is completely abolished 239. In contrast to CDA, the A3 members are unable 
to catalyse free cytosine nucleosides or nucleotides, preferring cytosines within oligo- or 
polynucleotides (Figure 1.1) 15, 26, 48. Early studies noted that the APOBEC family 
members (A4 excepted) contain two phenylalanine residues and an insert of four amino 
acids within the ZDD-motif (highlighted in grey in Figure 1.9) that are not present in the 
ancestral CDA. These residues were believed to permit the deamination of polynucleotide 
substrates and/or prevent deamination of single cytidines 2, 113, 184-185. Furthermore, strands 
β3-5 in polynucleotide zinc-dependent deaminases are parallel to each other, unlike the 
antiparallel arrangement in bacterial and yeast CDAs. This arrangement probably leads 
to substrate specificity and may distinguish polynucleotide from non-polynucleotide 
deaminases 53, 60, 158, 205. Finally, the A3 enzymes were found to require substrates with a 
minimum of three nucleotides 94, 180 to facilitate substrate binding and selectivity 239-240 
(discussed further in section 1.6.4).  
1.6.3.2 Nucleic acid preference of the A3 enzymes 
Originally, it was assumed that the A3 family were RNA-deaminases like the A1 enzyme 
(refer to 1.3.1), based on similarities between the amino acid sequences 113. However, the 
A3s were eventually found to be closer in sequence homology to AID, which is known 
to target DNA 95, 201. Numerous experimental investigations found that the A3 family and 
AID strongly prefer the deamination of ssDNA over RNA and other modified 
oligonucleotides (such as methylated cytosines), but they are still capable of binding to 
either of the aforementioned substrates 40-41, 95, 98, 148, 155, 179-181, 220. The main structural 
difference between DNA and RNA is the presence of a hydroxyl group on the C2'-
Figure 1.11 Model of the cytosine deaminase mechanism. 





position of RNA, see Figure 1.12B. An earlier study reported that upon substitution of 
the target 2'-deoxycytidine with a 2'-ribose-nucleotide the catalytic activity of AID is 
severely compromised 180. The slight change in the backbone sugar ring pucker, where 
DNA has a C2'-endo pucker (Figure 1.12A) and RNA has a C3'-endo pucker (Figure 
1.12B), is thought to account for the observed selectivity. The conformation of RNA 
causes steric constraints in the enzyme’s binding site, which cause alteration of the 
nucleotide’s conformation. In contrast, the flexible rotational conformation found in 2'-
deoxy-nucleotides better facilitates direct interaction with the enzyme promoting 
deamination of DNA over RNA (Figure 1.12A).  
This model was also supported by the recent molecular dynamics simulation of the A3B 
structure, suggesting that RNA substrates must undergo significant rearrangements with 
intermediate binding conformations to fit within the active-site 272. Nonetheless, the 
precise mechanism of selectivity is not well understood. Furthermore, studies have shown 
that the A3 members and related family favour the deamination of 2'-deoxycytidines in 
ssDNA, with no evident activity on dsDNA 26, 51, 111, 252.  
1.6.3.3 The A3 enzymes’ nucleic acid deamination sequence  
Studies have indicated that the A3s require ssDNA substrates with a minimum of three 
nucleotides, but to effectively bind and execute cytosine deamination five nucleotide 
bases are needed (note, length of oligonucleotide denoted by number followed by mer). 
As displayed in Figure 1.13, the target 2'-deoxycytidine (dC) is in position 0, whereas 
nucleotides 5'- of the target dC are given a negative number and nucleotides 3'- of dC are 
given a positive number. Three nucleotides must precede the target dC at the 5'-end 
(referred to as positions -1, -2 and -3), and a single nucleotide follows the target cytosine 
at the 3'-end (referred to as position +1) 94, 172, 180 (Figure 1.13). 
Figure 1.12 Major conformation of the 2'-sugar nucleotide in DNA and RNA. 








The A3 enzymes’ intrinsic deamination sequence not only dictates sequence recognition, 
but also the physiological role and signature markers of a variety of cancers (discussed in 
section 1.7.2 ). Based on mutation patterns and deep sequencing studies, the A3 members 
have been shown to deaminate the target dC based on the presence of a specific nucleotide 
base in the -1 position (refer to Figure 1.13) 11, 98, 123, 252, 255. The majority of the A3 
enzymes (A3A-F and A3H) prefer to deaminate cytosines preceded by a thymine (5'-TC, 
where the underlined C is the target), whereas A3G prefers to target cytosines preceded 
by another cytosine (5'-CC) as shown in Table 1.2. These enzymes have also been shown 
to be capable of targeting cytosines with other neighbouring nucleobases, but with lower 
efficiency 36-37, 239, 252. 
Table 1.2 A3 family intrinsic dinucleotide deamination sequence preference (cited from 8) 








Figure 1.13 A3BCTD preferred ssDNA deamination sequence. 




1.6.4 Structure of the inactive A3 domain in complex with ssDNA  
Biochemical studies noted that ssDNA binds to the A3 enzymes by forming interactions 
with residues near the active-site 41, 53, 122-123, 207, 240, 242, 252, 273. In 2016, the DNA-bound 
catalytically inactive A3A and the inactive A3BCTD-A3A loop 1 chimera (termed 
A3BCTD*) crystal structures were reported 
239. The conserved active-site Glu was mutated 
to Ala to destroy enzymatic activity. These structures demonstrated that their overall 
binding and mechanism selective to cytosine were essentially the same, so it is presumed 
that other A3 enzymes bind DNA in a similar manner. The DNA forms a kink at the target 
dC and preceding nucleobase (thymidine in the -1 position), adopting a U-shaped 
conformation 93, 239 (Figure 1.14A), which resembles the substrate-binding mode of a 
related adenosine deaminase (TadA) 158. The 5'-TC nucleobases are flipped-over into the 
active-site, with respect to the phosphodiester backbone, whereas the nucleotides flanking 
this dinucleotide sequence are positioned away from the active-site. This base-flipping 
mechanism facilitates direct interactions with residues both surrounding and within the 
active-site, which together help anchor the target dC and access the catalytic glutamic 
acid in the active-site core 93, 239, as shown in Figure 1.14A and B.  
Looking at the A3BCTD*-ssDNA structure, the substrate binds in the active-site while 
interacting with loops 1, 3, and 7 (Figure 1.14B). Taking a closer look, the 5'-TC motif is 
initially stabilised through van der Waals interactions with W281 (loop 5). The -1 T fits 
into a hydrophobic pocket near the active-site formed between W281 (loop 5), Y313 and 
Y315 (loop 7) via van der Waals interactions. In addition, the -1 T is hydrogen bonded to 
D314 and Y315 (loop 7) within this pocket to further position it in place (see Figure 1.14C 
and D). The target dC is inserted deep into the active-site core, which contains the 
catalytic glutamic acid (E255 in helix α2) and the coordinated Zn2+ ion (zinc-coordinating 
residues, H253 (α2), C284 (loop 5), and C289 (loop 5)). The target dC undergoes 
extensive hydrogen-bond interactions with several residues (Y313 (loop 7), A254 (α2), 
S282 (loop 5), T214 (loop 1)) and is inserted between T214 and H253 to position it in the 
correct orientation for deamination (Figure 1.14C and D). These interactions are 
essentially the same, involving equivalent residues of the A3A (cyan, Figure 1.14B), as 
A3BCTD and A3A share 90 % sequence identity. However, the A3A-ssDNA structure 
additionally shows that His29 from loop 1 forms essential interactions with the nucleic 




conformation of ssDNA 239. This is believed to be similar in the wild-type A3BCTD, where 
Arg211 seems to be equivalent to His29 of the A3A 239, 241, 272.   
Structure-based mutagenesis studies on A3A identified the specific residues required to 
dictate the A3 enzyme’s dinucleotide sequence selectivity and mediate its catalytic 
activity 239. As expected, mutating residues involved in cytosine deamination such as the 
catalytic glutamic acid and the zinc-coordinating histidine and two cysteines to alanine 
completely abolished the deamination of the target dC. A3A residues that interact with 
the target cytosine A71, S99, and Y130 (conserved in A3BCTD as A254, S282, and Y313, 
see Figure 1.14C and D) were also found to be essential in facilitating the deamination of 
the target dC. However, the other A3A cytosine contact with T31 (T214 for A3BCTD, 
Figure 1.14C and D) maybe dispensable, as the mutation T31A does not compromise 
cytosine deamination. However, T31 is believed to be phosphorylated in order to regulate 
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Figure 1.14 Crystal structure of inactive A3BCTD* in complex with ssDNA. 
Structure of the inactive A3BCTD* (A3BCTD-QM-ΔL3-A3ALoop1swap-E255A) in complex with a 
5mer ssDNA sequence (5'-TTCAT) (PDB 5TD5 239). (A) A3BCTD*-ssDNA structure showing ssDNA 
bound in  a U-shaped conformation with the target dC and -1T flipped into the active-site. (B) 
Comparison of the active-site of the inactive A3BCTD*-ssDNA (magenta) and inactive A3A-ssDNA 
(PDB, 5SWW 239) shows comparable structures. (C) Interactions between the A3BCTD* and the 5'- 
nucleotide of the oligonucleotide. (D) Interactions between the A3BCTD* and the -1T and the target dC 






the enzyme’s catalytic activity 67, 243, consistent with the observed lack of activity upon 
the introduction of a negatively charged amino acid, T31D. On the other hand, mutating 
the A3A residues W98 (W281 in A3BCTD), Y130 (Y313 in A3BCTD), and Y132 (Y315 in 
A3BCTD) (see Figure 1.14C and D) with alanine renders the enzyme catalytically inactive, 
but replacement with other aromatic amino acids restores function. Therefore, the 
aromatic nature of these residues is vital for the formation of the hydrophobic pocket to 
accommodate and stabilise the -1 nucleobase of the ssDNA, whereas interactions with 
residue D131 in loop 7 of the A3A (D314 in A3BCTD, Figure 1.14C and D) influence the 
selectivity of the -1 nucleobase towards thymine 239. This is consistent with studies where 
substituting loop 7 between the A3 enzymes causes a complete swap in the enzymes’ 
dinucleotide deamination preference 41, 122-123, 166, 207, 239, 256, 273.  
Although neighbouring nucleobases either side of the preferred dinucleotide local 
sequence (5'-TC) show weak enzyme preferences, as implied by deep deamination 
experiments, it is believed that they form surface interactions to sustain the U-shaped 
conformation 239-240. In the substrate-bound A3A and A3BCTD* structures, nucleobases in 
positions +1 and -2 form non-specific interactions with residues within loops 1 and 3 of 
the enzyme (Figure 1.14C), whereas nucleotides further away stack on top of one another 
through hydrophobic interactions (+2, +3 nucleobases stack on the +1 nucleobase, and -
3 nucleobase stacks on the -2 nucleobase) to stabilise U-shaped conformation 239 (Figure 
1.14A and B). This is consistent with the molecular dynamics simulations, where the 
flanking nucleotides at either end are not entirely fixed in place due to their limited 
interaction with the protein 93. Together, the additive effect of these non-specific 
interactions aids with overall stability of the conformation of the substrate, which in turn 
supports binding of ssDNA to the A3 enzymes.  
Comparison between the substrate bound and unbound A3A and A3BCTD* structures, 
illustrates that substrate binding to the A3s’ active-site requires rearrangements of loops 
surrounding the active site (loops 1, 3, and 7) (Figure 1.15). In particular, the unbound 
A3BCTD was shown to have a tightly closed active-site conformation stabilised largely by 
stacking interactions between loop 1 (Arg211) and loop 7 (Tyr315) 240 (Figure 1.15B i). 
To achieve a more open conformation, significant reorientation of these loops is believed 
to occur to facilitate binding of the ssDNA substrate, as displayed in Figure 1.15B ii 239. 
It is thought that this closed conformation maybe a mechanism to regulate the catalytic 




behind this remains elusive due to the lack of information on wild-type full-length A3B 
structure 241, 272. In comparison, the A3A structure in both the DNA-bound and -unbound 
forms has a more open conformation, as displayed in Figure 1.15A 239, consistent with 
having the highest catalytic activity and binding affinity towards DNA in comparison to 
the other A3 enzymes 36-37, 94, 135.  
Switching loop 1 of A3BCTD to the corresponding loop 1 of A3A led to the enhancement 
of deaminase activity in vitro 37, 135, 240, consistent with a more open structural 
conformation 239 demonstrating the importance of loop 1 in binding ssDNA 294. To 
accommodate binding of the nucleic acid substrate into the active site, interactions 
between residues in the loops surrounding the active site and the ssDNA cause a 
conformational change that further opens the active-site. This enables the dinucleotide 
sequence motif to establishment specific contacts in the active site, which then allows the 
Figure 1.15 Comparisons between the ligand-free and ssDNA-bound active-sites of A3A and 
A3B*. 
 (A) Surface structure of the (i) ligand-free A3A structure (PDB, 4XXO 23) and (ii) DNA-bound A3A 
structure (PDB, 5SWW 239). (B) Surface structure of the (i) ligand-free A3BCTD structure (PDB, 
5CQH) and the (ii) DNA-bound A3BCTD* form (PDB, 5TD5 239). Reprinted with permission from 
Springer Nature 239, copyright (2017). 
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target dC to be positioned deep into the catalytic site where it can be deaminated by the 
conserved catalytic glutamic acid and the H2O-coordinated Zn
2+ ion 239.  
1.7 A3s pathological consequences  
Although the A3s functions in the innate immunity by protecting against retroviruses and 
pathogens, misregulation of their mutagenic action can have adverse pathological 
consequences. 
1.7.1 Viral genome evolution 
Despite the mechanistic action of Vif to inhibit the A3s’ activity (described earlier in 
section 1.4.1), several studies found that G-to-A mutations of the HIV-1 genome persisted 
even in the presence of Vif 88-90, 174 (mechanism displayed in Figure 1.6). One study 
suggested that this may occur as A3F was more resistant to inhibition by Vif in 
comparison to A3G; however, this was only shown in vitro 154. An alternate in vivo study 
noted that there was a high prevalence of defective Vif variants that led to incomplete or 
partially inhibited A3 enzymes, which would allow the A3 enzymes to restrict HIV-1 246. 
Apart from compromising the virus via lethal mutations, strong evidence has suggested 
that low levels of A3 enzymes that are not inhibited induce non-lethal mutations, which 
enables the virus to maintain infectivity and to contribute to its rapid evolution 96, 115-116, 
219. The HIV-1 retrovirus exploits the A3s’ action by increasing mutation rates, which 
enable it to evade immunity clearance systems and develop antiretroviral drug resistance.  
1.7.2 A3B and cancer evolution  
In addition to targeting viral DNA and retrotransposons, several A3s have been 
implicated in mutations of genomic DNA, especially cancer cells 255. Specific regions of 
the genome, mainly late replicating and heterochromatic regions, are more prone to 
mutations by A3 members as a result of ssDNA intermediates during stalled replication 
forks 34, 156. DNA damage caused by cytosine deamination is usually restored in an error-
free manner using the base excision repair enzyme, human UDG 251. The uracil lesions 
obtained after misincorporation are excised using UDG resulting in abasic sites which 
can be cleaved by endonuclease to trigger repair mechanisms or the DNA is degraded 133, 
252. However, genomic uracil lesions and abasic site repair intermediates that fail to repair 
can become genotoxic and manifest as somatic mutations. These lesions and 
intermediates can promote a variety of mutations including C-to-T transition mutations, 




breaks (SSB) or double-stranded DNA breaks (DSB) 46, 149, 261, displayed in Figure 1.16. 
The accumulation of these genomic DNA mutations, therefore, enables accelerated 
cancer evolution. 
Multiple studies noted that the overexpression and activity of A3A, A3B, A3D, and A3H 
were associated with cancer mutagenesis 1, 34, 95, 138, 140, 213, 256. The C-to-T mutation 
signature in cancer was observed to occur within the hallmark 5'-TC(A/T) and 5'-TCG 
motifs, which are the preferred deamination motifs of both A3A and A3B. The given 
involvement of A3A and A3B in initiating cancer is yet not defined. However, A3B is 
thought to be the main contributor of genomic mutations as it is the only A3 member to 
Figure 1.16 C-to-T mutations driven by A3B during repair of genomic uracils. 
(A) Following deamination of genomic dC to dU by A3B, this event can be repaired by excising the 
uracils with UDG and triggering the base excision repair (BER) system (this includes APEX a BER 
protein, DNA polymerase termed Pol, and DNA ligase termed Lig). Misrepaired lesions or 
intermediates lead to a number of mutations. (B) Transition C-to-T mutations following DNA 
synthesis with a uracil in the template or an abasic site (DNA polymerases inserts dA opposite an 
abasic lesion). (C) Mismatch repair system (MMR) with a transition of transversion of C-to-T or A-to-
T lesions. (D) Transversion C-to-G mutations thought to occur when DNA repair protein (REV1) 
inserts dC opposite the abasic site, then followed by DNA synthesis or repair of lesion. (E) Single-
stranded DNA breaks (SSB) or double-stranded DNA break (DSB) result from phosphodiester 
backbone cleavage by APEX leading to recombination or further mutagenesis. Reprinted with 




be constitutively localised in the nucleus of the cell 12, 34, 137-138, 147, 253. A3A may facilitate 
genomic mutations and appear to be involved in some cancers 34-35, 190, 213, but, unlike 
A3B, is not found to be significantly overexpressed. On the other hand, A3B is found to 
be significantly overexpressed in a wide variety of cancers (including breast, bladder, 
cervix, lung, head, and neck) as a result of the high rate of mutations, suggesting that A3B 
is the predominant factor in cancer progression 1, 34-35, 39, 95, 101, 147, 149, 213.  
The mechanisms by which the A3 enzymes are upregulated in cancer cells are not well 
understood, but it is thought that they may be triggered by DNA-based viruses. HBV has 
been reported to be associated with the carcinogenesis of hepatocellular carcinoma (HCC) 
as a result of the upregulation of A3B. The hepatitis viral protein (HBx) is encoded by 
the HBV genome; HBx stimulates HBV replication and hepatocyte survival. The A3 
enzymes deaminate the HBV viral DNA generating a truncated form of HBx. This 
truncated HBx leads to neoplastic hepatocytes promoting HCC proliferation and survival 
284, through yet unknown mechanisms. Moreover, A3B has been noted to be upregulated 
in early stages of cancer by another DNA-based virus, HPV. Infection by this virus drives 
A3B oncogenic off-targets 101, 191, 269, 275. The elevated levels of A3B in tumours stimulate 
somatic mutations that promote cancer evolution, which in-turn causes cancer recurrence, 
metastasis, and resistance to anticancer therapies 146, 244.  
1.8 Therapy by hypermutation or hypomutation  
Viruses and cancer cells have developed methods to exploit the mutagenic action of A3s 
for their own gain, leading to severe consequences on human health 116, 259. Therefore, 
modulating the A3s’ action as therapeutic drugs may be used as a preventative measure 
against progression of viruses and cancers 195. Two strategies have been proposed, therapy 
by hypermutation or therapy by hypomutation. In regard to HIV-1, therapy by 
hypermutation involves blocking Vif which essentially restores the action of the 
A3G/A3D/A3F/A3H, preventing HIV-1 replication. Several small-molecule inhibitors of 
Vif have been identified, but are in the initial stages of development and require structure-
based information 7, 43, 159, 183, 200, 297. On the other hand, therapy by hypomutation entails 
direct inhibition of A3G/A3D/A3F/A3H, thereby preventing the diversification of the 
virus and development of drug resistance 96. Currently, low potency µM (3.9-21 µM) 
small-molecule inhibitors specific to A3G have been discovered 151, 194, 196. However, 
small-molecule inhibitors of other A3 members, such as the mutagenic action of the A3B 




would entail enhancement of the A3Bs mutational activity to toxic levels by small 
molecules to destroy cancer cells, though this strategy may be too difficult. Therefore, 
therapy by hypomutation by directly inhibiting A3B would provide mechanism in 




























































1.9 Approach of this study  
The fast-paced evolution of cancer facilitated by the hyperactivity of A3B deamination 
that leads to tumour recurrence, drug resistance, and poorer survival rates among patients 
is a growing area of concern. Notably, it has been reported that an A3B deletion 
polymorphism was found in a substantial fraction of the human population 114. Due to the 
non-essential nature of A3B indicated by these studies, its inhibition would unlikely cause 
a problem in normal cells. Therefore, the targeted inhibition of A3B, while retaining the 
activities of the other A3 enzymes involved in the innate immunity, may be used as a 
strategy to prevent cancer evolution and the development of drug resistances.  
1.9.1 Rationale of substrate-like ssDNA inhibitors   
The CDA replenishes pyrimidine nucleosides 296 but, several studies have noted that the 
CDA can also metabolise cytosine-based anticancer and antiviral drugs 57-58, 280. This led 
to the development of several cytosine analogue nucleosides as potent inhibitors of CDA, 
which could be used as therapeutic conjuvants 6, 45, 277. These cytosine analogues 
mimicked the transition state or intermediate structure of the substrate in an enzyme-
catalysed deamination reaction (as displayed in cytosine deamination mechanism in 
Figure 1.11). The crystal structures showed that these inhibitors bound tightly into the 
active-site of CDA 14, 56, 281, consistent with the conversion of the activation energy 
required for catalysis into static binding energy 227 (as illustrated in Figure 1.17).  
Figure 1.17 Scheme of cytosine deamination mechanism and associated conversion energy.  




The A3 enzymes are believed to have a similar cytosine deamination mechanism as that 
of CDA 14, 120, as the catalytic domain between these enzymes is conserved (refer to 
1.6.3.1). Therefore, the CDA cytosine analogue nucleoside inhibitors were presumed to 
inhibit the catalytic activity of the A3 enzymes in a similar manner. Initial assessment by 
our collaborators (Assoc. Prof. Daniel Harki’s team, University of Minnesota) on the 
inhibition potential of some of these cytosine analogue nucleosides (tetrahydrouridine 
(THU), zebularine (rZ) Figure 1.18 6, 45, 277, and a nucleotide 2'-deoxyzebularine (dZ)) on 
human A3A and human A3BCTD (expressed in human cells), indicated that these 
analogues did not inhibit the A3 enzymes 135. This is coherent with A3 enzymes preferring 
to bind and deaminate cytosines only in ssDNA (nucleotides ≥ 5) 15, 26, 48, instead of free 
nucleosides as in CDA.  
Therefore, our rationale to deliver these cytosine analogues into the A3s’ active-site was 
to incorporate the deoxynucleoside form of some of these cytosine analogues into a short 
ssDNA sequence (ssDNA with 9-10 nucleotides chosen based on binding studies 
conducted by Dr. Stefan Harjes 135). We embedded known CDA inhibitor cytosine 
analogue nucleosides, including 2'-deoxyzebularine (dZ), 2'-deoxy-5-fluorozebularine 
(5FdZ), 3-deaza-2'-deoxyzebularine (3dadZ), and 3-deaza-2'-deoxyuridine (3dadU), 
illustrated in Figure 1.19, in place of the target dC (position 0) within the A3B’s preferred 
deamination motif (5'-TC, Table 1.2), to facilitate specific inhibition of A3B’s catalytic 
activity. Modifying the chemical nature of the substrate ssDNA in this manner is believed 
to enhance its binding affinity towards the A3B by mimicking the transition state or 
intermediate of deamination (illustrated in Figure 1.17). The chemically modified ssDNA 
(termed modified-oligonucleotide) would therefore remain bound in the active site and 
thereby block the A3B’s catalytic activity, thus, creating an A3B-specific ssDNA-based 
inhibitor.   
Figure 1.18 CDA cytosine analogue nucleoside inhibitors. 





However, as A3B has an intrinsic deamination preference (5'-TC) similar to most A3s  
(except A3G) (see Table 1.2), these chemically modified inhibitors may not be selective 
towards A3B alone and inhibit other A3s. Apart from the A3’s intrinsic deamination 
motif, several studies have demonstrated that the nucleotides flanking this motif also 
influence the enzyme’s substrate recognition, and thereby deamination selectivity 37, 239-
240. Although the residues within the active site are highly conserved among A3 members, 
variations between the A3 members in loops 1, 3, and 7  that surround the active-site lead 
to differences in nucleotide contacts adjacent to the deamination motif 239-240. This is 
consistent with the A3A and A3BCTD being 90 % identical in amino acid sequence, both 
enzymes prefer to deaminate cytosines in the same ssDNA sequences (5'-(T/A)TCA-
motif), 239-240. A study noted that these enzymes can differentially deaminate cytosines in 
other motifs with less efficiency, for example substrates with a CCC-motif 37. A3A 
preferentially deaminates the dC at the 3'-end of the 5'-CCC motif as it prefers a purine 
in the +1 position, whereas A3B deaminates the dC at the 5'-end of the 5'-CCC motif as 
it prefers the presence of a thymine in the -1 position 8, 37, 239. Therefore, our approach 
was to exploit this behaviour of A3A and A3B, by placing our tested cytosine analogue  
inhibitor (dZ) in the A3B’s preferentially deaminated cytosine within the CCC-motif to 
determine if selective A3B inhibition is feasible (Table 5.1). 
Our chemically modified-oligonucleotides were synthesised in-house by Dr. Maksim 
Kvach and Mr. Harikrishnan Mohana Kurup. First the cytosine analogue nucleosides and 
their phosphoramidites were synthesised, then they were combined into a short ssDNA 
sequence (experimental details and oligos are described in section 2.3.2).  
Figure 1.19 Design of chemically modified ssDNAs incorporated with cytosine analogues as 




1.9.2 Aim of this study 
So far, no selective small-molecule inhibitors of A3B have been reported. Therefore, this 
research aimed at designing (see section 1.9.1) and evaluating substrate-like ssDNAs for 
their inhibitory potential on the A3B’s catalytic activity. We also examined how the active 
A3 complexes interact with the chemically modified ssDNA using binding and structural 
studies. In understanding the molecular basis of interactions, the longer-term aim of this 
project is to provide a tool that inhibits the cancer-progressing actions of A3B and 
prevents the development of drug resistance against existing anticancer therapies.  
(i) Express and purify A3BCTD for use in biophysical experiments. 
Based on reported problems with expression and purification of the two-
domain A3B, we opted to use the A3B catalytic C-terminal domain (termed 
A3BCTD), as it is associated with the majority of the deaminase activity 
78, 283. 
For our experiments, we required the production of milligrams of soluble 
A3BCTD (described in section 2.2). Catalytically inactive A3BCTD variants 
were produced for binding studies to prevent deamination of dC in a substrate 
ssDNA, whereas catalytically active A3BCTD constructs were purified to 
determine the deamination of dC-containing ssDNA and evaluate the 
inhibitory potential of our modified ssDNAs (described above 1.9.1).  
(ii) Evaluate the binding affinity of substrate ssDNAs and chemically modified 
ssDNAs on inactive A3BCTD. 
Using catalytically inactive A3BCTD constructs two methods, fluorescence-
based thermal shift assay and isothermal titration calorimetry (ITC) (described 
in sections 2.4.1 and 2.4.2), were selected to understand the basis of 
interactions between A3 and ssDNA. These methods were used to screen the 
affinity of substrate ssDNAs for the enzyme and to indicate the inhibitory 
potential of the chemically modified ssDNAs to A3B.  
(iii) Characterise the deamination potential of the active A3BCTD on substrate 
ssDNAs.  
The established 1D 1H-NMR-based activity assay 79, 94 (described in section 
2.5.2) was selected to quantitatively characterise the deamination rate of 
catalytically active A3BCTD on substrate ssDNAs.  





The chemically modified ssDNAs were evaluated for their inhibitory potential 
on our active A3BCTD constructs by using a 1D 
1H-NMR-based inhibitor assay 
(described in section 2.5.3).  
(v) Evaluate the ligand-free A3 and A3 in complex with ssDNA structures.  
Two approaches were taken to elucidate the structure and structural features 
of the single domain A3B, as ligand-free A3BCTD and A3BCTD in complex 
with ssDNA. Solution-state NMR and chemical shift perturbations (described 
in sections 2.6.1 and 2.4.3) used the catalytically inactive A3BCTD with and 
without a substrate ssDNA. Small angle X-ray scattering (SAXS) used 
catalytically active A3BCTD with or without ssDNA-based inhibitors to 
enhance the binding affinity of DNA to the enzyme (described in sections 
2.6.2). Furthermore, wild-type full-length A3G was used in SAXS studies to 
model the organisation of two-domain A3 with and without ssDNA-based 
inhibitors. 
1.9.3 Thesis outline 
Following the literature review and the approach of the study outlined in chapter 1, 
chapter 2 describes the methods used in this investigation. In chapters 3-6, I discuss the 
outcomes of this study. In chapter 3, I focus on understanding the molecular interactions 
between the purified inactive A3BCTD and ssDNAs through binding studies (i) and (ii), 
and also aimed at elucidating the solution-state NMR structures of the inactive A3BCTD 
and the A3BCTD-ssDNA complex (i)(v). Following this chapter, the objective in chapter 
4 centred on the assessment of the kinetic deamination of the target dC in the preferred 
ssDNA sequence (5'-TC, see section 1.9.1) by the catalytically active A3BCTD (iii). In 
addition, the inhibition potential of chemically modified ssDNAs containing cytosine 
analogue nucleosides was evaluated with the intention to obtain ssDNA-based inhibitors 
(iv). To further this study, in chapter 5, I explore whether selective inhibition of A3BCTD 
was feasible. Using the A3B discriminatory deamination of a suboptimal substrate (CCC-
oligo), a cytosine analogue nucleoside replaced the preferred dC (dZCC-oligo as 
described in section 1.9.1) and oligo was evaluated for selective inhibition of A3BCTD 
(aims iii and (iv). In chapter 6, I present the SAXS models of A3BCTD and two-domain 
A3 in complex with our chemically modified ssDNA (i)(v). Then the overall conclusions 
and future directions are elaborated in chapter 7. Finally, all supporting figures, tables, 





Incorporating cytosine-analogue nucleosides in place of the substrate 2'-deoxycytidine in 
short ssDNA sequences will mimic the transition state of deamination and would inhibit 


























































2.1.1 Water, chemicals, and oligonucleotides 
Unless specified otherwise, all water used for this work was milliQ, which was purified 
over two ion-exchange filters and two organic filters in a Barnstead NANOpure II system 
(Thermo scientific). MilliQ will be referred to as either water or H2O throughout this 
thesis. Chemicals used were of the highest grade available. Unmodified oligonucleotides 
were commercially synthesised by IDT (Singapore).  
2.1.2 Sterilisation 
Media and buffers were sterilised by autoclaving at 121 ̊C/15 p.s.i. for 20 minutes.  
2.1.3 Antibiotics  
Stock solutions of antibiotics were prepared as outlined in Table 2.1, filter sterilised 
through 0.22 µm Minisart filters (Sartorius Stedim), then stored as 1 mL aliquots at -20 ̊C 
for later use. Antibiotics were added to growth media or agar plates after autoclaving at 
working concentrations from stock to select for recombinant plasmid in E. coli.   







Kanamycin (Kan) H2O 100  100 
Ampicillin (Amp) H2O 100 50 
2.1.4 Luria-Broth (LB) medium and agar plates  
Luria broth (LB) medium (Invitrogen) was made up at a concentration of 25 g/L with 
H2O then sterilised by autoclaving. Once cooled to 50 °C, antibiotics were added to the 
medium at the working concentration described in Table 2.1. LB agar plates were made 
up by dissolving 25 g/L of LB and 15 g/L of agar bacteriological (Oxoid) in H2O then 
autoclaved. As described antibiotics are added to the medium once cooled, and the 




2.2 Protein Expression and Purification  
2.2.1 Plasmids  
Expression of the full-length A3B in E. coli was reported to be unsuccessful 240. As the 
catalytic C-terminal A3B domain (A3BCTD) constitutes the majority of activity, A3BCTD 
was studied to understand the catalytic and structural entities of A3B. Recombinant 
expression plasmids that improve protein expression and purification encoding A3BCTD 
derivative constructs were gifted by Assoc. Prof. Hideki Aihara and Prof. Reuben Harris, 
University of Minnesota 239-240. Plasmids utilised in this study are listed in Table 2.2, with 
modifications displayed in Figure 2.1.  
 
Table 2.2 Recombinant plasmids (gifted by Assoc. Prof. Hideki Aihara and Prof. Reuben Harris, 
University of Minnesota 240) 
Name Description Characteristics 
A3BCTD-QM-ΔL3 
A3BCTD residues 187 – 378 with quadruple 
mutations F200S/W228S/L230K/F308K, loop 3 
deleted (Ala242-Tyr250) and replaced with a 






A3BCTD residues 187 – 378 with quadruple 
mutations F200S/W228S/L230K/F308K, loop 3 
deleted (Ala242-Tyr250) and replaced with a 
serine residue, and amino acid substitution E255A; 





AL1swap - referred 
to as A3BCTD-AL1 or 
A3A-mimic 
A3BCTD residues 187 – 378 with quadruple 
mutations F200S/W228S/L230K/F308K, loop 3 
deleted (Ala242-Tyr250) and replaced with a 
serine residue, and substitution of A3B loop 1 
(DPLVLRRRQ) with A3A loop 1 (GIGRHK); 





A3BCTD residues 187 – 378 with double mutations 






SUMO protease encoded by ULP1 residues 1 – 







2.2.2 Preparation of chemically competent bacterial cells 
Bacterial strains listed in Table 2.3 used for transformations were first purchased from 
Lucigen. However, for cost and time efficiency these bacterial cells were made 
chemically competent using an in-lab established protocol. First, the desired E. coli strain 
was grown onto an LB plate at 37 ̊C overnight. Several colonies from the LB plates were 
inoculated into 250 mL SOB medium (0.5% Yeast Extract, 2% Tryptone, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4) and grown overnight at 19 ̊C to an OD of 
approximately 0.5-0.7 before being centrifuged at 2,500 × g for 10 minutes at 4 ̊C. The 
supernatant was discarded, while the cell pellet was resuspended in 80 mL ice-cold 
transformation buffer (TB) solution (10 mM PIPES, 15 mM CaCl2, 250 mM KCl, 
dissolved and adjusted to pH 6.7, 55 mM MnCl2) and incubated on ice for 10 minutes. 
The resuspended cells were centrifuged and the supernatant discarded as described 
previously, after which the pellet was resuspended in 20 mL of ice-cold TB solution with 
1.4 mL DMSO and stored in 100 µL aliquots at -80 ̊C. Recombinant plasmids were first 
transformed into HI-control™ 10G (Lucigen) E. coli cells to propagate plasmids (see 
section 2.2.3). Following plasmid amplification, the plasmids were transformed into a 
bacterial protein expression system, BL21(DE3) (Lucigen) or C41(DE3)pLysS (Lucigen) 
(Table 2.3) (see section 2.2.4). 
Figure 2.1 A3BCTD recombinant variants utilised in this study. 
* represents the same amino acid 
   
A3BCTD              --------------PDTFTFNFNNDPLVLRRRQTYLCYEVERLDNGTWVLMDQHMGFLCN 
A3BCTD-DM           ------EILRYLMDPDTFTFNFNNDPLVLRRRQTYLCYEVERLDNGTWVKMDQHMGFLCN 
A3BCTD-QM-∆L3       ------EILRYLMDPDTFTSNFNNDPLVLRRRQTYLCYEVERLDNGTSVKMDQHMGFLCN 
A3BCTD-QM-∆L3-E255A ------EILRYLMDPDTFTSNFNNDPLVLRRRQTYLCYEVERLDNGTSVKMDQHMGFLCN 
A3BCTD-QM-∆L3-AL1   ------EILRYLMDPDTFTSNFNNG---IGRHKTYLCYEVERLDNGTSVKMDQHMGFLCN 
                               *  ** ****         *********  * * *   *  *** * 
 
A3BCTD              EAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN 
A3BCTD-DM           EAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN 
A3BCTD-QM-∆L3       E--------SGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN 
A3BCTD-QM-∆L3-E255A E--------SGRHAALRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN                      
A3BCTD-QM-∆L3-AL1   E--------SGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN 
                            **** * ***..*   **  * **** * *******  ** *   *.  * 
 
A3BCTD              THVRLRIFAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW 
A3BCTD-DM           THVRLRIKAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW 
A3BCTD-QM-∆L3       THVRLRIKAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW 
A3BCTD-QM-∆L3-E255A THVRLRIKAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW 
A3BCTD-QM-∆L3-AL1   THVRLRIKAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW 
                   ** * *  *****       *.*  *  *** .***** ** .******  ******** 
 
A3BCTD              DGLEEHSQALSGRLRAILQNQGN 
A3BCTDDM            DGLEEHSQALSGRLRAILQ---- 
A3BCTD-QM-∆L3       DGLEEHSQALSGRLRAILQ---- 
A3BCTD-QM-∆L3-E255A DGLEEHSQALSGRLRAILQ---- 
A3BCTD-QM-∆L3-AL1   DGLEEHSQALSGRLRAILQ---- 





Table 2.3 E. coli strains  
E. coli cell strain  Genotype Source Use in study 
HI-ControlTM 
10G 
mcrA Δ(mrr-hsdRMS-mcrBC) endA1 recA1 
Φ80dlacZΔM15 ΔlacX74 araD139 
Δ(ara,leu)7697 galU galK rpsL (StrR) nupG λ¯ 






F –ompT hsdSB (rB- mB-) gal dcm (DE3) Lucigen Protein 
expression 
OverExpress 
C41(DE3) pLysS  




2.2.3 Plasmid amplification  
The recombinant plasmid constructs (Table 2.2) were transformed into chemically 
competent E. coli cells to amplify and create plasmid stocks using an in-lab established 
protocol. First, 1 µL of plasmid was mixed into 50 µL ice-thawed chemically competent 
HI-control™ 10G (Lucigen) E. coli cells (Table 2.3), then incubated on ice for 30 
minutes. The cells were placed in a TS1 Thermoshaker heating block (Biometra) at 42 ̊C 
for 30 seconds and then back on ice for 2 minutes. To allow the cells to recover from heat 
shock, 50 µL of LB media was added to the mix then incubated for 45 minutes at 37 C̊ 
with shaking at 225 rpm. The cell suspension was plated on LB agar plates (containing 
appropriate antibiotic) and incubated at 37 ̊C overnight for identification of successful 
transformants. For plasmid purification, a single colony from the overnight plates was 
then inoculated into 5 mL of LB-antibiotic medium and grown in a shaker overnight at 
37 ̊C. The culture was harvested by centrifugation and the plasmid was purified using a 
High Pure Plasmid Isolation Kit (Roche) according to the manufacturer’s instructions. 
Following isolation the plasmid was verified (see 2.2.3.1 and 2.2.3.2) then stored at -20 ̊C 
for later use.  
2.2.3.1 Agarose gel electrophoresis  
Agarose gel electrophoresis was used to verify the size of the extracted plasmids. This 
method separates DNA fragments of varying sizes ranging from 100 bp to 25 kb. Agarose 
gels were prepared by dissolving the appropriate mass of agarose (AppliChem) into TAE 
buffer (40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8.6) based on weight over 




dissolved. The solution was cooled before pouring into a gel casting apparatus (Owl™ 
EasyCast™ Mini Gel Electrophoresis System, Thermo Scientific) and allowed to set at 
room temperature. DNA samples were mixed with a 6X loading dye (30% glycerol, 
0.25% bromophenol blue) at a 1:1 (volume over volume, v/v) ratio before being loaded 
onto the gel and run at 100 V until the dye front migrated to the bottom of the gel. The 
agarose gels were then stained in ethidium bromide solution (0.5 µg/mL in H2O) for 30 
minutes before being transferred to H2O for 15 minutes to remove residual stain. Then 
these gels were visualized using a BioRad GelDoc XR gel documentation system with 
Image Lab™ software. 
2.2.3.2 Sequencing  
The isolated plasmids were sequenced to verify that the plasmid contained the correct 
A3BCTD insert. Sequencing reactions were setup with 200 ng/µL plasmid along with 4 
pmol of T7 forward primer (5' TAA TAC GAC TCA CTA TAG GG 3') in a total volume 
of 20 µL. Sequencing was performed by the Massey Genome Service (Massey University, 
Palmerston North), using a capillary ABI3730 Genetic Analyzer (Applied Biosystems 
Inc.). Nucleotide sequences were translated into amino acid sequences using ExPASy 
translate tool 83, then the amino acid sequences were aligned using protein BLAST® blastp 
suite 224.   
2.2.4 Protein expression  
Protein expression and purification of the A3BCTD constructs was mainly carried out as 
described previously 240. The purified recombinant plasmids were transformed into 
chemically competent E. coli protein expressing strains (Table 2.3) by the heat shock 
method described earlier in section 2.2.3. In particular, recombinant plasmids, bearing 
genes for A3BCTD-QM-ΔL3, A3BCTD-QM-ΔL3-E255A, and the SUMO protease ULP1, 
were transformed into BL21(DE3) E. coli strain (Lucigen), whereas the more catalytically 
active derivatives A3BCTD-QM-ΔL3-AL1swap and SUMO-A3BCTD-DM were 
transformed into C41(DE3) pLysS E. coli strain (Lucigen) to minimise background 
expression of toxic proteins.  
A single colony from the overnight transformed cells was inoculated into 10 mL of LB-
antibiotic medium and grown overnight at 37 ̊C as a starter culture. The overnight starter 
culture was inoculated into 2 L of LB-antibiotic medium and grown in a shaker at 37 ̊C 




and 0.6 for less active enzymes (mid-log growth phase). Cell culture OD600 is measured 
on a Smart SpecTM Plus Spectrophotometer (BioRad) using sterile LB medium as a blank. 
Once the optical density (OD) was established, the culture was cooled then supplemented 
with 100 µM final concentration of zinc chloride, to maintain Zn2+ within the A3B 
protein. Protein expression was induced by the addition of IPTG at a final concentration 
of 0.5 mM followed by incubation at 18 ̊C overnight. The cell culture was harvested via 
centrifugation at 4,000 × g for 30 minutes at 4 ̊C deriving a cell pellet which was frozen 
at -20 ̊C for further processing (see section 2.2.5). 
2.2.5 Protein purification 
The cell pellet was thawed then resuspended in lysis buffer (50 mM Tris-HCl pH 7.4, 150 
mM NaCl, 2 mM β-mercaptoethanol (β-ME)) containing one CompleteTM EDTA-free 
protease inhibitor tablet (Roche) and 0.5 mg/mL of lysozyme. The resuspended cells were 
then lysed by sonication at 30% amplitude for 5 minutes (10 short bursts of 30 sec) using 
a sonicator probe (Qsonica). The whole cell extract was pelleted at 14,000 × g for 20 
minutes to separate any unlysed cells, cellular debris, and insoluble protein.  
Purification of the histidine-tagged proteins was conducted using two consecutive 
methods, immobilised metal affinity chromatography (IMAC), followed by size 
exclusion chromatography-fast protein liquid chromatography (SEC-FPLC) to ensure the 
extraction of pure protein. In IMAC, the histidine-tagged protein binds to a metal ion 
(such as Co2+, Cu2+, Ni2+, and Zn2+) that is covalently immobilised to a stationary support 
matrix (NTA) in the column. Non-specifically bound proteins are washed away from the 
column, the His-tagged proteins are eluted off the column by displacing this interaction 
using imidazole. Then SEC-FPLC further separates the proteins based on their size. 
Proteins flow through pores in the column resin, where large proteins pass by pores and 
elute first from the column, while small proteins penetrate pores leading to a delay in 
retention time and eventually elute from the column. 
The clarified soluble cell lysate was filtered with a 0.8 µM filter before being loaded onto 
a pre-equilibrated with lysis buffer Ni2+-NTA affinity Econo- column (BioRad) and 
subjected to gravity flow. The column was systematically washed with 20 mL of lysis 
buffer containing low concentration of imidazole (0 mM - 100 mM imidazole) to remove 
unbound proteins. The immobilised His-tagged protein was then eluted from the column 




between 200 mM - 500 mM (dependent on protein construct). Fractions collected were 
then analysed by tricine SDS-PAGE gel (refer to 2.2.7.2), and the eluate was subsequently 
dialysed in high salt pH 7.4 buffer (50 mM Tris-HCl pH 7.4, 0.5 M NaCl, 2 mM β-ME) 
over 48 hours at 4 °C in a 10 kDa MWCO dialysis bag to remove imidazole. The dialysed 
protein was concentrated down to 0.5 mL in a 10 kDa cut-off Vivaspin 20 concentrator 
(GE Healthcare) then loaded onto a Superdex 75 10/300 GL column (GE Healthcare) 
using ÄKTA protein purification system (GE Healthcare) monitored using UV280 nm. 
The protein of interest was eluted using SEC-FPLC in SEC buffer (50 mM Tris-HCl pH 
7.4, 0.5 M NaCl, and 2 mM β-ME) at a flow rate of 0.5 mL/min. Fractions collected were 
then visualised by SDS-PAGE gels (refer to 2.2.7.2) and the fractions containing the 
purified protein of interest were concentrated (Vivaspin 20 kDa MWCO) and stored in 
aliquots at -80 ̊C for later work. 
2.2.5.1 Cleavage of fusion protein tag 
The SUMO-tagged fusion protein (SUMO-A3BCTD-DM) and SUMO protease (ULP1) 
were purified as described in section 2.2.5. Following purification, the SUMO-tag of the 
purified SUMO-A3BCTD-DM was cleaved off in a similar manner to a previously 
described study 152. In brief, the purified SUMO-A3BCTD-DM protein was incubated with 
the purified SUMO protease (ULP1) at a ratio of 1:5 (fusion protein to protease) overnight 
at 4 ̊C. After cleavage of the fusion protein, the sample was passed through a Ni2+-NTA 
affinity column, where the His-tagged SUMO and His-tagged SUMO protease bound to 
the column, and the A3BCTD-DM eluted off the column. The eluate was concentrated 
(Vivaspin 20 kDa MWCO) and stored in aliquots at -80 ̊C for further work.    
2.2.6 Expression and purification of uniform isotopically labelled proteins 
Uniform isotopically labelled proteins provide visible atomic nuclei used in 
multidimensional NMR experiments of proteins (further described in section 2.6). 
Proteins naturally contain 1H isotope at a high abundance, but other isotopes are 
artificially enriched by using minimal medium containing 13C as the sole carbon source 
or 15N as the sole nitrogen source; both isotopes have a nuclear spin of ½, allowing a 
nuclear magnetic moment. Isotopically labelled proteins were expressed in M9 minimal 
medium in a similar manner to previous studies 5, 53, 102, 164. Components of M9 minimal 
medium were first prepared as separate sterile stock solutions, outlined in Table 2.4 to 
Table 2.6. M9 minimal medium was then prepared, using either 15N isotope or both 15N 




to pH of 7.5 to maintain buffering capacity 5. Initially, a transformed starter culture (see 
to 2.2.4) grown to high densities in LB medium is pelleted then exchanged into 5 mL of 
isotopically labelled M9 minimal medium and incubated for an hour at 37 ̊C to adjust to 
medium. This culture is then inoculated into the larger 2L of labelled M9 medium 
(supplemented with either 15N or both 15N and 13C) and agitated at 37 ̊C in a shaker until 
the OD600 is around 0.4. Once the optical density was established the culture was cooled 
and its pH was adjusted to pH 7.5 using 1 M NaOH to obtain higher protein yields 5. Then 
ZnCl2 and IPTG were added at a final concentration of 100 µM and 0.5 mM to the culture 
respectively, and incubated overnight at 18 ̊C. The culture was harvested and the labelled-
proteins were purified using Ni2+-NTA affinity chromatography and SEC-FPLC as 
described earlier in section 2.2.5. The purified isotopically labelled proteins were then 
stored at -80 ̊C for future work. 
Table 2.4: M9 salts (5X) 
Component  Amount (g/L)  
Na2HPO4.6H2O 34  
KH2PO4.H2O 15  
NaCl 2.5  
 Made up with H2O to 1 L 
 
Table 2.5: Trace element solution (1000x) 
Component  per 100 mL  
CaCl2.2H2O 0.60 g 
FeSO4.7H2O 0.60 g 
MnCl2.4H2O 0.12 g 
CoCl2.6H2O 0.08 g 
ZnSO4.7H2O 0.07 g 
CuCl2.2H2O 0.03 g 
H3BO3 2 mg 
(NH4)6Mo7O24.4H2O 25 mg 
Na2EDTA 0.50 g 




Table 2.6: Vitamin solution (5 mg/mL) (stored at 4°C) 
Component  per 100 mL  
C12H18Cl2N4OS (Thiamine hydrochloride) 0.50 g 
C6H5NO2 (Nicotinic acid) 0.50 g 
 
Table 2.7: Isotopically labelled M9 minimal medium composition (15N,13C-labelled). 
Component  Amount 
M9 salts (5X) (see Table 2.4) 400 mL 
Vitamin solution (see Table 2.6) 12 mL 
Kanamycin (100 mg/mL) 700 µL 
Trace elements (1000x) 2 mL 
1 M MgSO4 6 mL 
(15NH4)2SO4 2 g 
13C D-glucose * 4 g 
 Made up with H2O to 2 L 
* note for 15N-labelled proteins standard D-glucose was used. 
2.2.7 Protein quantification  
2.2.7.1 Protein Concentration  
Protein concentrations were determined using the Bradford protein assay 25. Albumin 
from chicken egg white (Sigma-Aldrich) was used to prepare a standard curve. Briefly, 
in a plastic cuvette 20 μL of standard or protein sample was added to 1 mL of Bradford 
reagent (Table 2.8). Samples were incubated for 5 minutes then their absorbances were 
measured on a Smart SpecTM Plus Spectrophotometer (BioRad) at an absorbance of 595 
nm with the appropriate buffer used to blank the instrument. Protein concentration was 
calculated based on the standard curve, in which absorbance was plotted against varying 
concentrations of the albumin protein. Protein concentrations were also measured using 
a Nanodrop ND-1000 spectrophotometer (Thermo Scientific) at an absorbance of 280 nm 
(A280) with appropriate buffers used as a blank. Protein concentrations were calculated 
using Beers Law with the appropriate extinction coefficient calculated by ExPASy-




Table 2.8: Preparation of Bradford reagent 
Component Amount 
85 % Phosphoric acid 100 mL 
Brilliant blue G-250 100 mg  
 Made up with H2O to 1 L 
  
2.2.7.2 Tricine SDS-PAGE Electrophoresis  
To visualise proteins and assess molecular mass between 1-100 kDa Tricine SDS-
PAGE gel electrophoresis was utilised as described in a previous study 225. Tricine-SDS 
PAGE gels were utilised to resolve small proteins less than 30 kDa. Initially, buffers 
were prepared as outlined in Table 2.9. Gels were prepared using a Mini-Protean II 
Electrophoresis Cell System (Bio-Rad) at a thickness of 0.75 mm by first preparing the 
separating gel as outlined in Table 2.10, and casting in a gel cassette. Once the 
separating gel polymerised the stacking gel (also outlined in Table 2.10) was overlaid 
on top of it. Samples were mixed with the 2X SDS-treatment buffer at a 1:1 ratio ( 
Table 2.11), then were boiled for 5 minutes in a waterbath before being loaded onto the 
gel. Electrophoresis was conducted with 1X cathode buffer in the  upper tank and 1X 
anode buffer in the lower tank (Table 2.9) and run at 100 V until the dye front migrated 
to the bottom of the gel. The Tricine SDS-PAGE gels were then stained with Coomassie 
blue stain (0.25% Coomassie Brilliant Blue R-250, 40% methanol, and 7% acetic acid) 
for 30 minutes (or overnight) with gentle agitation, followed by replacing the stain 
solution with destain solution (40% methanol, 7% acetic acid) and incubating overnight. 
The gel was placed into H2O then imaged using BioRad GelDoc XR gel documentation 
system with Image Lab™ software. 
Table 2.9 Preparation of Tricine SDS-PAGE buffers. 
Component 
Anode buffer (10X) 
pH 8.9 
Cathode buffer (10X) 
Gel buffer (3X) pH 
8.45 
Tris HCl 1 M 1 M 3 M 
Tricine - 1M - 




Table 2.10 Preparation of Tricine SDS-PAGE gel. 
Component 4% Stacking gel 16% Separating gel 
Acrylamide (49.5%)/Bis-Acrylamide (3%) 0.5 mL 5 mL 
Gel buffer (3X) 1.5 mL 5 mL 
Glycerol - 1.5 mL 
H2O 4 mL 3.45 mL 
10% w/v ammonium persulfate 45 µL 50 µL 
TEMED 4.5 µL 5 µL 
Total  6 mL (1 mL used) 15 mL (3.5 mL used)  
 
Table 2.11 Preparation of 2X SDS-treatment buffer 
2.2.7.3 In-gel tryptic digest mass spectrometry 
To confirm the identity of the eluted proteins in-gel tryptic digest mass spectrometry was 
employed using an in-lab established protocol. To obtain enhanced staining of the gel, 
colloidal Coomassie was utilised due to its high sensitivity to protein and reduced 
background staining in contrast to standard Coomassie blue stain (described 2.2.7.2). 
First, the SDS-PAGE gel was fixed in solution (40 % methanol, 10 % acetic acid), for an 
hour, then the gel was washed with H2O, before being stained overnight in diluted 
colloidal Coomassie stain (working concentration made up of 4 parts stock to 1 part 
methanol) (Table 2.12). The gel was then washed in a 10 % acetic acid solution to remove 
any residual stain and readied for in-gel tryptic digest. 
Component Final concentration 
1 M Tris-HCl, pH 6.8 100 mM 
SDS 4 % (w/v) 
Glycerol 10 % v/v 
DTT 200 mM 




Table 2.12 Colloidal Coomassie stock solution. 
Components Concentration (w/v) 
Coomassie Brilliant Blue G250 0.1% 
Phosphoric acid 2% 
Ammonium sulfate 10% 
 Made up to 500 mL with H2O                                                                         
(working solution 4:1, stock to methanol) 
 
In-gel tryptic digest begins by excising the protein band of interest from the colloidal 
Coomassie-stained gel, then cutting it into smaller fragments and placing them in a 1.5 
mL Eppendorf tubes. The gel fragments are first destained by incubation with 300 µL 
fresh 50 mM ammonium bicarbonate (ABC) solution at 45 ̊C. Once the gel fragments are 
colourless the solution is decanted. Second, 300 µL of 80% aq. acetonitrile solution 
(ACN) is added then incubated for 1-2 minutes at room temperature, before discarding 
the solution. The gel fragments are dehydrated under a vacuum using a SpeedVac 
centrifugal evaporator (Thermo Scientific). This is followed by incubation with 50 µL of 
fresh reducing agent (10 mM DTT in 50 mM ABC) at 37 ̊C for 1 hour, then the reducing 
agent is removed. The gel fragments are washed with 50 mM ABC solution, then 80% 
aq. ACN solution, and dried using the SpeedVac as previously described. The gel 
fragments are incubated with 50 µL of fresh alkylation solution (20 mM iodoacetamide 
in 50 mM ABC) for 20 minutes in the dark at room temperature. After the alkylation 
solution is discarded, the gel pieces are again washed in 50 mM ABC, twice with 80% 
aq. ACN, and dried using a SpeedVac as described earlier. 
Gel fragments are digested with TPCK-treated trypsin (Proteomics Grade T6567, Sigma) 
(20 ng/µL trypsin in 50 mM ABC solution) then incubated for 10 minutes on ice, before 
discarding the solution. This is followed by the addition of 30 µL of 50 mM ABC solution 
and incubation overnight at 37 ̊C. After the incubation period, the samples are sonicated 
for 2 minutes and the supernatant is collected in a new Eppendorf tube. The gel fragments 
(in the original tube) can be further extracted; primarily 60 µL of extraction buffer 1 (5% 
formic acid in 80% aq. ACN) is added to the tube then sonicated for 2 minutes before 
pooling the supernatant with the previous collection; this is repeated with 60 µL of 




with the previous collection. The combined supernatant was concentrated down to 20 µL 
then transferred to HPLC sample vials ready for mass spectrometry. Mass spectrometry 
and analysis were then performed by Mr. Trevor Loo, by processing samples on an 
Agilent 6520 Q-TOF mass spectrometer (Agilent Technologies) and utilising Agilent 
MassHunter Workstation Qualitative Analysis software version B.03.01 (Agilent 
Technologies, Santa Clara, CA, USA) and Mascot servers (version 2.4.1) housed in 
Walter and Eliza Hall Institute (Melbourne, Australia). 
2.3 Single-stranded DNA substrates and potential inhibitors 
2.3.1 ssDNA substrates 
A3 enzymes deaminate cytosine residues in ssDNA with an intrinsic sequence preference. 
Several ssDNA sequences with 9-10 nucleotides were designed based on previously 
known sequences that interact with A3BCTD 
36-37, 47, 78, 94, 157, 172. The ssDNA 
oligonucleotides were commercially synthesised (IDT) containing 2'-deoxycytidine (dC) 
or 2'-deoxyuridine (dU) (substrate or product, respectively) (listed Table 2.13). These 
oligonucleotides were utilised in various experiments including thermal shift assay, 
isothermal titration calorimetry, and NMR titrations for relative binding capability to A3 
variants (see section 2.4.12.4.2, and 2.4.3), and used in NMR-based activity assay (section 
2.5.1).  
Table 2.13 ssDNA oligonucleotides commercially synthesised (IDT) used in this study 
Name Sequence 5' → 3' 

















2.3.2 Chemically modified ssDNA 
Towards the goal of blocking the progression of cancer evolution by A3B activities 34-35, 
68, 146, 244, chemically modified ssDNAs were designed and then evaluated for their 
inhibitory potential against the catalytic activity of A3BCTD. Known CDA inhibitor 
cytosine-analogue nucleosides, including 2'-deoxyzebularine (dZ), 2'-deoxy-5-
fluorozebularine (5FdZ), 3-deaza-2'-deoxyzebularine (3dadZ), and 3-deaza-2'-
deoxyuridine (3dadU), were incorporated in place of the target dC (position 0) in the 
A3B- and A3G-preferred ssDNA sequences (see Table 2.14). These analogues are 
believed to mimic the transition state of cytosine deamination, which increases the 
binding affinity owing to the conversion of the activation energy to static binding energy 
as no catalysis occurs 227. The cytosine analogue nucleosides, their phosphoramidites, and 
ssDNA (oligos) containing these cytosine-analogue nucleosides were synthesised in-
house by Dr. Maksim Kvach and Mr. Harikrishnan Mohana Kurup. Descriptions of the 
synthesis of these chemically modified oligos as well as data about composition and 
purity of modified oligos used in this work are available on-line in the supplementary 
information of our published articles (DOI:10.1021/acs.biochem.8b00858 135, DOI: 
10.1039/c9ob01781j 8, and DOI: https://doi.org/10.1002/cbic.201900505 136). These 
sequences were then tested for their inhibitory potential and binding affinity using 
isothermal titration calorimetry (section 2.4.2), NMR-based inhibition assay (section 
2.5.3), and then examined using SAXS (section 2.6.2).  
Table 2.14 ssDNA oligonucleotide synthesised in-house used in this study 
Name Sequence 5' → 3' Modification 
dZ-oligo 5'-ATTTdZATTT dZ; 2'-deoxyzebularine 
 
zebularine - 
5FdZ-oligo 5'-ATTT5FdZATTT 5FdZ; 2'-deoxy-5-fluorozebularine 
3dadZ-oligo 5'-ATTT3dadZATTT 3dadZ; 3-deaza-2'-deoxyzebularine 
3dadU-oligo 5'-ATTT3dadUATTT 3dadU; 3-deaza-2'-deoxyuridine 
dZCC-oligo 5'-ATTdZCCAATT dZ 
 











2.3.3 Nucleic acid concentration  
Nucleic acid (plasmids, and ssDNA) concentrations were evaluated on a Nanodrop ND-
1000 spectrophotometer (Thermo Scientific) at both 260 and 280 nm. Extinction 
coefficients (ε constant) were calculated using IDT OligoAnalyzer tool 197, then fed 
through ND-1000 software V3.1.0 (ThermoFisher) to calculate concentrations using the 
absorbance measured.  
2.4 Binding studies 
Binding interactions between the A3BCTD and ssDNA were studied using a combination 
of thermal shift assays and NMR titrations. Binding assays were typically conducted 
using a catalytically inactive A3BCTD variant to evade deamination of the cytosine in the 
sequence. Otherwise, binding of active A3BCTD variants to ssDNA inhibitors was 
assessed using isothermal titration calorimetry.  
2.4.1 Fluorescence-based thermal shift assay 
To investigate the binding of ssDNA to A3BCTD, a fluorescence-based thermal shift assay 
was performed as described in a previous study 112. This assay utilises a fluorescent dye 
to monitor the changes in the protein’s thermal stability upon binding of a ligand. Initially, 
the purified A3BCTD protein was appropriately diluted in a 50 mM citrate-phosphate 
buffer (50 mM citrate-phosphate pH 5.5, 200 mM NaCl, 2 mM β-ME, pH 5.5, 200 μM 
4,4-dimethyl-4-silapentane-1-sulfonic acid (DSS)). In a white Low-Profile 96-Well plate 
(Roche) assay reactions were setup in a total volume of 25 μL containing 20 μM A3BCTD 
protein, 100 μM ssDNA oligonucleotide, mixed with a final concentration of 10X 
SYPRO® orange dye (BioRad). The plate was sealed with optical tape, shaken, and 
centrifuged before being subjected to temperature cycling. Thermal scanning (20 ̊C to 
95 ̊C at 0.6 ̊C/min) was performed using a real-time PCR setup on a LightCycler 480 
instrument II (Roche) with fluorescence emission spectra recorded with combinations of 
excitation and emission filters (483–610 and 483–568 nm, respectively). Fluorescent 
intensity was normalised to percentage, then fit to curves to derive the melting 
temperature (Tm), which occurs at the midpoint of the unfolding transition. Binding of a 
ligand (ssDNA) to protein was evaluated by the change in melting temperature (ΔTm), by 
comparing Tm in the presence of a ligand versus the absence of a ligand (buffer). 
Experimental replicates (n = 3-8) were performed, which were analysed using a Q-test 




2.4.2 Isothermal titration calorimetry (ITC) 
ITC experiments were conducted to characterise the thermodynamic parameters of direct 
interactions between a protein and target ligand based on a previous study 76. ITC relies 
on monitoring the changes in heat that is either released or absorbed during a binding 
interaction in solution. Firstly, the oligonucleotide and the A3BCTD protein were dialysed 
separately in a 50 mM citrate-phosphate pH 5.5 buffer (50 mM citrate-phosphate buffer, 
200 mM NaCl, 2 mM β-ME, pH 5.5) for 2-3 days. ITC experiments were performed using 
a Micro-Cal ITC200 (Malvern Instruments) at 25 ̊C, where the sample cell was loaded 
with 100 µM A3BCTD protein and the syringe loaded with 300 μM ssDNA. The protein 
was titrated with oligonucleotide over an 18 step injection of 2.0 μL each (plus an initial 
injection with reduced volume of 0.4 μL to prevent dilution of the DNA in the syringe 
due to the long wait before the start of the experiment). Analysis of ITC data was 
performed using Origin 7 ITC200 software where the raw data were fitted to a one-site 
binding model to derive parameters including enthalpy (ΔH), entropy (ΔS), equilibrium 
binding association constant (Ka), and stoichiometry (N). The equilibrium dissociation 
binding constant (Kd) can then be derived as Kd=1/Ka, from which the Gibbs free energy 
(ΔGo = ΔHo-TΔSo = -RT ln (Ka/Q
o) can be calculated and combined with the measured 
ΔHo to give ΔSo, where T is temperature of 298 K). 
2.4.3 NMR titration 
NMR titration experiments were used to evaluate the binding site of ssDNA to the 
A3BCTD using a protocol previously described in several studies 
92-94. 2D-15N HSQC 
NMR experiments (as detailed in 2.6.1 and Table 8.1) were utilised by examining the 
chemical shift changes of amino acids upon titration with ssDNA. Initially, 15N-labelled 
A3BCTD (see 2.2.6) and the oligonucleotide were first dialysed separately in 50 mM 
citrate-phosphate pH 5.5 buffer (50 mM citrate-phosphate buffer, 200 mM NaCl, and 2 
mM β-ME, pH 5.5). A 15N-HSQC NMR spectrum was first recorded using 250 µM of 
15N-labelled A3BCTD in the 50 mM citrate-phosphate pH 5.5 buffer to entice interactions. 
This was followed by obtaining 15N-HSQC NMR spectra titrated with differing ratios of 




2.5 Evaluation of the A3-catalysed reaction  
2.5.1 In vitro DNA deamination gel-based assay 
A previously reported in vitro DNA deamination in-gel based assay 240 was initially used 
to assess the deamination activity of the purified A3 proteins. Initially, the fluorescently-
tagged oligonucleotide (TC-3' 6-FAM-oligo, see Table 2.13) and the purified proteins 
were buffer matched by diluting to required concentrations using a 1X HEPES pH 7.4 
buffer (10 mM HEPES-KOH, 50 mM NaCl at pH 7.4). In a PCR strip, reactions were 
setup using 5 µL of a 1.6 µM TC-3' 6-FAM oligo mixed with 5 µL of 10 µM of the 
purified protein (final concentrations of 800 nM DNA to 5 µM protein). The reaction 
mixtures were then subjected to temperature cycling in a thermocycler (Eppendorf) as 
follows: first, the mixtures were incubated for an hour at 37 °C, followed by incubation 
at 95 °C for 3 minutes (to denature the protein and prevent further substrate deamination), 
then cooled to 12 °C. The reaction mixtures were then treated with 1 µL of 120 nM uracil-
DNA glycosylase (UDG, which cleaves the uracil bases in the oligonucleotide) (New 
England Biolabs, Ipswich, MA USA) and incubated for 10 minutes at 37 °C. Following 
UDG treatment, 1.2 µL of a 1 M NaOH was added to the mixture and incubated for 5 
minutes at 98 °C to stop the reaction and cleave DNA with an abasic site. To separate and 
resolve small fragments of the ssDNA reaction products a 15% denaturing PAGE gel was 
used.  
A TBE-Urea PAGE gel was prepared by initially mixing 5.47 g of urea with 2.6 mL of a 
5X TBE buffer (445 mM Tris at pH 7.6, 445 mM boric acid, and 10 mM EDTA) and 
dissolving at 50 °C. To this mixture 4.88 mL of a 40% acrylamide (for 15% gel), 6.5 µL 
of TEMED, and 91 µL of 10% ammonium persulfate were added. The resulting gel 
mixture (13 mL) was cast in a Mini-Protean II Electrophoresis Cell System (Bio-Rad) gel 
cassette at a thickness of 1.5 mm. Once the gel was polymerised, it was placed in the gel 
tank with 1X TBE buffer and run without samples for 20 minutes at 100 V to equilibrate 
the gel. Samples were mixed with 2X formamide buffer (80% formamide, 1X TBE, 
bromophenol blue and xylene cyanol) at a 1:1 ratio and 3 µL was loaded onto the gel. 
Electrophoresis was conducted at 200 V for 40 minutes (or until the bromophenol blue 
front line is near the bottom and xylene cyanol is halfway down the gel). The gel was 
washed in H2O for 15 minutes before being scanned using fluorescence on a Typhoon 




2.5.2 1D 1H-NMR-based activity assay 
Kinetic characterisation of active A3BCTD variants (A3BCTD-QM-∆L3-AL1swap and 
A3BCTD-DM) on their preferred cytosine in ssDNA sequences (Table 2.13Table 2.14) 
was quantitatively evaluated using a previously established 1D 1H-NMR-based assay 79, 
94. This assay utilises the naturally abundant proton (1H) nuclei within ssDNA 
oligonucleotides and monitors the real-time deamination of dC (substrate) to dU 
(product). Experiments were conducted on a 700-MHz Bruker NMR spectrometer 
equipped with a 1.7-mm cryoprobe at 298 K. 1H NMR spectra of oligonucleotide 
standards containing dU were first recorded to determine where the H-5 proton doublet 
signal of the dU product appears. Initially, a series of 1H NMR spectra of the 
oligonucleotide substrate was recorded at concentrations ranging from 50 μM to 750 μM 
with either 50 nM of A3BCTD-QM-ΔL3-AL1swap or 2 μM of A3BCTD-DM enzyme ([E] 
initial enzyme concentration), in a 50 mM citrate-phosphate buffer (50 mM citrate-
phosphate, 200 mM NaCl, 2 mM β-ME, 200 μM DSS, pH 5.5 for A3BCTD-QM-ΔL3-
AL1swap, or pH 7.5 for A3BCTD-DM) with 10% deuterium oxide (D2O). A doublet of 
doublets occurring between 2.57 to 2.39 ppm originating from citrate in the buffer was 
used as an internal standard to determine the concentration of the substrate converted 
during the reaction. To determine the rate of deamination by the A3 enzyme, the H-5 
proton doublet signal of the dC/dU was integrated then converted to a substrate 
concentration (termed [S]), which was plotted against the time of the reaction (sec) to 
derive the initial speed (also termed rate) of the reaction). From this 1/V0 was plotted 
against 1/[S] producing the Lineweaver-Burk plot, from which one can determine the 
Michaelis-Menten parameters. The Michaelis-Menten equation is described in line 1 of 
Equation 2.1, where Vmax is described as the maximum rate when an enzyme is saturated 
with substrate, the Michaelis constant, Km, describes the substrate’s apparent binding 
affinity for the enzyme where [S] is at half of Vmax. The catalytic rate constant, kcat, 
describes the maximum number of substrate converted to product per enzyme per second 
(derived from line 2 in Equation 2.1, assuming Vmax is reached independent of [S] at high 
[S]). To conveniently derive these parameters the Michaelis-Menten plot is converted to 
a Lineweaver-Burk plot by taking the inverse V0 (1/V0) against the inverse [S] (1/[S]) as 
described by Equation 2.1 line 3. The Lineweaver-Burk plot was fitted with a linear 





These parameters were calculated using Equation 2.2. First, the Lineweaver-Burk 
equation (line 1, Equation 2.2) was substituted into a linear regression equation (line 2, 
Equation 2.2) as shown in line 3 (Equation 2.2). Using this equation, y represents the 
dependent variable (1/V0) and x was assigned as the independent variable (1/[S]). From 
the fitted line we can derive the value of the constant number a and b, where a is the y-
intercept when x = 0, while b is equivalent to the slope of the line. Substituting values of 
a and b and rearranging each equation, kcat (line 4, Equation 2.2) and Km parameters are 
derived. Uncertainties of Km and kcat were calculated using the error-propagation method 
based on uncertainties in a and b from linear regression obtained using LINEST function 
in Excel described in the appendix (Equation 8.1).  
y = 𝑉ₒ = 𝑉max ×
[S]
𝐾m + [S]
                                                                 (1)   
𝑉max = 𝑘cat[E]                                                                                        (2) 
y = 𝑉ₒ = 𝑘cat[E] ×
[S]
𝐾m + [S]


































)                                                 (1) 




                 𝑏 =
1
𝑘cat[E]


















Equation 2.1 Michaelis-Menten and Lineweaver-Burk equations. 
 





2.5.3 1D 1H-NMR-based inhibitor assay   
NMR-based inhibition assays were carried out to determine the deaminase activity of A3 
variants in the presence of the chemically modified ssDNA (Table 2.14) to assess the 
inhibitory potential. Similar to the NMR activity assay described above in section 2.5.2, 
a series of 1H NMR spectra was recorded using 350 µM substrate oligo [S] along with 
varying concentrations of chemically modified ssDNA (5 µM to 100 µM) with either 50 
nM of A3BCTD-QM-∆L3-AL1swap or 2 µM of A3BCTD-DM in the buffers mentioned 
earlier in section 2.5.2. Integration of the H-5 proton doublet signal of the dC or dU was 
converted to substrate concentration and plotted against the time of the reaction to obtain 
the initial rate of the reaction (V0). From this the inverse rate of the reaction (1/V0) was 
plotted against the inhibitor concentration (termed [I]) to produce the Dixon plot at a 
given [S], as shown in line 1 Equation 2.3, under the assumption that our inhibitors are 
competitive inhibitors, as then  validated experimentally in Figure 4.11.  
The Dixon plot was fitted with a linear regression equation (terms described in section 
2.5.2) to calculate the inhibition constant (Ki). The Dixon plot equation (line 1, Equation 
2.3) was substituted into a linear regression equation (line 2, Equation 2.3) as shown in 
line 3 (Equation 2.3). Values of a (y-intercept), b (slope of line), and values of the 
Michaelis  parameters obtained earlier (Km and kcat, Equation 2.2) were substituted and 
the equation was solved. Uncertainty of Ki was calculated using error-propagation method 







𝐾i × 𝑉max × [S]
× [𝐼] + 
𝐾m + [S]
𝑉max × [S]
                               (1)  
y = 𝑎𝑥 + 𝑏                                                                                              (2) 
𝑎 =
𝐾m
𝐾i × 𝑉max × [S]
              𝑏 =
𝐾m + [S]
𝑉max × [S]
                                   (3)  
𝑉max = 𝑘cat[E]                                                                                       (4) 
𝐾i =
𝐾m 
𝑎 × 𝑘cat × [E]  × [S]
                                                                  (5) 
[E] =
𝐾m + [S] 
𝑏 × 𝑘cat × [S]
                                                                            (6) 
Equation 2.3 Calculation of Ki from the Dixon plot using the linear regression equation.  




2.6 Structural studies 
2.6.1 Analysis of the proteins structure using nuclear magnetic resonance (NMR) 
spectroscopy 
To provide insight into a protein’s structure, dynamics, and binding interactions in 
solution, multidimensional (2D and 3D) NMR experiments utilise radiofrequencies to 
detect the nuclei of proteins. Multidimensional experiments rely on the transfer of 
magnetisation energy between nuclei, providing specific connections between nuclei. To 
enable these experiments, proteins are artificially enriched with isotopes containing 
nuclei with an odd number of protons and/ neutrons which leads to a nuclear magnetic 
moment in the magnetic field (refer to preparation of isotopically labelled protein section 
2.2.6) allowing assignment of signals in NMR spectra to atoms in the protein.  
Several multidimensional NMR experiments listed in Table 8.1 (in the appendix) were 
conducted on A3BCTD. Experiments were setup using 250 - 350 µM of labelled A3BCTD 
(15N-labelled for 2D experiments or 15N, 13C-double-labelled for 3D experiments) in a 
volume of 300 µL high salt NMR buffer (50 mM Tris-HCl at pH 7.4, supplemented with 
0.5 M NaCl, and 2 mM β-ME) along with 10% D2O. To improve the signal to noise ratio, 
samples were measured in 5 mm high-throughput NMR tubes (Wilmad®). The sample 
was degassed for 30 minutes before being placed in a salt-tolerant susceptibility matched 
slot tube (Shigemi Inc.) and measured using a 700 MHz spectrometer (Bruker Avance) 
equipped with a 1.7-mm cryoprobe at 298 K.  
2.6.2 Small-Angle X-ray Scattering (SAXS)  
In the last few years, structures of the catalytically inactive single domain A3 bound to a 
ssDNA substrate were reported 129, 161, 239. However, the structure of two-domain A3 in 
complex with ssDNA remains unclear due to the limitations of crystallography. 
Therefore, small-angle X-ray scattering (SAXS) was used to provide structural 
information on the protein and its complexes in solution. Low-resolution models of full-
length A3-ssDNA obtained by SAXS can be combined with A3 domain structures to 
understand the arrangement of domains upon the binding DNA. Due to difficulties in 
producing full-length A3B, the closely related full-length A3G (provided by Linda 
Chelico from the University of Saskatchewan) was utilised.  
Measurements were conducted at the Australian Synchrotron on the SAXS/WAXS 




a camera length of 1.6 m and frames were taken at one second intervals. Samples of A3 
proteins (0.5 – 10 mg/mL) with and without ssDNA at varying ratios were loaded in a 96 
well plate (50 µL) and degassed for 30 minutes. Scattering data were obtained using co-
flow SEC-SAXS mode. Samples were injected onto a pre-equilibrated SEC column 
(Superdex® 200 Increase 5/150) then run at a flow rate of 0.2 mL/min while 
simultaneously SAXS measurements were acquired. All buffers listed in Table 2.15 
contained 5-10% glycerol to limit radiation damage of samples. SEC UV elution profile 
recorded at various wavelengths (A280, A260, A220, and A480) over time (seconds), while 
SAXS data was collected per frame, but lagged 1.05 seconds/frame between the SEC 
elution profile.  
Table 2.15 Buffers used in SAXS studies 
Buffer name Buffer composition 
Kinetic pH 5.5 buffer (for A3B) 50 mM citrate-phosphate pH 5.5, 200 mM NaCl, 2 mM β-
ME, 200 μM DSS, 10% glycerol 
High salt pH 7.4 buffer (for A3B) 50 mM Tris-HCl pH 7.4, 0.5 M NaCl, and 2 mM β-ME, 
10% glycerol 
A3G pH 6 buffer 50 mM phosphate pH 6.0, 200 mM NaCl, 2mM β-ME, 5% 
glycerol, 200 µM Na2EDTA 
 
Raw SAXS data frames were first reduced by intensity normalisation, background 
subtraction, and scattering vector calibration using SCATTERBRAIN 2.82 program 
(http://www.synchrotron.org.au/aussyncbeamlines/saxswaxs/software-saxswaxs). A 
SAXS profile plot was then derived by plotting the normalised integrated intensity of the 
scattering signal against the frame number using CHROMIX (ATSAS 2.8.3 suite 75). The 
frames of interest are averaged and are subtracted from the buffer frames using 
CHROMIX. Then the processed scattering data are transformed into a 1D-scattering 
curve using the PRIMUSQT program from ATSAS 2.8.3 suite 75, where log of scattering 
intensity (log(I)) was plotted against the scattering vector (q) (q = 4πsin(θ/λ), 2θ is the 
scattering angle, and λ is the x-ray wavelength of 1.0332 Å). When data are partially 
resolved they underwent evaluation using singular value decomposition (SVD) and 
evolving factor analysis (EFA) (BioXTAS RAW 105 or US-SOMO HPLC-SAXS module 




data were not resolved, they must undergo deconvolution using Gaussian decomposition 
methodologies through US-SOMO HPLC-SAXS module 31-33. 
Characteristic parameters can be retrieved from the scattering pattern of the samples that 
describe the homogeneity, fold, size, and overall shape of the sample. Several important 
parameters derived include the radius of gyration (Rg, Å), molecular weight (MW, kDa), 
excluded particle volume (Porod volume) (V, Å3), maximum dimension (Dmax, Å), and 
the extrapolated intensity at zero scattering angle (I(0), cm-1) obtained by analysis of the 
scattering curve using several programs that are part of the ATSAS package (programs 
include PRIMUSQT, AUTORG, DATPOROD, and AUTOGNOM) 75. Errors reported 
for parameters refers to a weighted least square fit of the intensity. The scattering curve 
can be compared to generated 1D-scattering curves calculated from high resolution 
structures using either CRYSOL 75 or the FoXS server 74, 226. Envelope dummy atom 
models can additionally be generated using DAMMIF from the pair distribution function 
(P(r)) of the data (ATSAS 2.8.3 suite 75), and superimposed with high resolution 





3. Evaluation of the binding affinity 

























Some of the work reported in this chapter was presented in the conference listed below.  
Barzak, F. M., Harjes S., Filichev, V. V., Harjes, E. Stopping cancer evolution: towards 
understanding of APOBEC3B-DNA interactions. Poster presentation at the 9th Australian and 
New Zealand Magnetic Resonance Society (ANZMAG) conference 2015 held between the 29th of 
November - 3rd of December 2015 at the Copthorne hotel and resort, Paihia, Bay of Islands, New 
Zealand. 
At the time of the research conducted in this chapter there were no available structures of 
A3 proteins in complex with ssDNA, only ligand-free structures 22, 36, 94, 103, 233. Therefore, 
we initially aimed to structurally characterise the A3B-ssDNA complex to understand the 
molecular basis of interactions to provide structurally informed design of drugs that 
specifically target A3B. Reported difficulty in the expression and purification of the full-
length recombinant two-domain A3B prompted the characterisation of the CTD of A3B 
240, as this domain constitutes the deaminase activity 78, 283.  
In the beginning, we focused on producing sufficient quantities of soluble A3BCTD 
proteins to explore the molecular basis of interactions and obtain the structure of the 
A3BCTD-ssDNA complex. Catalytically inactive (on the experimental time scale) A3BCTD 
variants were selected to avoid deamination of ssDNA containing dC during binding 
studies. Substrate oligonucleotide sequences specific for A3B were designed (described 
in section 2.3.1) and evaluated for their binding affinity towards A3BCTD. Initially, 
ssDNA sequences were screened for their binding capability to the purified A3BCTD 
protein variants. Then the chosen oligonucleotide was examined using biophysical 
experiments to understand the binding interactions between the A3BCTD protein and 
ssDNA. In an attempt to characterise the binding location of ssDNA onto the surface of 
the A3BCTD, solution-state NMR was first used to assign the A3BCTD spectrum, then 
chemical shift perturbations were monitored upon titration with ssDNA to potentially 
identify the oligonucleotide’s binding site. However, during this study the crystal 
structures of the A3BCTD and the closely related A3A in complex with ssDNA were 




3.2 Protein expression and purification of A3BCTD variants: A3BCTD-
QM-ΔL3 and A3BCTD-QM-ΔL3-E255A 
A3BCTD variant constructs; A3BCTD-QM-ΔL3 and A3BCTD-QM-ΔL3-E255A, cloned into 
pET24a vector to obtain C-terminally His6-tagged proteins (listed in Table 2.2), were used 
for this study 240. These variants contained four substitution mutations of hydrophobic 
amino acids, situated away from the active-site, to hydrophilic residues (F200S, W228S, 
L230K, F308K), and the removal of the flexible loop 3 (Figure 3.1). The A3BCTD-QM-
ΔL3-E255A variant had an additional modification where the active-site glutamic acid 
(E255A) was replaced with an alanine, making the protein catalytically inactive (Figure 
3.1).  
3.2.1 Transformation of A3BCTD constructs (A3BCTD-QM-ΔL3 and A3BCTD-QM-
ΔL3-E255A) 
Expression of the recombinant A3BCTD variants, A3BCTD-QM-ΔL3 and A3BCTD-QM-
ΔL3-E255A, began by transforming constructs into chemically competent E. coli cells 
(as described in section 2.2.3). The A3BCTD plasmid variants isolated from the 
transformed colonies were run on a 1% agarose gel as described in section 2.2.3.1, 
confirming that an intact plasmid with the expected recombinant plasmid size of 
approximately 6 kb had been obtained (pET24a recombinant plasmid ~ 5.4 kb, A3BCTD 
187-387 amino acid sequence insert 0.6 kb) as shown in Figure 3.2. The isolated plasmids 
were then sequenced using the method described in section 2.2.3.2, confirming that the 
Figure 3.1 A3BCTD variants amino acid sequence used for binding studies.  
A3BCTD residues 187 to 388. A3BCTD-QM-ΔL3 (Quadra Mutant, delta loop 3): F200S, W228S, 
L230K, and F308K, loop 3 deletion. A3BCTD-QM-ΔL3-E255A: F200S, W228S, L230K, and F308K, 
loop 3 deletion, active-site glutamate mutated to alanine (E255A). Constructs kindly provided by 
Assoc. Prof. Hideki Aihara and Prof. Reuben Harris, University of Minnesota 240. 
A3BCTD              --------------PDTFTFNFNNDPLVLRRRQTYLCYEVERLDNGTWVLMDQHMGFLCN 
A3BCTD-QM-∆L3       ------EILRYLMDPDTFTSNFNNDPLVLRRRQTYLCYEVERLDNGTSVKMDQHMGFLCN 
A3BCTD-QM-∆L3-E255A ------EILRYLMDPDTFTSNFNNDPLVLRRRQTYLCYEVERLDNGTSVKMDQHMGFLCN 
                                      *                           * *  
 
A3BCTD              EAKNLLCGFYGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN 
A3BCTD-QM-∆L3       E--------SGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN 
A3BCTD-QM-∆L3-E255A E--------SGRHAALRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQEN                      
                    *********    *  
 
A3BCTD              THVRLRIFAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW 
A3BCTD-QM-∆L3       THVRLRIKAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW 
A3BCTD-QM-∆L3-E255A THVRLRIKAARIYDY-DPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPW 
                          * 
 
A3BCTD              DGLEEHSQALSGRLRAILQNQGN 
A3BCTD-QM-∆L3       DGLEEHSQALSGRLRAILQ---- 
A3BCTD-QM-∆L3-E255A DGLEEHSQALSGRLRAILQ---- 




correct amino acid sequence of the A3BCTD variant was present in the plasmids that were 
isolated. The isolated plasmids were then transformed into a protein-expressing BL21 
(DE3) E. coli strain (Lucigen) as described in section 2.2.4.  
3.2.2 Expression of the A3BCTD constructs (A3BCTD-QM-ΔL3 and A3BCTD-QM-
ΔL3-E255A) 
Initially, small-scale expression trials of the A3BCTD variants, A3BCTD-QM-ΔL3 and 
A3BCTD-QM-ΔL3-E255A, were conducted to assess the level of soluble protein 
production. Note that expression and purification of both variants were carried out but for 
optimisation was conducted on the A3BCTD-QM-ΔL3 variant. The A3BCTD constructs 
were mainly expressed and purified as previously reported 239-240 with minor 
optimisations detailed here. Briefly, the recombinantly transformed A3BCTD culture was 
cultivated in LB medium at 37 °C until OD600 ~ 0.6 (mid-log phase) was established. The 
culture was then supplemented with zinc chloride to a final concentration of 100 µM and 
protein expression induced by IPTG at a final concentration of 0.5 mM, followed by 
incubation at 18 °C overnight as described in section 2.2.4. Examination of the overnight 
cultures on a tricine SDS-PAGE gel stained with Coomassie blue (see materials and 
methods 2.2.7.2), showed that upon IPTG induction an overexpressed protein band 
appears estimated to be around 22 kDa in size (arrow in Figure 3.3). The size of the 
overexpressed protein was consistent with the estimated molecular weight of the A3BCTD 
protein of 23 kDa, and since the protein was only expressed upon activation of the T7 









Figure 3.2 Agarose gel (1% ) of the isolated A3BCTD plasmid variants. 
Lane 1: 1kb plus DNA standard ladder, lane 2: pET24a-A3BCTD-QM-ΔL3, lane 3: pET24a-A3BCTD-




promoter system by IPTG, it was presumed that this A3BCTD protein variant had been 
obtained. 
To confirm the identity of the overexpressed protein attained upon IPTG induction 
(Figure 3.3), mass spectrometry was employed. First, the induced sample was run on a 
tricine SDS-PAGE gel, which was stained with colloidal Coomassie stain and in-gel 
tryptic digest was carried out on the protein band of interest, as outlined in section 2.2.7.3. 
Samples were then run on ESI-QUAD-TOF mass spectrometer and analysed by Mr. 
Trevor Loo (2.2.7.3). Analysis reports with peptides scoring greater than 39 of individual 
ions indicates identity or extensive homology (p<0.05). The protein band of interest had 
four high quality unique peptide hits associated with the A3B C-terminal region 
highlighted in Figure 3.4, with ion scores greater than 39, concluding that the protein band 









kDa         1           2           3        
Figure 3.3 Tricine SDS-PAGE gel (16%) of A3BCTD-QM-ΔL3 protein expression trial.  
Lane 1: SeeBlue Plus2 Pre-stained protein standard ladder, lane 2: uninduced cell culture of A3BCTD-
QM-∆L3, lane 3: induced cell culture of A3BCTD-QM-∆L3 with final concentration of 0.5 mM IPTG.  
Figure 3.4 In-gel tryptic digest mass spectrometry analysis of the A3BCTD-QM-ΔL3 protein 
band. 
A3BCTD-QM-ΔL3 sequence with four unique peptides (29% coverage) identified by mass 
spectrometry. Peptides highlighted with four different colours.  
 
 190                  200                  210                  220                  230                      240          250                 260       
EILR YLMDPDTFTS NFNNDPLVLR RRQTYLCYEV ERLDNGTSVK MDQHMGFLCN E--------S GRHAELRFLD  
                270                 280                    290                   300                 310                320                    330       
LVPSLQLDPA QIYRVTWFIS WSPCFSWGCA GEVRAFLQEN THVRLRIKAA RIYDYDPLYK EALQMLRDAG  
  340                  350                     360                 380                                     




Additional expression trials were conducted to determine if the expressed A3BCTD-QM-
ΔL3 protein construct was soluble. The A3BCTD variant was expressed as described 
earlier (see above), followed by harvesting the cell culture by centrifugation. The cells 
were lysed using a high salt buffer containing 50 mM Tris-HCl pH 7.4, 500 mM NaCl, 
and 2 mM β-ME with 0.5 mg/mL lysozyme, sonicated, then the whole cell lysate was 
pelleted. Assessment of the fractions on tricine SDS PAGE gel revealed that the protein 
was partly soluble; however, a considerable proportion of the protein was insoluble 
remaining in the pellet fraction (see buffer A, Figure 3.5).  
In an attempt to enhance the solubility of the A3BCTD protein, several protein induction 
conditions, such as induction temperature (15 – 25 °C), IPTG concentration (0.2 mM - 1 
mM), and Zn2+ concentration (20 - 100 µM), were trialled. However, no notable 
improvements were obtained. Next, various lysis buffer compositions were trialled to 
determine if they can improve the release of soluble proteins. Upon changes in osmotic 
pressure caused by a decrease in the salt concentration of the lysis buffer from 500 mM 
to 150 mM NaCl, the cells lysed more efficiently leading to a significant improvement in 
the solubility of the protein, seen by the major increase in the band density of the 
supernatant fraction buffer B in comparison to buffer A (Figure 3.5).  
Figure 3.5 Tricine SDS-PAGE (16%) gel of a lysis buffer screen for the extraction of A3B CTD-
QM-∆L3.  
A3B CTD-QM-∆L3 cell culture treated with lysis buffers A-E. Loaded samples: M: SeeBlue Plus2 Pre-
stained protein standard ladder, L: cell lysate at a 1:2 sample to dye ratio, S: supernatant at a 1:1 
sample to dye ratio, P: pellet at a 1:1 sample to dye ratio. Buffer A: 50 mM Tris-HCl pH 7.4, 500 mM 
NaCl, and 2 mM β-ME with 0.5 mg/mL lysozyme, Buffer B: 50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, and 2 mM β-ME with 0.5 mg/mL lysozyme, Buffer C: 50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, and 2 mM β-ME, 0.1 % TWEEN with 0.5 mg/mL lysozyme, Buffer D: 50 mM Tris-HCl, pH 
7.4, 150 mM NaCl, and 2 mM β-ME, 1 mM EDTA with 0.5 mg/mL lysozyme, Buffer E: 50 mM 




Trials to further enhance the efficacy of the lysis buffer by either adding a detergent (0.1% 
TWEEN), a chelating agent (1 mM Na2-EDTA) or switching the buffering agent (50 mM 
HEPES pH 7.5 buffer) were conducted. However, this resulted in no further 
improvements in the proteins’ solubility as observed by the band eluting in the 
supernatant of Buffers C-E in Figure 3.5. Therefore, lysis buffer B with the lower salt 
concentration was selected for future protein extractions.  
3.2.3 Purification of the A3BCTD constructs (A3BCTD-QM-ΔL3 and A3BCTD-QM-
ΔL3-E255A) 
Next, a large scale protein expression of the A3BCTD variants (A3BCTD-QM-ΔL3 and 
A3BCTD-QM-ΔL3-E255A) was carried out, induced, harvested, and the clarified soluble 
cell lysate was obtained for protein purification (as in section 2.2.4). Purification of the 
histidine-tagged A3BCTD proteins (A3BCTD-QM-ΔL3 and A3BCTD- QM-ΔL3-E255A) 
was conducted as described in section 2.2.5. Originally, it was vital to carry out various 
iterations to develop optimum conditions to purify the A3BCTD proteins. The collected 
fractions were analysed by tricine SDS-PAGE revealing that most of the contaminating 
proteins were removed in the initial wash stages observed in lanes 6-8 of Figure 3.6. The 
A3BCTD protein variant specifically bound to the Ni
2+-NTA matrix and eluted from the 
column upon washing with buffer containing higher imidazole concentrations (200-300 
mM), as indicated by the presence of a 22 kDa protein band corresponding to the size of 
the protein of interest in lanes 9-10 of Figure 3.6.  
Figure 3.6 Tricine SDS-PAGE (16%) gel of IMAC protein purification of the A3BCTD-QM-∆L3 
variant. 
Lane 1: SeeBlue Plus2 Pre-stained protein standard ladder, lane 2: cell lysate, lane 3: pellet, lane 4: 
supernatant, lane 5: supernatant flow-through off column, lanes 6-8: buffer wash fractions *, lanes 9-10: 
eluted fractions +. *Wash buffer: 50 mM Tris-HCl pH 7.4, 0.5 M NaCl, 2 mM β-ME, with 10 mM, 50 
mM, or 100 mM imidazole. +Elution buffer: 50 mM Tris-HCl pH 7.4, 0.5 M NaCl, 2 mM β-ME, with 200 













Following IMAC, the fractions collected that contained the A3BCTD were pooled together, 
then dialysed in high salt pH 7.4 buffer to remove residual imidazole. The dialysed sample 
was further purified using SEC-FPLC to remove any contaminating proteins as described 
in section 2.2.5. SEC resulted in the appearance of a single peak eluting after 90 mL of 
buffer flow through as seen in the chromatogram in Figure 3.7. Based on the appearance 
of a single eluting peak during SEC-FPLC purification and its eluting retention volume it 
was confirmed that these A3BCTD variants (A3BCTD-QM-ΔL3 and A3BCTD-QM-ΔL3-
E255A) behaved as monomers. Fractions from the eluted peak were examined by tricine 
SDS-PAGE (2.2.7.2), confirming the presence of a clean A3BCTD band running at 22 kDa. 
The A3BCTD variants discussed in this chapter (A3BCTD-QM-ΔL3, and A3BCTD-QM-
ΔL3-E255A) were successfully purified in high quantities (mg/mL) for use in biophysical 
studies. 
3.3 Examination of the catalytic activity of the purified A3BCTD 
constructs (A3BCTD-QM-ΔL3 and A3BCTD-QM-ΔL3-E255A) using 
an NMR-based activity assay  
A fluorescence-based in vitro deaminase activity assay originally reported that the 
A3BCTD-QM-ΔL3 variant was catalytically active 
240. Using this method described in 
section 2.5.2, our purified A3BCTD-QM-ΔL3 variant was assessed, confirming these 
observations (see appendix Figure 8.2). However, to quantitively characterise the 
Figure 3.7 Size exclusion chromatography showing the protein purification of A3BCTD-QM-∆L3. 
A3BCTD-QM-∆L3 purified through a Superdex 75 10/300 GL column at a flow rate of 0.5 mL/min. 















deamination rate of the A3BCTD enzymes an established NMR-based activity assay was 
used 79, 94 (described in section 2.5.1). This assay monitors the real-time deamination of 
dC (substrate) to dU (product) in ssDNA by exploiting the naturally abundant proton (1H) 
isotope within ssDNA using one-dimensional proton-NMR spectroscopy (1H-NMR). 
Kinetic studies can be conducted by observing the formation of the proton (1H) product 
signal or disappearance of the 1H substrate signal over time. The 1H signal appears as a 
peak (or peaks) at a specific position on the δ scale (in ppm) defined as a chemical shift 
(Figure 3.8).   
The A9C oligonucleotide (5'-AATTCAAAA) was selected for deamination assessment 
by A3BCTD-QM-ΔL3, as it had the best binding capability to A3BCTD (discussed further 
in section 3.4.3). First, 1H-NMR spectra of the substrate oligonucleotide (A9C-oligo, 5'-
AATTCAAAA) and product oligonucleotide (A9U-oligo, 5'-AATTUAAAA) were 
recorded to look for suitable chemical shifts to distinguish between the substrate and the 
product. The H-5 proton doublet signal of dC appears at 5.84 ppm (J = 7.5 Hz), while the 
H-5 proton doublet of dU is present at 5.665 ppm (J = 7.65 Hz) (Figure 3.8A and B i) 
(Table 8.5). Those signals were used in previous studies 79, 94. However, we noted that the 
observed H-5 chemical shift of dU overlapped with another proton signal. The H-5 proton 
doublet of dU appeared to arise within a doublet of doublet signal (between 5.70 – 5.65 
ppm) corresponding to the chemical shift of H-1 of 2'-deoxyadenosine (dA) within the 
sequence. Therefore, an additional region of the spectrum (between 7.43 – 7.32 ppm) was 
utilised as an indicator of cytosine deamination (Figure 3.8A ii and B ii). In this region, a 
doublet signal corresponding to H-4 of 2'-deoxythymidine (dT) is present at 7.41 ppm (J 
= 7.72 Hz), as well as a single peak resultant of H-6 of dA at 7.345 ppm within the A9C-
oligo sequence. Upon deamination the H-4 dT doublet disappears, while the H-6 dA peak 
shifts slightly to 7.345 ppm as indicated using the A9U-oligo (product) standard sequence 




Next, the assay was set up using 1 mM of substrate oligonucleotide (A9C-oligo) 
incubated along with 100 µM of the purified A3BCTD enzyme in a 50 mM citrate-
phosphate pH 7.5 buffer. Examination of the NMR spectrum after 12 hours of conducting 
the reaction showed that there was only a minor conversion of dC to dU, as indicated by 
the appearance of a rather small peak corresponding to H-6 dA (7.345 ppm) (Figure 3.8A 
ii). After incubation overnight (24 hours) only half of dC was converted to dU, as shown 
by a reduction in the H-5 dC doublet and the emergence of the H-5 dU doublet (Figure 
3.8A i). In contrast to the aforementioned study 239, this recombinantly purified A3BCTD-
QM-ΔL3 protein was comparatively inactive as indicated by the slow deamination of the 
Figure 3.8 1D 1H-NMR-based activity assay of the deamination of dC in ssDNA by A3BCTD 
variants over time.  
(A) Assay using A3BCTD-QM-ΔL3, (B) or A3BCTD-QM-ΔL3-E255A. (i) 1H-NMR spectrum 5.85-5.65 
ppm, (ii) 1H-NMR spectrum 7.40-7.30 ppm. Assay setup using 1 mM substrate A9C-oligo (5'-
AATTCAAAA) along with 100 µM A3BCTD in a 50 mM citrate-phosphate, pH 7.5 buffer (50 mM 
citrate-phosphate buffer, 200 mM NaCl, 2 mM β-ME, 200 µM DSS, pH 7.5, with 10% D2O) and 
monitored over 48 hours. Product A9U-oligo (5'-AATTUAAAA). 
(A) 
 (i)                              (ii) 
  
(B) 




oligonucleotide. On the other hand, the recombinantly purified A3BCTD-QM-ΔL3-E255A 
protein led to no chemical shift changes (Figure 3.8B), validating that it is catalytically 
inactive. These A3BCTD variants (A3BCTD-QM-ΔL3 and A3BCTD-QM-ΔL3-E255A) are 
unsuitable for catalytic studies. However, the lack of cytosine deamination is useful for 
evaluating the binding behaviour of A3BCTD to ssDNA to prevent substrate conversion 
during the experiment.  
3.4 Binding affinity of ligands to A3BCTD variants examined by protein 
thermal stability 
The protein’s thermal stability was examined using an established fluorescence-based 
thermal shift assay 93 to evaluate the biomolecular interactions between A3BCTD proteins 
and ligands (ssDNA in our case) as described in section 2.4.1. This assay relies on 
monitoring the fluorescent signal upon thermal denaturation of the protein. As the protein 
unfolds due to heat exposure, a fluorescent dye (SYPRO® orange dye, BioRad) binds 
non-specifically to the exposed hydrophobic regions of the protein, which leads to an 
increase in the fluorescent signal until the protein is completely denatured. The protein’s 
melting temperature (Tm) is derived from the thermal denaturation curve where the protein 
transitions between folded and unfolded state, defined as the midpoint (Figure 3.9). An 
increase in Tm upon the presence of a ligand is an indication of the formation of a complex 
that stabilises the protein’s conformational state.  
To promote formation of an A3BCTD-ssDNA complex several conditions were employed. 
First, the experiment was setup using 100 µM oligonucleotide to 20 µM protein 59. 
Second, a mildly acidic buffer was utilised (50 mM citrate-phosphate buffer at pH 5.5, 
containing 200 mM NaCl, 2 mM β-ME, and 200 µM DSS) to favour formation of 
electrostatic interactions and hydrogen bonding between the ssDNA phosphate backbone 
and the amino acids in A3BCTD loop regions. Lastly, catalytically inactive or weakly 
inactive A3BCTD proteins (A3BCTD-QM-ΔL3 and A3BCTD-QM-ΔL3-E255A, assessed 
earlier in section 3.3) were used to prevent the catalysis of the ssDNA substrate during 
the experiment. Assays were setup as outlined in section 2.4.1. Thermal shift experiments 
(Figure 3.9 - Figure 3.12) showed that the presence of substrate ssDNA led to a small 
increase in the melting temperature (ΔTm) of the A3BCTD (maximum ΔTm ~ 2.0 °C). In 
contrast, S. Harjes et al 93 reported that the catalytically inactive A3A enzyme (A3A-




~ 4.3 °C using the same method. This implied that the A3BCTD binds ssDNA with a 
relatively weak affinity in comparison to A3A 93, 135. From the structure, it was found that 
loop 3 interacts with the phosphate backbone of the ssDNA +1 nucleotide through a 
hydrogen bond to stabilise the oligonucleotide’s binding conformation 93, 239. Therefore, 
deletion of loop 3 in our A3BCTD variants may account for this observed weaker binding 
affinity. Moreover, in contrast to the ligand-free A3A and ligand-free A3GCTD structures, 
the ligand-free A3BCTD has a tightly closed active site formed through stacking 
interactions between the side chains in loops 1 and 7 that require comprehensive 
rearrangements to bind ssDNA, thereby leading to a weaker binding affinity 239-240. 
3.4.1 Catalytic glutamic acid determines binding of ssDNA to A3 
 To investigate A3 enzymes bound to ssDNA, our catalytically inactive (under our 
conditions) A3BCTD variants were used to prevent complications of catalysis 
129, 239. 
Kouno et al, showed that the replacement of the catalytic glutamic acid with alanine 
causes an inactive A3 enzyme, but does not alter the shape of the A3 active-site. The 
crystal structure showed that in place of the glutamate side chain a water molecule was 
present, suggesting that the active-site would still be accessible to bind to the 
oligonucleotide 129. Binding assays were performed using two A3BCTD variants, A3BCTD-
QM-ΔL3 and A3BCTD-QM-ΔL3-E255A, that differed by a single point mutation (E255A) 
to assess the importance of the catalytic glutamate (E255) in binding ssDNA. The 
proteins’ thermal stability was evaluated as described earlier (see section 3.4).  
Figure 3.9 Thermal denaturation profiles of A3BCTD variants.  
Thermal shift assay of (A) A3BCTD-QM-ΔL3-E255A and (B) A3BCTD-QM-ΔL3 in the presence of buffer 
(black), dU-containing ssDNA (5'-ATTTUATTT, magenta), dC-containing ssDNA (5'-ATTTCATTT, 
blue) run in a 50 mM citrate-phosphate, pH 5.5 buffer containing 10X SYPRO® orange dye (BioRad). 
Data were normalised to percentage of fluorescence intensity plotted against temperature, to calculate the 
Tm midpoint.  





At first glance, the presence of ssDNA leads to an observable increase in the melting 
temperature (Tm) of the A3BCTD variants, but more prominently for the A3BCTD-QM-ΔL3 
derivative (Figure 3.9). More specifically, the substrate oligonucleotide containing dC 
had a slightly higher change in the melting temperature (ΔTm) than the product 
oligonucleotide containing dU, as a direct consequence of a lower binding affinity 
towards the product of deamination 23, 93, 245. On closer inspection, we showed that the 
substrate binds considerably tighter to the A3BCTD-QM-ΔL3 (ΔTm = 1.73 ± 0.21 °C, mean 
± SD) (Figure 3.9B) than to the A3BCTD-QM-ΔL3-E255A (ΔTm = 0.30 ± 0.05 °C, mean 
± SD) (Figure 3.9A).  Moreover, the A3BCTD-QM-ΔL3-E255A Tm values (48.9 - 49.1 °C) 
were comparatively lower than the A3BCTD-QM-ΔL3 derivative (53.9 - 55.6 °C) with the 
intact catalytic glutamate in the active site. This indicates that the catalytic glutamate 
(E255) is essential in forming specific interactions with the oligonucleotide. As well as 
causing a decrease in thermal stability of the protein, the absence of the catalytic 
glutamate causes the loss of specific hydrogen bond interactions that lead to the lack of 
deamination of the target dC, consistent with the cytosine deamination model where 
glutamic acid initiates deamination by protonating the N3 of cytosine 100, 120, 188. These 
results highlight the significance of having an intact catalytic glutamate in binding to 
ssDNA.   
3.4.2 Binding of dZ-modified oligonucleotides to inactive A3BCTD variants     
It was assumed that cytosine analogues would mimic the transition state of cytosine 
deamination and therefore bind to A3 enzymes with a stronger affinity than the substrate 
(dC) or product (dU), by converting the activation energy required for catalysis into static 
binding energy. Therefore, a chemically modified oligonucleotide containing 2'-
deoxyzebularine (dZ) (see Figure 3.10A) in place of the target cytosine (5'-
ATTTdZATTT, see 2.3.2) was assessed to determine its binding capability to our inactive 
A3BCTD variants, using the thermal shift assay (as described in 3.4.1). This assay showed 
that the modified oligo containing dZ bound better to the A3BCTD-QM-ΔL3 protein than 
did the substrate oligo containing dC as reflected by an increase in the stability of the 
protein (ΔTm = 0.72 ± 0.10 °C) (Figure 3.11). This result is consistent with cytosine 
analouges mimicking the transition state or an intermediate of the cytosine deamination 
reaction. The lack of the catalytic glutamate (E255) resulted in a poor binding affinity of 




containing oligos. Therefore, the A3BCTD-QM-ΔL3 variant was selected for all further 
binding studies. 
Figure 3.11 Binding capability of ssDNA to A3BCTD variants using thermal shift assay. 
A3BCTD‑QM-ΔL3 (green) and A3BCTD-QM-ΔL3-E255A (red) in the presence of a dU-containing 
oligo (5'-ATTTUATTT), dC-containing oligo (5'-ATTTCATTT), or dZ-containing oligo (5'-
ATTTdZATTT). The assay was conducted using 20 μM protein with 100 μM oligo in the 50 mM 
citrate-phosphate pH 5.5 buffer (50 mM citrate-phosphate, 200 mM NaCl, 2 mM β-ME, and 200 μM 
DSS, pH 5.5). Confidence intervals (95%) are shown as error bars. ΔTm was calculated by taking the 






Figure 3.10 Proposed inhibitory mechanism of dZ-containing oligo.  
(A) dZ-modified oligonucleotide as potential inhibitor of cytosine deamination, (B) dZ through its 






These results illustrate that the catalytic glutamate is essential for binding dZ as well as 
dC-containing oligos. Therefore, the protonation of N3 of the dZ by the catalytic 
glutamate must be a very significant initial step in the mechanism. The protonation 
renders C4 to become electrophilic and more prone to the nucleophilic addition of a water 
molecule (as hydroxide). Therefore, this nucleophilic attack on C4 would transform dZ 
into a stable tetrahedral transition state of cytosine deamination permitting dZ to remain 
bound in the A3 active site as we illustrate in Figure 3.10. The potential of dZ-containing 
oligos to bind to the enzyme with a much higher affinity than the dC-containing oligo 
suggests that the dZ-containing oligos can inhibit the activity of A3BCTD (later described 
in chapter 4) and be further used for structural studies (described in chapter 6). 
3.4.3 Finding oligonucleotide sequence for further A3BCTD-QM-ΔL3-binding 
studies      
Initially, short oligonucleotide sequences containing A3B’s preferred deamination motif 
TCA were designed based on previous studies 36-37, 47, 78, 94, 157, 172. Structural studies noted 
that residues surrounding the active site form interactions with nucleotides flanking the 
preferred dinucleotide deamination motif (5'-TC) 239-240, thereby influencing the A3’s 
substrate recognition and deamination selectivity 175 (described in section 1.6.4). 
Therefore, several sequences were designed with various nucleotides flanking the TCA 
motif (see Table 2.13) and assessed using the fluorescence-based thermal shift assay for 
their capability to bind to A3BCTD-QM-ΔL3.  
As observed earlier (Figure 3.9), a noticeable increase in the protein’s Tm occurs upon 
binding of an oligonucleotide to the A3BCTD-QM-ΔL3 (0.7-2.0 °C, Figure 3.12). 
Nevertheless, this assay displayed that the substrate-bound enzyme (dC) had a slightly 
higher change in the melting temperature in comparison to product-bound enzyme (dU), 
consistent with previous reports of better substrate binding to A3 enzymes 23, 93, 239, 245. 
Structural studies have implied that only upon the presence of oligonucleotides with dC 
that sequence-specific interactions with the protein occur, allowing for the 
oligonucleotide to fit deeper into the enzyme’s active-site pocket, which may justify the 
stronger preference of dC-containing oligonucleotides 93, 239.  
Although wild-type A3BCTD was reported to have a slight (1.4 fold) preference for an 
adenine in the -2 position (5'-ATCA) over a thymidine (5'-TTCA) 37, 47, 157, A3BCTD-QM-




oligonucleotide. The A9C-oligo (5'-AATTCAAAA) resulted in the largest ΔTm of 1.96 ± 
0.14 °C, followed closely by the 9merC-oligo (5'-ATTTCATTT) with a ΔTm of 1.73 ± 
0.06 °C, whereas the ATC oligonucleotide containing an adenine in the -2 position (5'-
ATCA) resulted in a reduction in the protein’s ΔTm of 1.03± 0.08 °C (Figure 3.12). 
However, our outcome is consistent with the ssDNA bound A3BCTD (A3BCTD-QM-ΔL3-
AL1swap-E255A) crystal structure, which showed that an arginine (R211) from loop 1 
interacts with the backbone phosphate of a thymidine in the -2 position, whilst retaining 
the U-shaped DNA binding conformation 239-240 (described in section 1.6.4). Based on 
this assay, the A9C-oligo had the highest binding affinity for A3BCTD-QM-ΔL3. 
Therefore, this oligonucleotide was selected for further experiments.  
Moreover, to directly characterise the molecular interaction between A3BCTD-QM-ΔL3 
and the substrate oligonucleotide isothermal titration calorimetry (ITC) was utilised. ITC 
hinges on assessment of fluctuations in heat that is released or absorbed upon the 
occurrence of a binding interaction in a solution. The experiment was setup using 100 
µM A3BCTD-QM-ΔL3 titrated with 300 µM substrate oligo (A9C-oligo) in the 50 mM 
Figure 3.12 Oligonucleotide binding capability to A3BCTD assessed using a thermal shift 
fluorescense assay.  
Change of melting temperature (ΔTm) of A3BCTD-QM-ΔL3 calculated from the difference between the 
melting temperature (Tm) of the protein in presence of ssDNA and Tm of the protein in the buffer 
(control). Assays were setup using 20 μM A3BCTD-QM-ΔL3 protein along with 100 μM ssDNA 
oligonucleotides in 50 mM citrate-phosphate pH 5.5 buffer (50 mM citrate-phosphate buffer, 200 mM 
NaCl, 2 mM β-ME, 200 µM DSS, pH 5.5) containing 10X SYPRO® orange dye (BioRad). 


















citrate-phosphate pH 5.5 buffer (refer to section 2.4.2). However, under these conditions 
the determination of a very weak binding interaction between the enzyme and substrate 
oligonucleotide was difficult. Characterising this weak binding event by ITC would 
require much higher concentrations of reactants, which is not feasible for the protein as it 
is inclined to precipitation at increased concentrations.  
3.5 NMR structural studies of A3BCTD-QM-ΔL3   
To gain insight into the molecular mechanisms underlying the binding of ssDNA to the 
A3BCTD-QM-ΔL3 nuclear magnetic resonance (NMR) spectroscopy was used. NMR is a 
distinctive technique that reveals the atomic structure of proteins in solution and their 
dynamic behaviours. This technique exploits the fact that certain atomic nuclei, such as 
1H, 15N, and 13C isotopes, are magnetic when placed in a magnetic field. One-dimensional 
proton-NMR (1D 1H-NMR) examines with high sensitivity the naturally abundant proton 
(1H) isotope nuclei within molecules. However, in comparison to small-molecule 
compounds, complicated overlapping signals arise in 1D 1H-NMR of proteins due to a 
high number of protons leading to complex spectra analysis. Therefore, multidimensional 
(2D and 3D) NMR experiments are used to resolve the overlapping signals. 
Multidimensional experiments rely on the transfer of magnetisation energy between 
nuclei, providing specific correlations between nuclei. To enable these experiments, 
proteins are labelled with isotope nuclei (13C, and 15N) (refer to 2.2.6) to observe chemical 
shifts in NMR spectra.  
3.5.1 Uniform isotopically-labelled A3BCTD-QM-ΔL3 protein 
Proteins are naturally abundant with proton (1H) isotope nuclei, but to enable 
multidimensional NMR experiments proteins are isotopically labelled. Proteins are 
expressed in minimal medium artificially enriched with an isotope nucleus of interest. 
The A3BCTD-QM-ΔL3 variant was prepared in minimal medium enriched with either 
15N 
isotope to produce single-labelled protein (15N-A3BCTD-QM-ΔL3) for use in 2D NMR 
experiments, or with both 15N and 13C isotopes to obtain double-labelled protein (15N,13C-
A3BCTD-QM-ΔL3) for use in 3D-NMR experiments (refer to 2.2.6).    
Initial expression of the isotope-labelled A3BCTD-QM-ΔL3 protein in minimal medium 
led to very poor protein yields, in contrast to expression in the nutrient rich LB medium, 
which results in high protein yields (Section 3.2 and Figure 3.6). To obtain high protein 




conditions were assessed. We mainly found that induction of protein expression during 
the early growth phase of cells (OD600 between 0.3-0.4) led to a modest improvement in 
the production of the labelled A3BCTD-QM-ΔL3 protein. Additionally, it was noted that 
a decrease in the pH occurs during cell growth in minimal medium as a consequence of 
the accumulation of acidic by-products and deficiency of buffering capacity. This pH 
drop may potentially cause cell stress and consequently the observed decrease in the 
protein yield as found in previous studies 5, 248. Therefore, to maintain the buffering 
capacity of the minimal medium during cell growth, the pH of the minimal medium was 
adjusted to pH 7.5 with 1 M NaOH before culture inoculation and just before induction 
of the protein. These adjustments led to a significant increase in the expression of the 
isotopically labelled A3BCTD-QM-ΔL3 variant as shown in lanes 4 and 8-10 in Figure 
3.13. Using these conditions, the labelled A3BCTD-QM-ΔL3 protein was expressed in a 
large-scale setup (outlined in section 2.2.6), for use in multidimensional NMR 
experiments.    
3.5.2 2D 1H,15N-HSQC spectrum of A3BCTD-QM-ΔL3 
At first, a 1D 1H-NMR spectrum of A3BCTD-QM-ΔL3 was recorded to test the proton 
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Figure 3.13 Tricine SDS-PAGE (16%) gel of purification of 15N, 13C-A3BCTD-QM-∆L3.  
Lane 1: SeeBlue Plus2 Pre-stained protein standard ladder, lane 2: unlabelled A3BCTD-QM-ΔL3 as 
control, lane 3: pellet, Lane 4; supernatant, lanes 5-7: buffer wash fractions *, lanes 8-9: eluted 
fractions +, lane 10: eluted SEC fraction X. *Wash buffer: 50 mM Tris-HCl pH 7.4, 0.5 M NaCl, 2 mM 
β-ME, with either 10 mM, 20 mM, or 50 mM imidazole. +Elution buffer: 50 mM Tris-HCl pH 7.4, 0.5 
M NaCl, 2 mM β-ME, with either 200 mM, or 300 mM imidazole. XSEC buffer: 50 mM Tris-HCl pH 





high-resolution NMR experiments. Next, a 2D 1H,15N-heteronuclear single quantum 
coherence (1H,15N-HSQC) spectrum was acquired to assess the overall quality of the 
protein as described in section 2.6.1. Each cross peak (resonance) represents the 
correlation between the proton nuclei directly bound to the nitrogen nuclei (amide bond) 
and can be assigned to a particular amino acid residue in the protein.  
We expected to observe 187 amide proton resonances, which constitute the amino acids 
of A3BCTD-QM-ΔL3 excluding 9 prolines (which do not contain amide protons), along 
with six amino acids of the histidine-tag (His6). The spectrum showed that the protein 
contained the approximate correct number of cross peaks (Figure 3.14). In addition, the 
spectrum indicated that 15N-A3BCTD-QM-ΔL3 was well-folded, with generally 
distinguished and well-dispersed resonances, apart from several overlapped resonances 
shown in Figure 3.14. To be able to assign the resonances of the HSQC spectrum 3D-








Figure 3.14 1H,15N-HSQC of the 15N-A3BCTD-QM-ΔL3.  
700 MHz NMR spectrum of 350 µM of 15N-A3BCTD-QM-ΔL3 in high salt pH 7.4 buffer (500 mM 
NaCl, 50 mM Tris-HCl pH 7.4, 5 mM β-ME, 10% D2O) at 298 K. Each peak in the spectrum 
represents a bound N-H pair corresponding to an amino acid residue of the protein. Axes correspond 
to chemical shifts of 1H and 15N in ppm. Map in top left corner represents pattern of 1H-15N 









3.5.3 Assignment of A3BCTD-QM-ΔL3 using 3D-NMR experiments 
At the time of this study only the single-domain A3A NMR structure was available 36. 
Based on the 89 % sequence identity between A3A and A3BCTD seen in Figure 3.15, the 
A3A assignment was utilised as a starting point for the assignment of the A3BCTD variant 
resonances.  
Nonetheless, to enable the assignment of the protein backbone, numerous triple-
resonance (3D) NMR experiments were conducted (detailed in Table 8.1). These 
experiments provide sequential connectivities (1H, 13C, 15N) between residues by directly 
transferring magnetisation over the peptide bond and are named accordingly based on the 
magnetisation path between the nuclei. Experiments were carried out using purified 
double-labelled 15N, 13C-A3BCTD-QM-ΔL3 as described in the method 2.2.6. Assignment 
was conducted by Dr. Elena Harjes using the collected 3D-NMR spectra and based on 
the published A3A assignment.  
HNCO and HN(CA)CO NMR spectra were first collected to obtain CO chemical shifts 
that aid in the prediction of the secondary structure and the protein backbone. The highly 
sensitive HNCO experiment produced a relatively good spectrum; however, the 
HN(CA)CO spectrum was unable to be collected. As both these spectra were required in 
conjunction, the residue connectivities were unable to be resolved. Next, an HNCA 
spectrum was acquired resulting in a comparatively good spectrum. An HNCA 
experiment transfers the magnetisation between HN and CA of the same and preceding 
amino acid and therefore is useful for the assignment of the protein’s backbone. To further 
resolve degenerate resonance frequencies two complementary experiments, HNCACB 
Figure 3.15 Sequence alignment of A3A and A3BCTD. 
Alignment of the amino acids of the single domain A3A and the C-terminal domain of A3B using 





and CBCA(CO)NH, were recorded to provide sequential connectivities of the resonances. 
However, owing to the long acquisition period (over 5 days) some protein precipitation 
occurred resulting in poor quality spectra. Despite this, these spectra were still able to 
provide some information that supported the assignment of the protein backbone.  
The combination of the triple resonance NMR experiments and NOESY spectrum with 
the short mixing time facilitated the assignment of nearly all the backbone amide signals 
(175 out of the 187 observable), as well as most of the hydrogens linked to the alpha 
carbons and side chain (>70%) of A3BCTD-QM-ΔL3 as shown in Figure 3.16 and listed 
in Table 8.1.  
During this study, the NMR solution state structure of A3BCTD-Wt 
37 and the crystal 
structure of an A3BCTD variant 
240 were published. Therefore, we did not proceed with 
structure determination of our ligand-free A3BCTD-QM-ΔL3, instead choosing to focus 








Figure 3.16 A3BCTD-QM-ΔL3 assigned 1H,15N-HSQC spectrum.  
3D-NMR experiments conducted for assignment of the spectrum using 350 µM of 15N,13C-A3BCTD-
QM-ΔL3 in high salt pH 7.4 buffer (500 mM NaCl, 50 mM Tris-HCl pH 7.4, 5 mM β-ME, 10% D2O) 
at 298 K. Assignments of the 1H,15N-HSQC spectrum resonances indicated with the name and number 









3.5.4 Chemical shift perturbations to identify ssDNA binding site in A3BCTD-QM-
ΔL3  
As chemical shifts are sensitive to the local electronic environment of the nucleus, 
chemical shift perturbation experiments can be utilised to identify the location and affinity 
of a ligand for a protein. Exploiting 1H,15N-HSQC experiments, chemical shift changes 
can be monitored upon the addition of increasing amounts of ligand to protein. These 
changes give an indication of residues that may be involved in interactions between the 
ligand and protein, allowing for the identification of the binding site.  
In attempt to study the binding of ssDNA to A3BCTD-QM-ΔL3, samples were setup in the 
previously mentioned 50 mM citrate-phosphate pH 5.5 buffer (50 mM citrate-phosphate 
buffer, 200 mM NaCl, 2 mM β-ME, and 200 µM DSS, pH 5.5, 10% D2O) to entice 
interactions between the protein and ssDNA. Initially, a 1H,15N HSQC spectrum of 250 
µM 15N-A3BCTD-QM-ΔL3 was compared to spectra of the protein titrated with varying 
amounts of the A9C-oligo (5'-AATTCAAAA) in the pH 5.5 buffer, as described in 
section 2.4.3. However, assessment of the spectra found that upon titration of the protein 
with increasing amounts of oligonucleotide the majority of the peaks shifted in one 
direction. This was presumed to be caused by the addition of large amounts of DNA, 
leading to changes in the pH of the solution as a consequence of the negative charges on 
the DNA phosphates. Hence, the protein and oligonucleotide were dialysed in a matched 
buffer, and the pH of the sample was monitored following data acquisition to ensure that 
changes in cross-peaks in the NMR spectra occur only as a result of the addition of ssDNA 
to the protein.  
Using this method, we trialled titration of the A3BCTD-QM-ΔL3 with A9C-oligo at a 1 to 
5 and a 1 to 20 ratio. This resulted in a few signals shifting (Figure 3.17), which was a 
good indication that the ssDNA was bound to the protein in a pH-controlled environment. 
Determining the surface where the  ssDNA binds to the protein and its binding affinity 
required further titrations with a range of substrate concentrations. However, during this 
study the structure of ssDNA bound to an inactive A3BCTD variant (A3BCTD-QM-ΔL3-
AL1swap-E255A) was published 37, 239. So, the study then focused on the evaluation of 
A3B inhibitors. Nevertheless, the assignment obtained for our A3BCTD-QM-ΔL3 variant 





We first purified catalytically inactive (on the time scale of our experiments) A3BCTD 
variants (A3BCTD-QM-ΔL3 and A3BCTD-QM-ΔL3-E255A) for the assessment of the 
binding affinity of ssDNA sequences and to prevent complications of cytosine 
deamination during a reaction. One key finding indicated that the catalytic glutamate 
(E255) within the A3 enzymes’ active site was critical for binding ssDNA, in particular 
dZ- or dC-containing oligos. Furthermore, the presence of this glutamate resulted in a 
higher binding affinity towards the dZ cytosine analogue over the dC substrate, indicating 
that dZ would mimic the transition state or an intermediate in the cytosine deamination 
reaction and potentially inhibit the activity of the A3BCTD. From these results, we 
proposed the A3 inhibition mechanism by dZ, whereby the essential E255 would initiate 
the reaction by protonating N3 of dZ resulting in an electrophilic C4 which can be 
attacked by a water molecule. This effectively would convert the dZ into a rigid 
tetrahedral transition state of cytosine deamination that would bind tighter in the the active 
Figure 3.17 1H,15N-HSQC spectra overlay of a 15N-A3BCTD-QM-ΔL3 spectrum against a 15N-
A3BCTD-QM-ΔL3 titrated with A9C-oligo.  
1H,15N-HSQC 700 MHz spectrum of 250 µM 15N-A3BCTD-QM-ΔL3 (blue) titrated with A9C-oligo 
(5'-AATTCAAAA) at a 1:20 ratio (red) (protein to oligonucleotide) in a 50 mM citrate-phosphate pH 
5.5 buffer (50 mM citrate-phosphate buffer, 200 mM NaCl, 2 mM β-ME, and 200 µM DSS, pH 5.5, 











site than the substrate, as observed in our thermal shift experiments, and effectively inhibit 
the catalytic activity. 
Therefore, the A3BCTD-QM-ΔL3 variant with the intact catalytic glutamate was used for 
out binding studies. Using NMR spectroscopy, we assigned the resonances of the ligand-
free A3BCTD-QM-ΔL3, but as ligand-free A3BCTD structures 
37, 240 became available we 
focused on identifying the binding site and affinity of substrate oligonucleotides to our 
inactive A3BCTD variant using chemical shift perturbations. From this experiment we 
identified that the ssDNA bound to the protein, though further assessment using substrate 
ssDNA was not continued as the structures of inactive A3BCTD in complex with ssDNA 
were published 37, 239. Using the thermal shift assay and ITC, we found that the inactive 
A3BCTD had a very weak binding affinity for ssDNA. As binding was not the best 
indicator of the inhibitory potential of the cytosine analogue-containing ssDNA using an 
inactive A3BCTD, the study moved its focus to directly evaluate the inhibition of 
catalytically active A3BCTD by our modified-oligonucleotides using an 
1H-NMR based 





4. Inhibition of APOBEC3B 
























The majority of the work reported in this chapter was incorporated in the following two 
published journal articles:  
1) Kvach, M. V., Barzak, F. M., Harjes, S., Schares, H. A., Jameson, G. B., Ayoub, A. M., Moorthy, 
R., Aihara, H., Harris, R. S., Filichev, V., Harki, D. A., and Harjes, E. Inhibiting APOBEC3 
activity with single-stranded DNA containing 2'-deoxyzebularine analogues. Biochemistry 2019, 
58 (5), 391- 400.   
doi: 10.1021/acs.biochem.8b00858. 135. 
Joint first author. In this article, I expressed and purified all the A3BCTD variant enzymes (A3BCTD-
QM-ΔL3, A3BCTD-QM-ΔL3-E255A, A3BCTD-QM-ΔL3-AL1swap, and A3BCTD-DM). Applying 
these enzymes, I performed thermal shift assays and ITC experiments to assess the binding affinity 
of dC- and dZ-containing-ssDNA towards the A3BCTD enzymes. I conducted 1H-NMR based 
activity assays, characterising the kinetic deamination activity of the A3BCTD variants on substrate 
oligonucleotide (Oligo-2). In addition, I characterised the A3BCTD enzymes’ inhibition mode and 
inhibition potency against our dZ-containing oligonucleotide using a 1H-NMR based inhibition 
assay. I performed all analysis of the derived data.  
2) Kvach, M. V., Barzak, F. M., Harjes, S., Schares, H. A., Kurup, H. M., Jones, K. F., Sutton, L., 
Donahue, J., D’Aquila, R. T., Jameson, G. B., Harki, D. A., Krause, K. L., Harjes, E., and Filichev 
V. Differential inhibition of APOBEC3 DNA‐mutator isozymes by fluoro‐ and non‐fluoro‐
substituted 2'‐deoxyzebularine embedded in single‐stranded DNA. ChemBioChem 2020, 21 (7), 
1028-1035. doi.org/10.1002/cbic.201900505 136. 
Joint first author. In this article, I expressed and purified the catalytically active A3BCTD variant 
enzymes (A3BCTD-AL1 and A3BCTD-DM). I quantitatively screened our modified oligonucleotides 
(3dadZ-oligo, 3dadU-oligo, dZ-oligo, and 5FdZ-oligo) against the deamination activity of 
A3BCTD-AL1 to assess their inhibitory potential by using the 1H-NMR based inhibition assay. 
From this screen the 5FdZ-oligo was identified as a new inhibitor, for which I characterised its 
inhibition constant against A3BCTD-AL1 using the 1H-NMR based inhibition assay. I preformed 
all analysis of the derived data. 
The work reported in this chapter was also presented in the conference listed below.  
Barzak, F. M., Kvach, M. V, Harjes S., Jameson G.B, Aihara, H., Harris R. S., Harki, D. A., 
Filichev, V. V., Harjes, E. DNA-based inhibitors of the human APOBEC3B DNA cytosine 
deaminase. Invited oral presentation at ComBio2018 held between the 23rd - 26th of September 





Earlier studies reported several small molecule inhibitors of A3G 151, 196. However, so far 
no selective inhibitors have been reported for the tumour-promoting A3B (and A3A). 
Therefore, modified oligonucleotides, in which cytosine analogues known to inhibit the 
closely related CDA were incorporated in place of the target dC, were synthesised and 
evaluated for their inhibitory potential of the A3BCTD.   
This chapter first describes the production and purification of catalytically active A3BCTD 
constructs. The Michaelis-Menten constants of the rate of deamination on a substrate 
oligonucleotide by active A3BCTD variants were then characterised using a 1D-NMR 
activity assay 79, 94. Using this assay, chemically modified ssDNAs were screened for their 
inhibitory potential on A3BCTD. Two modified oligos showed significant inhibition of the 
A3BCTD catalytic activity. Qualitative revaluation of these ssDNA-containing transition-
state analogues against active A3BCTD variants showed that these modified oligos had low 
micromolar inhibition constants. These oligonucleotides constitute the first substrate-like 
A3 inhibitors. 
4.2 Protein expression and purification of A3BCTD variants: A3BCTD-
QM-ΔL3-AL1swap and A3BCTD-DM  
To investigate the potency of the chemically modified ssDNA-based inhibitors against 
the A3B enzyme, catalytically active A3BCTD enzymes were required. Since wild-type 
A3BCTD was unable to be expressed and purified effectively, catalytically active A3BCTD 
derivatives were utilised, which were described by Shi et al 240.  
The A3BCTD-QM-ΔL3-AL1swap variant (for simplicity referred to as A3BCTD-AL1 in 
this chapter) contained four substitution mutations (F200S, W228S, L230K, F308K), the 
removal of loop 3, and the transplant of loop 1 from A3A, as shown in Figure 4.1. The 
SUMO-A3BCTD-DM variant had two mutations (L230K and F308K) away from the 
active-site displayed in Figure 4.1 and had a His6-SUMO fusion protein (not shown in 




4.2.1 Expression of A3BCTD variants (A3BCTD-QM-ΔL3-AL1swap and A3BCTD-
DM) 
The active A3BCTD plasmid variants, pET24a-A3BCTD-QM-ΔL3-AL1swap and pE-
SUMO-A3BCTD-DM (acquired from Assoc. Prof. Hideki Aihara and Prof. Reuben Harris, 
University of Minnesota) 240, were expressed in a similar manner to our inactive A3BCTD 
proteins described earlier (see section 3.2). Briefly, the plasmids were transformed into 
chemically competent E. coli cells, before being isolated, and sequenced confirming 
inserts (refer to 2.2). The isolated plasmids were then visualised on an agarose gel (Figure 
4.2).  
The presence of a band in lane 2 that migrated at around 6.4 kb for the putative SUMO-
A3BCTD-DM plasmid, and in lane 3 the band present at around 6 kb for the pET24a-
A3BCTD-QM-ΔL3-AL1swap plasmid were consistent with the overall size of the plasmid 
with the A3BCTD insert (pET24a plasmid ~ 5.4 kb, pE-SUMO plasmid ~ 5.7 kb, A3BCTD 
insert ~ 0.6 kb).  
 
Figure 4.1 A3BCTD variants amino acid sequence used for deamination assays.  
Amino acid sequence of the wild-type A3BCTD residues 187 to 388. A3BCTD variants are A3BCTD-DM 
(L230K and F308K) and A3BCTD-QM-ΔL3-AL1swap (F200S, W228S, L230K, and F308K, loop 3 
deletion, loop 1 from A3A) 240. Asterisks represents the variations and modifications in comparison to 




These A3BCTD plasmids were first expressed in a BL21(DE3) E. coli strain in a small-
scale trial as described in the previous chapter (see section 3.2.2). However, during the 
incubation period the cells ceased to grow exponentially (mid-log phase), which was 
attributed to be a consequence of cell toxicity caused by leaky expression of the 
catalytically active A3BCTD leading to mutagenesis of the bacterial DNA. Therefore, the 
BL21(DE3) E. coli derivatives (OverExpress; C41(DE3), C43(DE3), C41(DE3) pLysS, 
and C43(DE3) pLysS cells) that tolerate toxic proteins by minimising background 
expression were screened. We found that the C41(DE3) pLysS E. coli strain was the most 
suitable at expressing the active A3BCTD.  
Further optimisations were conducted to improve the protein solubility. First, the 
incubation temperature was lowered from 37 °C to 25 °C, then protein expression was 
induced at an earlier OD600 of 0.3 to limit solubility issues. It can be seen on the SDS-
PAGE gel that only upon IPTG induction does an additional band appear implying that 
the A3BCTD constructs are expressed. A band present with a size of approximately 22 kDa 
corresponded to the A3BCTD-AL1 protein, seen in lane 3 in Figure 4.3A. The dense band 
corresponding to the fusion SUMO-A3BCTD-DM protein migrated at around 38 kDa 
(6XHis-SUMO is 16 kDa and A3BCTD-DM is 22 kDa) (observed in Figure 4.3B).  











Figure 4.2 Agarose gel (1%) of the isolated A3BCTD plasmid variants.  
Lane 1: 1kb plus DNA standard ladder, lane 2: pE-SUMO-A3BCTD-DM plasmid isolate, lane 3: 




In addition to the appearance of bands following induction, the proteins’ identities were 
validated using mass spectrometry as described in an earlier chapter (see section 3.2.2). 
Noticeably, the SUMO-A3BCTD-DM protein was expressed in higher concentrations in 
comparison to the A3BCTD-AL1 protein as seen by a higher density of the protein band 
(Figure 4.3), which may be associated with the slightly lower deamination activity of the 
A3BCTD-DM protein in comparison to the other construct, as reported 
240. 
4.2.2 Purification of A3BCTD variants (A3BCTD-QM-ΔL3-AL1swap and A3BCTD-
DM) 
Using the optimised conditions discussed earlier (refer to section 3.2.2), large-scale 
productions of the histidine-tagged active A3BCTD proteins (SUMO-A3BCTD-DM and 
A3BCTD-QM-ΔL3-AL1swap) were conducted. The collected protein fractions from 
IMAC were visualised on SDS-PAGE gels, showing that the proteins of interest 
(A3BCTD) had eluted off the column, as indicated by the presence of the correct-sized 
band (His6-A3BCTD-QM-ΔL3-AL1 ~ 21 kDa, His6-SUMO-A3BCTD-DM ~ 38 kDa) 
(Figure 4.4). However, background contaminant proteins eluted off the column along 
with the A3BCTD proteins following IMAC; therefore, further purification was employed 
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Figure 4.3 Tricine SDS-PAGE gels (16%) of the protein expression of the active A3BCTD 
constructs. 
(A) A3BCTD-QM-ΔL3-AL1swap, (B) SUMO-A3BCTD-DM Lane 1: Blue Prestained protein standard 
ladder, lane 2: uninduced cell culture, lane 3: induced cell culture with 0.5 mM IPTG. Arrows point to 




The A3BCTD fractions from IMAC were combined and run through a Superdex 75 10/300 
GL column to purify the A3BCTD protein by means of size. The SUMO-A3BCTD-DM SEC 
profile showed a major peak with a maximum around 77 mL eluting off the column with 
several smaller peaks eluting off earlier. Assessment of the fractions collected from SEC-
FPLC of the major peak (peak maximum 77 mL) on an SDS-PAGE gel showed a very 
dense 38 kDa band had eluted corresponding to the size of the SUMO-A3BCTD-DM 
protein, with minor background contaminants (see Figure 4.4B). After SEC, the fractions 
containing the most pure SUMO-A3BCTD-DM fractions were pooled together and 
incubated with SUMO protease (ULP1) to cleave off the His6-SUMO tag as described in 
section 2.2.5.1. Following cleavage, the sample was purified using IMAC to remove the 
His-SUMO, which binds to the Ni2+-NTA column. The A3BCTD-DM protein then eluted 
directly off the column, which was confirmed by the size of a 22 kDa protein as visualised 
by Tricine SDS-PAGE (Figure 8.1).  
We noticed that upon purification of the A3BCTD-AL1 variant two major peaks eluted off 
the SEC column. The first peak eluting off the column (after 74 mL, Figure 4.5A) was 
identified to be a dimeric form of the A3BCTD-AL1 protein (further discussed in section 
6.3), while the peak corresponding to the monomeric A3BCTD-AL1 form eluted after 90 
mL of buffer (see Figure 4.5A). The monomeric A3BCTD-AL1 fractions were collated 
then run through the SEC column once again ensuring that a homogeneous monomeric 
(A) (B) 
Figure 4.4 Tricine SDS-PAGE gels (16%) of IMAC protein purification of the A3BCTD variants. 
(A) A3BCTD-QM-ΔL3-AL1swap, (B) SUMO-A3BCTD-DM. Lane 1: Blue Prestained protein standard 
ladder, lane 2: supernatant flow-through, lanes 3-4: buffer wash fractions *, lanes 5-10: eluted 
fractions +. *Wash buffer; 50 mM Tris-HCl pH 7.4, 0.5 M NaCl, 2 mM β-ME, with 10 or 50 mM 
imidazole. +Eluting buffer: 50 mM Tris-HCl pH 7.4, 0.5 M NaCl, 2 mM β-ME, with 200 to 500 mM 





form was isolated. The purified A3BCTD variants were then used in NMR-based activity 
and inhibition assays.    
4.3 Evaluation of the catalytic activity of A3BCTD-AL1 and A3BCTD-DM 
using an 1H-NMR-based activity assay  
4.3.1 A3BCTD-AL1 and A3BCTD-DM variants catalytic activity 
The A3BCTD-AL1 and A3BCTD-DM variants were previously stated to be catalytically 
active using a fluorescence-based deaminase activity assay 240. However, to quantitatively 
assess the catalytic activity of the purified A3BCTD variants (A3BCTD-AL1 and A3BCTD-
DM) on a dC-containing oligonucleotide, an established 1D-1H-NMR-based activity 
assay (previously described in section 3.3) was used 79, 94. However, in place of the A9C-
oligo, the 9merC-oligo (from now on referred to as the TCA-oligo) was used for our 
kinetic studies (see Table 2.13), as it allowed better dispersion of the dC and dU 
resonances in the 1H-NMR spectra (Figure 4.6), and additionally was shown using 
thermal shift assay to be capable of binding to our A3BCTD-QM-ΔL3 variant (see Figure 
Figure 4.5 SEC protein purification of the active A3BCTD variants.  
(A) A3BCTD-QM-ΔL3-AL1swap (i) SEC profile, (ii) SDS-PAGE (16%) gel with SEC fractions 
between 90 – 110 mL, (B) SUMO-A3BCTD-DM, (i) SEC profile, (ii) SDS-PAGE (16%) gel with SEC 
fractions between 70 – 90 mL. SEC buffer is 50 mM Tris-HCl, pH 7.4, 0.5 M NaCl, 2 mM β-ME.  
 (A)                                                  (B) 
 (i)                                                  (i) 







3.12). Initial experiments performed under the same conditions as described in section 
3.3 with 1 mM TCA-oligo along with 100 µM A3BCTD enzyme under 50 mM citrate-
phosphate, pH 7.5 buffer. This assay indicated that these A3BCTD variants were 
catalytically active, consistent with the aforementioned study 239, although under these 
conditions the dC of the oligo was rapidly converted to dU (< 5 minutes). Therefore, to 
examine the deamination of dC to dU qualitatively and quantitatively the concentration 
of the enzymes were adjusted. We determined that a concentration of 50 nM of A3BCTD-
AL1 or 2 µM of A3BCTD-DM was suitable to observe deamination of the TCA-oligo in a 
timely manner (several hours), as displayed in Figure 4.6A.  
To further optimise the rate of enzyme activity a pH screen was conducted, and the initial 
deamination rate was calculated. The assay was set up using 500 µM TCA-oligo along 
with either 50 nM of A3BCTD-AL1 or 2 µM A3BCTD-DM in the formerly mentioned 
citrate buffer over a pH range from 4.5 - 7.5. We observed that our A3 variants were 
catalytically active between pH 4.5–7.5, and therefore would support activity and 
inhibition of wild-type A3B in physiological pH at around 7 37. However, to kinetically 
characterise these enzymes, use of the same but suboptimal pH is not feasible in NMR 
assays, as each variant has a distinct optimal pH condition (Figure 4.7). We found that 
Figure 4.6 Time-resolved deamination of 5'-ATTTCATTT by A3BCTD and assessment of the 
initial speed of the reaction monitored by 1H-NMR.  
(A) A series of 1H spectra was recorded at different time points during the deamination reaction of 
350 µM 5'-TCA oligo by 50 nM A3BCTD-AL1 in 50 mM citrate-phosphate, pH 5.5 buffer (50 mM 
citrate-phosphate buffer, 200 mM NaCl, 2 mM β-ME, 200 µM DSS, pH 5.5, with 10% D2O) 
monitored over 5 hours. The decrease in the H5 dC proton signal (5.91 ppm) was concurrent with an 
increase in the H5 dU proton signal (5.73 ppm). (B) The H5 proton signal of dC was integrated, 
calibrated against a standard citrate buffer signal, and plotted against the initial time of the reaction 
(~3000 sec) to derive the initial rate of deamination, which was then fitted with a linear regression. 
1H-NMR spectra were recorded on a 700 MHz spectrometer every 298 sec at 298 K. 




our A3BCTD-DM variant was most active (in the range tested) at pH 7.5 buffer, similar to 
that reported for wild-type A3BCTD 
37. Meanwhile, the A3BCTD-AL1 variant  was 
approximately 6-fold more catalytically active in the more acidic pH 5.5 buffer as shown 
in Figure 4.7 and Table 4.1. This difference is the result of the transfer of the A3A loop 1 
into the A3BCTD essentially gaining characteristic properties of A3A as  reported in the 
literature 37, 107. Therefore, these pH conditions resulted in an optimum deamination rate 
for each A3BCTD variant and were selected for our NMR-based activity and inhibition 
assays.  
4.3.2 Kinetic characterisation of the A3BCTD-AL1 and A3BCTD-DM activity in 
deaminating dC of  5'-ATTTCATTT  
Assays were setup using the defined optimal conditions (listed above in section 4.3.1) to 
quantitatively characterise the rate of the deamination of the substrate oligonucleotide by 
our active A3BCTD variants. 
1H NMR spectra were recorded at varying concentrations of 
the TCA-oligo (50 μM -700 μM) along with 50 nM of A3BCTD-AL1 or 2 μM of A3BCTD-
DM in 50 mM citrate- phosphate buffer (pH 5.5 or 7.5, respectively). Examination of the 
NMR spectra showed that within an hour (2980 sec, Figure 4.6A) of initiating the reaction 
an initial conversion of dC to dU occurred, as indicated by the appearance of the H-5 dU 
doublet peaks (5.73 ppm, Figure 4.6A). After an incubation period of approximately 4 
Figure 4.7 pH dependence on the rate of deamination of 5'-ATTTCATTT for A3BCTD-AL1 and 
A3BCTD-DM. 
NMR-activity assays were setup using 500 µM 5'-TCA-oligo with 50 nM A3BCTD-AL1 or 2 µM 
A3BCTD-DM in a 50 mM citrate-phosphate buffer with a pH range of 4.5 – 7.5, in 10% D2O. The ionic 
strength of buffer was adjusted by the addition of similar levels of sodium phosphate. The initial speed 




hours ~70 % of the dC was converted to dU (14900 sec, Figure 4.6A). These observations 
were apparent for both the A3BCTD-AL1 and A3BCTD-DM enzymes under our given 
conditions (for simplicity, data shown for A3BCTD-AL1, Figure 4.6). To calculate the 
concentration of conversion of the substrate during the reaction, a doublet of doublets 
(2.57 to 2.39 ppm) arising from citrate (in the buffer) was used as a concentration 
standard. The area of the H-5 dC proton doublet (5.92 to 5.88 ppm) was integrated, then 
was converted into a substrate concentration and plotted against the reaction time. From 
this the speed of the reaction can be established as it follows a linear relationship (Figure 
4.6B). In an ideal situation, it should be possible to obtain Km and kcat values by direct 
fitting of the substrate/initial rate data. However, due to the instability of the A3 enzymes 
during long experiments analysis of product formation becomes complicated. Therefore, 
the initial rate of deamination was calculated by performing experiments at various 
substrate concentrations for reliability of Km values.  
Plotting the initial rate of deamination against substrate concentration revealed a 
hyperbolic plot (see Figure 4.8), consistent with the A3BCTD variant enzymes following 
Michaelis-Menten kinetics. Initially the reaction rate increases as the substrate increases, 
but at higher substrate concentrations the reaction rate plateaus as the enzyme is saturated. 
The data obtained can be fitted with a straight line in a double-reciprocal plot 
(Lineweaver-Burk plot) by plotting the inverse rate of deamination against the inverse 
substrate concentration, which is visually easier to analyse. From this plot the Michaelis-
Menten constants (Km, kcat) can be calculated as described in section 2.5.2, and their 
uncertainties can be determined based on the fit of the experimental data (see Equation 
8.1). As each point on this plot represents an individual experiment at various substrate 
concentrations monitored over time using the same enzyme concentration, more data 
points were obtained leading to more reliable Michaelis-Menten values than performing 
the same experiment multiple times. Fitting the data using non-linear least squares using 
a global fit, we obtain fits and parameter values that are not significantly different from 




 Table 4.1 Kinetic parameters of the active A3BCTD variants determined by 1H-NMR-based assay at  
298 K. 
Protein Km (μM) kcat (s-1) kcat/Km (s-1 μM-1) 
A3BCTD-AL1swap 197 ± 31 0.28 ± 0.04 0.0014 
A3BCTD-DM 317 ± 55  0.0082 ± 0.0014 0.000025 
 
Interestingly, the cytosine deamination of the TCA-oligo by our A3BCTD-DM was slower 
than the A3BCTD-AL1 variant, reflected by a kcat of 0.0082 s
-1 for A3BCTD-DM, in contrast 
to a kcat ~ 0.28 s
-1 for the A3BCTD-AL1 variant. These results coincide with A3BCTD-DM 
having a lower affinity for the TCA-oligo in contrast to A3BCTD-AL1, as indicated by a 
higher Km ~ 320 µM for A3BCTD-DM in comparison to a reduced Km  ~ 200 µM for the 
A3BCTD-AL1 variant (see Table 4.1). In addition, the specificity constant defined by 
Figure 4.8 Kinetic charachterisation of A3BCTD-AL1 and A3BCTD-DM cytosine deamination of 
5'-ATTTCATTT.   
Initial speed of cytosine deamination of the 5'-TCA-oligo at various concentrations (50 – 600 µM) by 
(A) 50 nM A3BCTD-AL1 or (B) 2 µM A3BCTD-DM at 298 K. (i) Plot of the initial speed of 
deamination as a function of substrate concentration, (ii) Lineweaver-Burk plot of the inversed initial 
speed of deamination as a function of inversed substrate concentration to derive Km and kcat 
parameters. 
(B) 
(i)                  (ii) 






127 reinforced that the A3BCTD-AL1 variant was ~ 60 fold more efficient at 
converting the TCA-oligo to TUA-oligo than A3BCTD-DM as indicated in Table 4.1, 
consistent with previous reports 37. The transfer of the A3A loop 1 into A3BCTD led to a 
more catalytically active version of A3BCTD 
21, attributed to a more open active-site 
conformation as reported for A3A 23, 36, 239. Therefore, this variant was used for initial 
screenings of potential inhibitors discussed further in section 4.4.   
4.4 Evaluation of modified-ssDNA for their inhibitory potential on 
A3BCTD variants using 1H-NMR-based inhibitor assay 
A3 inhibitors were designed based on the previously described inhibitors of the closely 
related CDA enzymes, such as 3-deazauracil (Ki ~ 100 µM) 
45, zebularine (Ki ~ 2.3 µM) 
6, and 5-fluorozebularine (Ki ~ 0.3 µM) 
6. As A3 enzymes prefer ssDNA substrates 180, 
these cytosine analogues had to be synthesised as 2'-deoxynucleosides and be 
incorporated into the preferred A3 ssDNA sequence (referred to as modified-ssDNA). 
Several modified-oligos including 2'-deoxy-3-deazauridine (3dadU), 2'-deoxy-3-
deazazebularine (3dadZ), 2'-deoxyzebularine (dZ), 5-fluoro-2'-deoxyzebularine 
(displayed in Figure 4.9) were synthesised by Dr. Maksim Kvach and Mr. Harikrishnan 
Mohana Kurup 135-136 as described in section 2.3.2. For this research, I examined the 
inhibitory potential of these modified-oligos on the A3BCTD enzymes. As the active site 
and deamination mechanism for CDA and A3 enzymes are believed to be conserved, we 
anticipate that a comparable inhibitory effect of the A3 enzymes would arise using these 
modified oligos.  
Figure 4.9 Modified oligonucleotides containing cytosine analogues as potential inhibitors of A3. 
The cytosine of the TCA-oligo is replaced with a modified nucleoside such as 2'-deoxyzebularine 






To evaluate our modified oligos, the previously described 1H-NMR-based activity assay 
was used to directly monitor the rate of deamination of the active A3BCTD on the preferred 
substrate oligonucleotide in the presence or absence of our modified-oligos. This was 
followed by the evaluation of the inhibition constant (Ki) 
79, 135, as described in section 
2.5.3. In a similar manner as described earlier in section 4.3, experiments were conducted 
at various inhibitor concentrations, which allowed Ki values to be derived from the linear 
fit of the data in the Dixon plots. Fitting the data using non-linear least squares, we obtain 
fits and parameter values that are not significantly different from using linear analysis 
(see appendix section Figure 8.5 and Table 8.4). By using the same experimental 
conditions, the inhibitory potential of the modified oligos can be evaluated by comparing 
the Km value of the substrate to the Ki value of inhibitors.  
4.4.1 Qualitative characterisation of the inhibition of cytosine deamination of 
A3BCTD  
Our modified-oligos were initially screened for their inhibitory effect on our most 
catalytically active A3BCTD-AL1 variant. Assays were setup using 350 µM of the 
preferred TCA-oligo along with 50 nM A3BCTD-AL1 in the presence of 50 µM modified 
oligo in the citrate- phosphate pH 5.5 buffer. A series of 1H-NMR spectra were recorded 
and the initial deamination speed of A3BCTD-AL1 in the presence of these modified-
oligos were determined (Figure 4.10).  
Oligonucleotides possessing the 3dadU and 3dadZ in place of dC led to no change in the 
initial deamination speed of A3BCTD-AL1, relative to the control assay without an 
inhibitor (Figure 4.10). This indicated that both of these modified oligonucleotides were 
unable to inhibit A3BCTD-AL1 under our conditions. Previous studies reported that the 
ribose analogue of 3dadU nucleoside is a very weak inhibitor of the human liver CDA 
with a Ki ~ 100 µM 45. Increasing the concentration of the 3dadU oligo may lead to an 
observable inhibition of A3BCTD-AL1, but as it might only offer a minimal inhibition 
effect its development was not further advanced. However, the dZ- and 5FdZ-containing 
oligonucleotides resulted in significant inhibition of A3BCTD-AL1, as shown in Figure 
4.10 by the substantial decrease in the speed of deamination upon their addition to the 




The observed inhibition of the A3BCTD by the 2’-deoxyzebularine derivatives dZ-oligo 
and 5FdZ-oligo can be described by our inhibitory mechanism model displayed earlier in 
Figure 3.10 135-136 (based on the CDA mechanism 281). As revealed earlier by our thermal 
shift assay results (refer to section 3.4.2), the catalytic glutamic acid (E255) in the A3’s 
active site is essential for the initial step of protonation of N3 of dZ (and 5FdZ). This 
protonation makes C4 electrophilic and more susceptible to a nucleophilic attack by a 
water molecule (or hydroxide ion). Upon this attack the nucleoside (dZ or 5FdZ) 
transforms into a rigid tetrahedral transition state of cytosine deamination (Figure 3.10). 
This formation allows dZ (5FdZ) to stay bound in the A3 active-site and thereby inhibit 
the deamination activity of the enzyme. The lack of inhibition of the A3BCTD enzyme by 
3dadZ-oligo showcases the importance of the initial protonation of N3 atom in the 
inhibitory mechanism, as 3dadZ has a non-protonable CH group in place of an N3 atom. 
Furthermore, the tetrahedral geometry of C4 in the transition state is equally important 
for this mechanism, as noted when utilising the 3dadU nucleobase with C4 in planar 
geometry. 
Figure 4.10 Qualitative screen of modified-oligos on the inhibition of A3BCTD-AL1 catalysed 
deamination of the substrate oligonucleotide (5'-ATTTCATTT).  
Plot of the initial speed of deamination of 350 µM TCA-oligo by 50 nM A3BCTD-AL1 in the presence 
of 50 µM ssDNA containing the modified nucleoside (X) in citrate-phosphate pH 5.5 buffer at 298 K. 
Experiments repeated 2-3 times and the mean value was taken and plotted. Error bars reported as 




4.4.2 Quantitative characterisation of dZ and 5FdZ-containing ssDNAs as 
inhibitors of A3BCTD  
To establish the mode of enzyme inhibition by these inhibitors, the rate of deamination 
of the substrate oligonucleotide at varying concentrations (50 μM – 700 μM) by A3BCTD-
AL1 was monitored using the 1H-NMR-based activity assay, with and without the dZ-
oligo inhibitor (Figure 4.11). From the Lineweaver-Burk plot, where inverse speed is 
plotted against inverse substrate concentration, the maximum rate of reaction (Vmax) is 
calculated as 1/Vmax at the intercept of the y-axis and Km is determined as -1/Km from the 
x-axis intercept. This plot revealed that in the absence and presence of the inhibitor the 
linear regression lines cross the y-axis at practically the same position, indicating that Vmax 
remains essentially the same (without inhibitor; 1/Vmax = 71 ± 12 s/μM, with inhibitor; 
1/Vmax = 83 ± 32 s/μM). Moreover, in the presence of the inhibitor the slope increases 
leading to an increase in the apparent Km ~ 450 μM, in comparison to the reaction without 
inhibitor Km ~ 200 μM. The decrease in the apparent affinity of the substrate to the enzyme 
in the presence of the inhibitor is the result of competition of the substrate and inhibitor 
to bind in the active site of the enzyme. Taken together these results indicate that the 
modified-oligos are competitive inhibitors of the A3 enzymes. As our inhibitors have 
similar structures, they are all assumed to be competitive inhibitors. 
Figure 4.11 Lineweaver-Burk plot of competitive inhibition of A3BCTD-AL1 by the dZ-oligo. 
Deamination rate of the substrate oligonucleotide (5'-ATTTCATTT) by 50 nM A3BCTD-AL1 at varied 
substrate concentrations (50 – 600 µM) in the absence and presence of 20 μM dZ-oligo, in citrate-
phosphate pH 5.5 buffer measured at 298 K. Data are plotted as inversed initial speed of deamination 




To calculate the inhibition constant (Ki) of the modified oligos (dZ-oligo and 5FdZ-oligo) 
the deamination reaction of substrate oligonucleotide by A3BCTD was monitored by 
1H-
NMR (as previously described 4.3.2) in the presence of various inhibitor concentrations. 
Assuming competitive inhibition for the inhibitors (see earlier Figure 4.11), the linear 
dependence of the inverse deamination speed as a function of the inhibitor concentration 
was analysed as described in section 2.5.3. First, we determined that for the dZ-oligo on 
our A3BCTD-AL1 variant Ki  was ~7.5 ± 1.7 µM (Figure 4.13B). Comparison of the 
substrate Km (~ 200 µM, Table 4.1) to this Ki value, indicated that the dZ-containing oligo 
had an inhibition potential of Km/Ki of ~30-fold on the A3BCTD-AL1 enzyme. Moreover, 
the dZ-oligo had essentially the same overall inhibition effect of ~30 fold on the A3BCTD-
DM variant (Km/Ki ~320/11; see Table 4.1 and Figure 4.13A). This implied that the 
replacement of dC with dZ causes the observed inhibitory effect in both A3BCTD variants; 
therefore, for simplicity we continued our evaluations of the modified-oligos with our 
most active A3BCTD-AL1 variant.   
ITC was used as an additional method to compare the binding affinity of the dZ-
containing oligo to the A3BCTD-AL1 variant. ITC was performed as described in section 
2.4.2. The dZ-containing oligo was found to be capable of binding to A3BCTD-AL1, under 
these conditions. This binding event was noted to be driven by a large negative enthalpy 
(ΔH ~ 42 kcal/mol, Figure 4.12) leading to an overall favourable interaction as indicated 
by a negative ΔG ~ -7.2 kcal/mol (ΔG = ΔH-TΔS, where T is temperature of 298 K). 
These results are consistent with earlier observations noting that the presence of a dZ-
containing oligo increased the thermal stability of the A3BCTD protein in contrast to the 
weaker binding affinities of the dC/dU-containing oligos (see Figure 3.11 for the A3BCTD-
QM-ΔL3 results, and section 3.4.3 for the ITC experiment). Therefore, binding affinities 
can be determined. We found that under our conditions where 100 µM A3BCTD-AL1 was 
titrated with 300 µM dZ-containing oligo the generated curve reached saturation (Figure 
4.12). However, as a consequence of the low protein concentration used to prevent protein 
aggregation, the curve did not result in the expected sigmoidal shape and lacked an 
inflection point. Therefore, the binding stoichiometry (N) was fixed to a constant value of 
1 (representing a 1 to 1 ratio) to derive the thermodynamic parameters. The directly 
measured dissociation constant Kd ~ 5.5 ± 0.5 μM obtained from ITC was noted to be 




4.13B). Deriving similar binding affinities using two independent methods further 
supports that in the dZ-oligo the dZ causes the inhibitory effect.  
Next, we determined the inhibition potency of the 5FdZ-oligo on our A3BCTD-AL1 
variant. We found that the 5FdZ-oligo (Ki ~ 2.1 ± 0.8 µM) had a 3.5 times lower Ki than 
the dZ-oligo (Ki ~ 7.5 ± 1.7 µM) (see Figure 4.13B and C), indicating that the 5FdZ-
containing oligo was much more potent than the dZ-containing oligo (dZ- ~ 30 fold, 5FdZ 
~ 100 fold). These findings were also echoed by results obtained by our collaborators 
(Assoc. Prof. Daniel Harki’s team, University of Minnesota) on an active wild-type A3A 
(expressed in human cells), which was not surprising as the residues in the active-site of 
A3BCTD and A3A are conserved 
239.They used a fluorescence polarisation competition 
assay, whereby a fluorescently labelled ssDNA containing a TC-motif was pre-bound to 
A3A then was competed with unlabelled dZ- and 5FdZ-oligo inhibitors to assess their 
binding affinities and calculate the half maximal inhibitory concentration (IC50). These 
assays demonstrated that the 5FdZ-containing oligo (IC50 ~ 0.16 ± 0.01 μM) was ~2.4 
times a more potent inhibitor of the wild-type A3A than the dZ-containing oligo (IC50 ~ 
0.39 ± 0.03 μM) 136, in a similar manner as determined for our A3BCTD-AL1.  
Figure 4.12 ITC experiment of A3BCTD-AL1 titrated with dZ-containing oligo. 
ITC was performed using 100 µM A3BCTD-AL1 titrated with 300 μM dZ-containing oligo (5'-
ATTTdZATTT) in 50 mM citrate-phosphate pH 5.5 buffer at 25 °C as described in section 2.4.2. (A) 
Raw injection data, (B) data of integrated injection enthalpies fitted with a one-site binding model to 
obtain the thermodynamic parameters; enthalpy (ΔH), entropy (ΔS), equilibrium binding association 
constant (Ka), and stoichiometry (N).  




It is thought that due to the electron-withdrawing fluorine of 5FdZ in the heterocycle 136 
causes C4 to be become more electrophilic and therefore more susceptible to the 
nucleophilic attack of H2O/
-OH. This enhances inhibition of A3BCTD and A3A by the 
5FdZ-oligo in comparison to the dZ-oligo. This observed trend of inhibition was 
consistent with previous reports where the 5-fluorozebularine was determined to be a 
better inhibitor of CDA than zebularine and 3-deazauracil (Ki ~ 0.3 µM, 2.3 µM, 
6 and 
100 µM 45, respectively). This observation further reinforces our rationale that the 
structure of the cytosine analogues, placed instead of the dC in the preferred A3 ssDNA 
substrate, primarily determines the inhibitory potential of the modified oligonucleotides 
on the A3 enzymes.  
Figure 4.13 Dixon plots of the inhibition of the A3BCTD variants by dZ- and 5FdZ-containing 
oligos monitored by 1H-NMR inhibition assay.  
Deamination of the 350 µM TCA-oligo (5'-ATTTCATTT) by (A) 2 µM A3BCTD-DM in the presence 
of varying concentration (2-50 µM) of the dZ-containing oligo citrate-phosphate pH 7.5 buffer, (B) 50 
nM A3BCTD-AL1 in the presence of varying concentration (5-100 µM) of the dZ-containing oligo 
citrate-phosphate pH 5.5 buffer, (C) 50 nM A3BCTD-AL1 in the presence of varying concentration (5-
100 µM) of the 5FdZ-containing oligo citrate-phosphate pH 5.5 buffer. Measured by 1H-NMR-based 
inhibition assay at 298 K . 
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Two active A3BCTD variants, A3BCTD-AL1 and A3BCTD-DM, were purified to study their 
catalytic deamination activity on the preferred substrate oligonucleotide (TCA-oligo) and 
to evaluate this activity in the presence of modified oligonucleotides. Using these active 
A3BCTD variants we characterised their kinetic parameters in regard to their deamination 
activity on the dC in the preferred TCA-oligo, using the previously described 1H-NMR 
based activity assay 94. We found that the A3BCTD-AL1 variant (Km ~ 200 µM) was 
significantly more active than the A3BCTD-DM (Km ~ 320 µM) variant, suggestive that 
the replacement of loop 1 of A3BCTD with that from A3A enhanced the activity of our 
A3BCTD-AL1 variant by mimicking a more open active-site conformation allowing easier 
binding of ssDNA, as shown in the A3A structure, Figure 1.15A 23, 36, 239.  
Using A3BCTD-AL1 variant (as it was the most active A3BCTD) our modified 
oligonucleotides containing cytosine analogues 3dadU, 3dadZ, dZ, and 5FdZ were 
evaluated for their inhibitory potential. We discovered that the dZ- and 5FdZ-containing 
oligos significantly inhibited the deamination activity of A3BCTD-AL1, whereas 3dadZ- 
and 3dadU-containing oligos had no impact on the activity. These results validated our 
proposed inhibition mechanism (described in Figure 3.10), which highlights the 
importance of the protonation of N3 in dZ by the A3’s active-site catalytic glutamic acid 
(E255), which triggers the conversion of the dZ nucleoside into the rigid hydrated 
tetrahedral transition state of cytosine deamination. Therefore, protonation of the N3 of 
dZ and the 5FdZ nucleosides initiates this reaction allowing their transition states to 
remain tightly bound in the A3’s active site and thereby blocking further catalysis by the 
enzyme. On the other hand, for 3dadZ, which contained a CH group in place of the N3 
atom and for 3dadU, for which C4 had a planar geometry in the transition state, the lack 
of inhibition of both these nucleoside-containing oligos demonstrated the importance of 
the protonation of the N3 atom and the tetrahedral geometry of C4 in the transition state 
to achieve inhibition.  
Using our 1H-NMR based inhibitor assay, the inhibition constants of the dZ-oligo on the 
activity of the A3BCTD variants were characterised first. The dZ-oligo was determined to 
be binding competitively into the active-site of A3BCTD and as our cytidine analogue 
inhibitor (5FdZ) had a similar structure we presumed that it would also be competitive. 
The dZ-containing oligo was found to be capable of inhibiting both our A3BCTD variants 




A3BCTD-DM Ki ~ 11 µM). The overall inhibition effect (Km/Ki ~ 30 fold) of this 
oligonucleotide on the A3BCTD-DM and A3BCTD-AL1 variants were the same. 
Furthermore, the 5FdZ-containing oligo was determined to be a more potent inhibitor 
than the dZ-containing oligo for both our A3BCTD-AL1 (Km/Ki ~ 100 fold) and A3A (as 
reported by our collaborators 136), in a similar manner as the previously reported 5-
fluorozebularine on CDA 6. Moreover, Dr. Stefan Harjes also showed that the 
incorporation of dZ or 5FdZ into the A3G’s preferred deamination CCC-motif 
(underlined is preferred dC replaced with dZ or 5FdZ) in short ssDNA (~10 nucleotides) 
inhibited both A3GCTD and a full-length A3G (expressed in human cells) with low 
micromolar inhibition constants (further elaborated on in section 6.4.3.1 and Figure 6.21) 
135-136. Thus, the structure of the cytosine analogue nucleoside must directly influence the 
inhibition of the A3 enzymes. Notably, inhibition of A3GCTD was comparable to the 
inhibition of the full-length A3G 18, indicating that the catalytic activity is largely 
attributed to the CTD in two-domain A3 enzymes. This result justifies the rationale to 
investigate  modified-ssDNA inhibitors on A3BCTD to illustrate inhibition of the full-
length A3B. 
Overall, we discovered the first specific substrate-like ssDNA inhibitors capable of 
targeting A3 enzymes. These nucleoside-containing oligonucleotides would not target 
CDA, as CDA prefers free nucleosides over oligonucleotides as reported in the literature 
14, 120. Moreover, as most A3 enzymes (except A3G) prefer to deaminate a dC within a 
5’-TC-motif, replacement of this dC with the cytosine analogue inhibitors (dZ or 5FdZ) 
would specifically target most of these A3 enzymes, as indicated by the inhibition of both 
A3BCTD and A3A. As A3B has been noted to drive the mutagenic evolution of cancer 
cells, its selective inhibition is crucial, whilst preserving the action of the other A3 


































5. Selective inhibition of A3 enzymes 
























The majority of the work reported in this chapter was incorporated from our published 
journal article:  
1) Barzak, F. M., Harjes, S., Kvach, M. V., Kurup, H. M., Jameson, G. B., Filichev, V. V., & Harjes, 
E. Selective inhibition of APOBEC3 enzymes by single-stranded DNAs containing 2′-
deoxyzebularine. Organic & Biomolecular Chemistry. 2019, 17 (43), 9435-9441. Doi: 
10.1039/c9ob01781j 8. 
In this article, I hypothesised and tested whether selective inhibition using the differentially 
deaminated suboptimal CCC-oligo was feasible. First, I expressed and purified the A3BCTD variant 
enzymes (A3BCTD-QM-ΔL3-AL1swap (termed here A3A-mimic) and A3BCTD-DM), then 
performed 1H-NMR based activity assays to characterise the kinetic deamination activity of these 
enzymes on the preferred dC in the CCC-oligo, dZCC-oligo, and CCdZ-oligo. I characterised the 
inhibition potency of dZ-containing oligonucleotides using the 1H-NMR based inhibition assay. I 
performed all analysis of the derived data and wrote the first draft of article.  
The work reported in this chapter was also presented in the conference listed below.  
Barzak, F. M., Kvach, M. V, Harjes S., Jameson G.B, Aihara, H., Harris R. S., Harki, D. A., 
Filichev, V. V., Harjes, E. DNA-based inhibitors of the human APOBEC3B DNA cytosine 
deaminase. Selected oral and poster presentations at the NZMS/NZSBMB ‘Microbes and 
molecules’ Meeting 2018 held between the 26th – 29th November 2018 at the University of Otago, 
Dunedin, New Zealand. 
 
A central innate immune defence mechanism against pathogens occurs through the 
deamination of cytosine in foreign ssDNA by the A3 enzymes 99. In addition, human 
nuclear and mitochondrial genomes are susceptible to editing of their cytosines by several 
A3 enzymes, predominantly A3A, A3B, and A3G 255. In particular, A3B has been 
identified as the major source of genetic mutations in multiple cancers, which in turn leads 
to the development of drug resistance. 34, 82, 146, 244, 268, 270, 295. Due to the fundamental role 
of A3 enzymes in the defence against pathogens, the selective inhibition of A3B is vital 
to suppress its mutagenic action, while maintaining the activity of other A3 enzymes.  
Selective small-molecule A3G inhibitors have been reported 151, 196. We described the 
first substrate-like competitive A3 inhibitor with a low micromolar inhibition constant 
(refer to section 4.4) 135, in which the target dC was substituted with dZ in the preferred 
ssDNA (5’-ATTTCATTT) of our A3BCTD variant. However, as most A3 enzymes (except 




preceded by a thymine, this inhibitor is not selective and it is uncertain as to whether a 
selective A3B inhibitor can be obtained. In this chapter, we first demonstrate that 
neighbouring nucleotides in the ssDNA sequence influence the deamination selectivity 
of our engineered A3 enzymes in the same way as they do for the wild-type sequences 
(see section 4.3). Utilising this knowledge, we designed and tested oligonucleotides 
containing dZ surrounded by different nucleotides. This illustrated that the nucleobases 
in the oligonucleotide strongly influence the specificity of our inhibitor, leading to the 
first selective oligonucleotide inhibitor of A3 enzymes. These findings provide a platform 
for further development of selective A3 inhibitors. 
5.2 Preference of A3 enzymes to deaminate cytosine is dependent on 
neighbouring nucleotides in sequence 
Although A3A and A3B favour the deamination of a TC motif (underlined C is 
deamination target) where the target dC is preceded by a thymidine, these enzymes are 
also capable of deaminating cytosines in ssDNA with other adjacent nucleobases, 
although with lower efficiency 36, 252. One example, wild-type A3A and A3BCTD can 
deaminate dC within sequences with a CCC-motif 37, which is the most favoured 
deamination motif for the A3G (A3GCTD, 5’-ATTCCCAATT, Km ~ 570 µM 94). A3A and 
A3G  preferentially deaminate dC at the 3’-end of the CCC-motif, where the target dC is 
followed by a purine (dA or dG) at the 3’-end 37, 41, 122-123, 207, 252. A3B prefers the dC at 
the 5’-end of this motif, denoted CCC 36-37, flanked by a thymidine in the adjacent 5’-
position. The other non-preferred dCs in the CCC motif are less efficiently deaminated 
by A3A and A3B as the recognition site is not favoured by the enzymes 37. Moreover, 
A3GCTD does not deaminate dC at the 5’ position of the CCC-motif and has little 
enthusiasm for the middle dC of the CCC-motif (5’-ATTCCUAATT Km ~ 3.6 mM) 
94. 
Thereby, nucleobases surrounding the target dC significantly influence the substrate 
recognition of the A3 enzymes 37, 47, 208. 
5.2.1 Evaluation of the deamination preference of cytosines within the 5’-
ATTCCCAATT sequence by our active A3BCTD variants  
Based on the literature, we wanted to examine how our active A3 variants, A3BCTD-AL1 
and A3BCTD-DM (described in chapter 4), deaminate dC in a suboptimal substrate 
oligonucleotide containing the CCC-motif. Several oligonucleotides were used in this 




Table 5.1 Oligonucleotides used in this study 
Name DNA sequence Rational 
TCA-oligo 5’-ATTTCATTT Used as preferred substrate sequence of A3A and A3BCTD 37 
CCC-oligo 5’-ATTCCCAATT The 3rd dC (from 5’ to 3’ ends) is the preferred substrate of 
A3GCTD-WT 94 and preferentially deaminated by A3A 37. The 
1st dC is preferentially deaminated by A3BCTD 37 
UCC-oligo 5’-ATTUCCAATT Used as a standard for the chemical shift of the H-5 proton 
doublet of the 1st dU, as a partial product in NMR assay  
CUC-oligo 5’-ATTCUCAATT Used as a standard for the chemical shift of the H-5 proton 
doublet of the 2nd dU, as a partial product in NMR assay 
CCU-oligo 5’-ATTCCUAATT Used as a standard for the chemical shift of the H-5 proton 
doublet of the 3rd dU, as a partial product in NMR assay  
CUU-oligo 5’-ATTCUUAATT Used as a standard for the chemical shift of the H-5 proton 
doublet of the 2nd  and 3rd dU, as a partial product in NMR assay 
UUU-oligo 5’-ATTUUUAATT Used as a standard for the chemical shift of the H-5 proton 
doublet of the 1st – 3rd dU, as a full product in NMR assay 
 
First, 1D 1H-NMR spectra were recorded of the substrate CCC-oligo (5’-
ATTCCCAATT) and subsequent standard oligonucleotides containing dU in various 
positions (described in Table 5.1, partial and full products), to confirm that the chemical 
shifts of the H-5 proton doublet of dU can be used for monitoring of product formation. 
The H5-proton doublet of dU in the 5’ position in of the UCC-oligo appeared at 5.775  
ppm (J = 8.50 Hz), a doublet for dU in the middle position of CUC appeared at 5.748 
ppm (J = 8.43 Hz), and the doublet for dU at the 3’ position in CCU appeared at 5.67 ppm 
(J = 8.49 Hz). The H-5 signals of uracils in these oligonucleotides were well dispersed 
(Figure 5.1), simplifying future detection of product (dU) peaks as a result of A3-




Next, we monitored the deamination pattern of the CCC-oligo by A3BCTD-AL1 and 
A3BCTD-DM. Experiments were setup with an excess of 800 µM CCC-oligo along with 
2 µM of either A3 variant in 50 mM citrate-phosphate buffer at their respective pH 
optimum (A3BCTD-AL1 in pH 5.5 buffer, A3BCTD-DM in pH 7.5 buffer, Figure 4.7) and 
the deamination rates were monitored using 1H-NMR. Our A3BCTD-DM variant favoured 
the deamination of the first dC at the 5’ position of the CCC motif (Figure 5.2B), 
consistent with the selective deamination behaviour reported for the wild-type A3BCTD 
37. In contrast, our A3BCTD-AL1 variant favoured the deamination of the third cytosine in 
the CCC motif (dU position 3, Figure 5.2A), similar to the preference of the wild-type 
A3A and A3GCTD.  
The observed variation in the deamination preference of the CCC-oligo between these 
A3BCTD variants (Figure 5.2) was caused by the transplant of loop 1 of A3A into A3BCTD, 
leading to the transfer of A3A characteristics to A3BCTD, which was previously reported 
37. This loop swap not only affected CCC-motif substrate specificity, but as described 
earlier led to a more catalytically active A3BCTD construct in comparison to A3BCTD-
DM (see Table 4.1) and shifted the pH optimum from pH 7.5 to 5.5 (Figure 4.7) as 
discussed in section 4.3. Therefore, in regard to the deamination of the CCC-oligo, the 
A3BCTD-AL1 variant reflects the selective deamination of the wild-type A3A in ssDNA 
substrates containing several cytosines 37. Thus, the A3BCTD-AL1 variant can be used to 
Figure 5.1 1D 1H-NMR spectra of CCC-oligo and standards of possible products of dC 
deamination. 
1H-NMR spectra recorded on a 700-MHz spectrometer using 500 µM oligonucleotide in 50 mM 
citrate-phosphate pH 5.5 buffer (50 mM citrate-phosphate, 200 mM NaCl, 2 mM β-ME, 200 µM DSS, 
pH 5.5) containing 10 % D2O. Peaks are numbered to indicate the position of dU in the 




model A3A in the selective deamination of the CCC-oligo and will therefore be referred 
to as A3A-mimic in the remainder of this chapter.  
Regarding Figure 5.2B, we observed that A3BCTD-DM systematically deaminates the dC 
in position 1 of the CCC motif first, followed by the middle dC (UCC) and finally the dC 
at position 3 (UUC), under our conditions. On the other hand, A3A-mimic first 
deaminates the dC in position 3 (CCU), but subsequent deamination of the CCU species 
is random forming multiple intermediate species until all the dC nucleotides are 
deaminated, as displayed in Figure 5.2A. The deamination of only one dC at the beginning 








Figure 5.2 1D 1H-NMR spectra of the deamination of the CCC-oligo by our active A3 variants.  
Assays were setup using 800 µM CCC-oligo with either (A) 2 µM A3BCTD-AL1 (A3A-mimic) or (B) 
2 µM A3BCTD-DM, in 50 mM citrate-phosphate buffer containing 200 mM NaCl, 2 mM β-ME, 200 
µM DSS, pH 5.5 or pH 7.5, respectively, in 10 % D2O. The experiment was monitored using 1H-NMR  
recorded at 298 K. Note that the spectra shown here are recorded every 15 minutes and that the 






between deamination events, since the concentration of the substrate greatly exceeds the 
concentration of the enzyme. In addition, the deamination products of the less preferred 
dCs were detected at later time-points and were always less intense in comparison with 
the signal from the preferred dC indicating that deamination of the non-preferred 
cytosines was incomplete during the time frame of this experiment (~2 hours, Figure 5.2).  
5.2.2 Kinetic characterisation of A3A-mimic and A3BCTD-DM for deamination of 
preferred dC in 5’-ATTCCCAATT oligonucleotide 
To evaluate the rate of deamination of the A3 variants on their preferred dC within the 
CCC-oligo, the aforementioned NMR-based activity assay was performed 94 (as 
described in sections 2.5.2 and 4.3). Typically, direct fitting of the rate of substrate 
conversion is possible to obtain the Km and kcat values. However, for A3 enzymes several 
factors complicate the analysis of product formation over long periods of time. First, 
during long experiments the enzymes tend to become unstable; second, when substrate 
concentration decreases throughout the experiment the A3 enzymes begin to deaminate 
other cytosines in the CCU- and UCC-motifs. Therefore, to address these issues the initial 
deamination rate of the preferred cytosine (first dC deaminated) was obtained using NMR 
assays.  
A series of 1H NMR spectra was recorded of the CCC-oligo at varying concentrations (50 
– 750 µM) with either 50 nM A3A-mimic or 2 µM A3BCTD-DM in their respective buffers 
(citrate-phosphate buffer at pH 5.5 or pH 7.5). The initial speed of the reaction was 
calculated as described in Materials and Methods 2.5.2 (using the dU H-5 proton doublet 
of CCU at 5.67  ppm and the H-5 proton doublet of UCC at 5.775  ppm, see Figure 5.1). 
Plotting the initial speed of deamination against substrate concentration a hyperbolic plot 
is obtained, where the A3 enzymes become saturated at high substrate concentrations, 
indicating Michaelis-Menten kinetics (Figure 5.3A i and Figure 5.3B i). From this the 
Lineweaver-Burk plot (1/rate versus 1/[substrate]) was fitted with linear regression 
(Figure 5.3A ii & Figure 5.3B ii) and the Michaelis-Menten constants were derived as 




fit, we obtain parameter values that are not significantly different from the linear analysis 
(see appendix Figure 8.6 and Table 8.3)  
The apparent binding affinities of our A3 variants on their preferred dC within the CCC-
oligo (A3A-mimic Km ~ 400 µM for CCC, A3BCTD-DM Km ~ 600 µM for CCC) were 
determined to be 2-fold weaker than the target dC in the TCA-oligo (where for A3A-
mimic (A3BCTD-AL1) Km ~ 200 µM, and for A3BCTD-DM Km ~ 300 µM, as described in 
Table 4.1) 135. Furthermore, the deamination of the TCA-oligo by the A3 enzyme was 60 
times more efficient than that of the enzymes’ preferred dC in the CCC-oligo, as implied 
by the specificity constant (kcat/Km 
127, Table 5.2), consistent with the CCC-motif being a 
suboptimal substrate for A3A and A3BCTD 
37.  
Figure 5.3 Kinetic characterisation of A3A-mimic and A3BCTD-DM on the deamination of their 
preferred dC within 5'-ATTCCCAATT.  
(A) Speed of deamination of the dC at the 3'-end in the CCC-oligo with 50 nM A3A-mimic (A3BCTD-
AL1) in 50 mM citrate-phosphate pH 5.5 buffer, (B) speed of deamination of the dC near the 5'-end in 
the CCC-oligo with 2 µM A3BCTD-DM in 50 mM citrate-phosphate pH 5.5 buffer. Speed of 
deamination was  obtained using the 1H-NMR based-activity assay at 298 K with varying substrate 
concentrations (20 – 800 µM) (i) Plot of the initial speed of deamination as a function of substrate 
concentration, (ii) Lineweaver-Burk plot of the inversed initial speed of deamination as a function of 
inversed substrate concentration to derive Km and kcat parameters. 
 
(A) 
 (i)                             (ii) 
(B) 




Table 5.2 Kinetic parameters of A3A-mimic and A3BCTD-DM determined by the 1H-NMR-based 
activity assay at 298 K. 
Enzyme Oligonucleotide Km (μM) kcat (s-1) kcat/Km (s-1 μM-1) 
A3A-mimic CCC-oligo 440 ± 80 0.38 ± 0.06 0.00086 
 TCA-oligo 135 197 ± 30 0.28 ± 0.041 0.0014 
A3BCTD-DM CCC-oligo 590 ± 90  0.009 ± 0.001 0.000015 
 TCA-oligo 135 317 ± 55  0.0082 ± 0.0014 0.000025 
5.3 Evaluation of dZCC and CCdZ oligonucleotides as selective 
inhibitors of A3  
The first modified-oligo inhibitor of the A3s was developed by incorporating dZ into the 
enzymes’ preferred deamination motif (5'-TC), as discussed earlier in section 4.4 135. The 
dZ-containing oligo was non-selective as it inhibited both A3A-mimic (A3BCTD-AL1) 
and A3BCTD-DM with similar inhibition constants (discussed in section 4.4.2), as both 
A3A and A3B preferred deaminating cytosines preceded by thymine 135. However, based 
on the nature of selective deamination of A3A and A3BCTD on DNA substrates containing 
several cytosines, selective inhibition of A3B was theorised to be feasible. We 
hypothesised that by replacing the dC at the 5' end of the CCC motif by dZ, the 5'-dZCC 
oligo would selectively inhibit A3B, and conversely by placing dZ near the 3'-end of the 
CCC motif, the 5'-CCdZ oligo would inhibit A3A and A3G, but not A3B.  
To test this hypothesis, modified-oligos with dZ incorporated into the CCC-oligo as 
CCdZ and dZCC oligos (rationale described in Table 5.3) were synthesised by Dr Maksim 
Kvach  and Harikrishnan Mohana Kurup as described in section 2.3.2 8. Placement of dZ 
in either the middle position (CdZC-oligo, dU labelled 2 Figure 5.1) or in both the 5' and 
3' position (dZCdZ-oligo, dU labelled 1 and 3 Figure 5.1) of the CCC-oligo was expected 
to lead to non-selective inhibition of the A3 variants, so was not explored. To investigate 
selective inhibition of the A3 enzymes by the above-mentioned modified oligos, the 
A3BCTD-DM variant and A3A-mimic were employed to model A3BCTD and A3A, 
respectively. The TCA-oligo was a better substrate for the A3A-mimic and A3BCTD-DM 
than the CCC-oligo (CCC-oligo Km ~2 fold higher than TCA-oligo, see Table 5.2), 
therefore the TCA-oligo was used as a substrate in our NMR-based inhibition assay to 




Table 5.3 Modified oligonucleotides used in this study  
Name DNA sequence Rational 
dZ-oligo ATTTdZATTT Non-selective inhibitor of A3A and A3BCTD 135 
CCdZ-oligo ATTCCdZAATT Modified oligonucleotide to compare with the substrate (CCC) 
and study inhibition of A3A-mimic. Determine if it is a 
substrate of A3BCTD (the 1st dC). Inhibitor of A3GCTD-WT 94  
dZCC-oligo ATTdZCCAATT Modified oligonucleotide to compare with the substrate (CCC) 
and study inhibition of A3BCTD. Determine if it is a substrate 
of A3A and A3GCTD (the 2nd dC in the sequence) 
5.3.1 Qualitative characterisation of the inhibition of A3A-mimic and A3BCTD-DM 
by the dZCC and CCdZ-oligos  
To assess whether selective inhibition of our A3 variants can be achieved using the CCdZ-
and dZCC-oligos, an initial screen was performed. The deamination of 350 µM substrate 
TCA-oligo by our A3 variants was monitored by 1H-NMR in the absence and presence 
of 50 µM oligonucleotides (CCC-oligo, CCdZ-oligo, or dZCC-oligo), to examine the 
residual enzyme activity (see Figure 5.4 and Figure 5.5).  
Figure 5.4 shows the setup of the assay using 350 µM TCA-oligo deaminated by 50 nM 
A3A-mimic in the absence and presence of 50 µM CCdZ-oligo monitored by 1H-NMR 
under our standard conditions (for simplicity data shown for A3BCTD-AL1, Figure 5.4). 
The H-5 proton doublet signal of the cytosine from the TCA-oligo (Figure 5.4A i and B 
i) was integrated then converted into a concentration and plotted against the time of the 
reaction to determine the speed of the reaction from the linear regression equation 
(demonstrated in Figure 5.4A ii and B ii). Examination of the NMR spectrum showed 
that the presence of the CCdZ-oligo significantly slows the A3A-mimic’s rate of 
deamination (Figure 5.4B ii) as observed by the lack of dC to dU conversion (5.73 ppm, 
Figure 5.4B i), in comparison to the control experiment without the CCdZ-oligo (Figure 
5.4A). Consistent with our hypothesis, the CCdZ-oligo was found to significantly inhibit 
A3A-mimic (Figure 5.5A) (also the A3GCTD as reported in 
135), but not A3BCTD-DM 
(CCdZ, Figure 5.5B). In contrast, dZCC-oligo inhibited the A3BCTD-DM variant (Figure 
5.5B) but no inhibition of A3A-mimic (dZCC, Figure 5.5A) (or A3GCTD 







Figure 5.5 Screening of dZ-containing oligos for the selective inhibition of A3 enzymes.  
Initial speed of the deamination (V) of 350 µM TCA-oligo (substrate) in the absence (buffer) and 
presence of 50 µM oligos (dZCC-oligo, CCdZ-oligo, or CCC-oligo control) by (A) 50 nM A3A-
mimic (blue) in citrate-phosphate pH 5.5 buffer or (B) 2 µM A3BCTD-DM (red) in citrate-phosphate 
pH 7.5 buffer measured at 298 K. Experiments were repeated twice and the mean value was plotted 
with error bars reported as standard deviations (SD). 
 
(A) 
 (i)                               (ii) 
(B) 
 (i)                    (ii) 
Figure 5.4 Time resolved deamination of TCA-oligo by A3A-mimic in the absence and presence 
of the CCdZ-oligo and assessment of the initial speed of the reaction using 1H-NMR.  
A series of 1H-NMR spectra was  recorded on a 700-MHz spectrometer every 298 sec using 350 µM 
TCA-oligo (substrate) during the deamination reaction by 50 nM A3A-mimic (A3BCTD-AL1) in 
citrate-phosphate pH 5.5 buffer, with 10% D2O in the (A) absence or (B) presence of 50 µM CCdZ-
oligo at 298 K. (i) 1H-NMR spectra at various time points during the deamination reaction. (ii) Plot of 





To confirm that these selective inhibitors are not further processed by the inhibited 
enzymes, we recorded a 1H-NMR spectrum of the CCdZ-oligo in the presence of A3A-
mimic, which is the most active deaminase in our A3 variants. Examination of the NMR 
spectrum over ~ 4 hours revealed that no signals change, but importantly the other non-
preferred dCs in the motif (CCdZ) were not deaminated as displayed by the lack of the 
dU signals in the range of 5.5 - 6.0 ppm (Figure 5.6). These observations confirm that the 
A3A-mimic strongly binds dZ in the CCdZ-oligo and is inhibited. Taken together, these 
results provide proof of concept that selective inhibition of A3 catalytic activity is feasible 
by using dZ instead of dC in different positions in a suboptimal DNA substrate containing 
the CCC motif. 
5.3.2 Quantitative characterisation of selective inhibition of A3A-mimic and 
A3BCTD-DM using 1H-NMR inhibitor assay 
Next, we wanted to quantitatively characterise the extent of the inhibition of our A3A-
mimic and A3BCTD-DM by the aforementioned selective dZ-inhibitors (CCdZ-oligo and 
dZCC-oligo, respectively). The deamination of the TCA-oligo by our A3 variants was 
monitored using the previously described 1H-NMR-based-inhibiton assay (see section 
2.5.3) 94 in the presence of various concentrations of CCdZ-oligo or dZCC-oligo (2 – 100 
µM). The inhibition constants (Ki, Figure 5.7 and Table 5.4) were derived from analysis 
of the linear dependence of the inverse deamination speed on inhibitor concentration 
based on a competitive mode of inhibition 135 (as described in section 4.4.2). As 
mentioned earlier, fitting the data using non-linear least squares, we obtain similar 
parameter values consistent with linear analysis (see appendix section Figure 8.7 and 
Table 8.4). We found that the Ki values of the selective dZ-oligos on our A3 variants (Ki 
Figure 5.6 1H-NMR spectrum of CCdZ-oligo in the presence of A3A-mimic at different time 
points. 
Experiment conducted using 350 µM CCdZ-oligo with 50 nM A3A-mimic in citrate-phosphate pH 





~12 µM for A3A-mimic CCdZ-oligo, and Ki ~ 19 µM for A3BCTD-DM dZCC-oligo, 
Figure 5.7 and Table 5.4) were approximately two-fold weaker than the Ki values of our 
previously reported non-selective dZ-oligo inhibitor 135 (see Table 5.4). This is consistent 
with the two-fold weaker Km’s of the CCC-oligo of these enzymes in contrast to the Km’s 
of the preferred TCA-oligo (reported in Table 5.2). Nonetheless, we still observe a thirty-
fold increase in the apparent affinity (Km/Ki) when dZ is placed in the ssDNA sequence 
instead of the preferred dC for A3BCTD-DM and A3A-mimic, as reported earlier in section 
4.4.2 for the preferred TCA-motif. Although the CCdZ-oligo inhibited both the A3A-
mimic and A3GCTD, we noted that the A3A-mimic had a 2.8 times higher affinity (Ki ~ 
19 µM) for this oligonucleotide in comparison to the A3GCTD (Ki ~ 53 µM) indicating 






Figure 5.7 Quantitative characterisation of our A3 variants inhibition by the CCdZ-oligo and 
dZCC-oligo.  
Inverse deamination velocity of 350 µM TCA-oligo by A3 variants in the presence of varying 
concentrations of selective dZ-inhibitors measured using 1H-NMR at 298 K. (A) 50 nM A3A-mimic 
with CCdZ-oligo (2-50 µM) in citrate-phosphate pH 5.5 buffer, or (B) 2 µM A3BCTD-DM with dZCC-






Table 5.4 Inhibition constants (Ki, µM) for our A3 variants derived from 1H-NMR-based inhibition 
assay. 






A3GCTD  (conducted by 
Dr. Stefan Harjes 135) 
Ki, µM 
dZ-oligo  7.5 ± 1.7 135 11.4 ± 2.6 135 Not an inhibitor * 
CCdZ-oligo 12.3 ± 1.8 Not an inhibitor * 53 ± 10 135 
dZCC-oligo Not an inhibitor * 18.5 ± 5.5 Not an inhibitor 
* Not an inhibitor means that dZ is not incorporated in the preferred substrate sequence or dC deamination 
target.   
Lastly, we wanted to assess the deamination of the A3 enzymes preferred dC in these 
inhibitors to test the stability of the inhibitors against other A3 enzymes. Using the dZCC-
oligo and CCdZ-oligo as substrates we determined the kinetic parameters of the A3A-
mimic, A3BCTD-DM (refer to Figure 8.3), and A3GCTD (experiments on A3GCTD 
conducted by Dr. Stefan Harjes 8) as described earlier in section 5.2.2 using the 1H-NMR 
based-activity assay (section 2.5.2).  
Table 5.5 Kinetic parameters for A3 enzymes deaminating dC in different DNA substrates .  
Oligonucleotides A3A-mimic  
Km, µM (kcat, s-1) 
A3BCTD-DM  
Km, µM (kcat, s-1) 
A3GCTD  (conducted by 
Dr. Stefan Harjes 8, 94) 
Km, µM (kcat, s-1) 
TCA-oligo 135 197 ± 30                
(0.28 ± 0.041) 
317 ± 55            
(0.0082 ± 0.0014) 
Not a substrate * 
CCC-oligo 440 ± 80                
(0.38 ± 0.06) 
Not a preferred 
substrate + 
570 ± 90                
(0.10 ± 0.04) 94 
CCC-oligo Not a preferred 
substrate +  
590 ± 90              
(0.009 ± 0.001) 
Not a preferred 
substrate + 
dZCC-oligo 520 ± 90                
(0.44 ± 0.06) 
Not a substrate * ≈ 1 mM                      
(≈ 0.1) 8   
CCdZ-oligo Not a substrate * 1370 ± 270               
(0.010 ± 0.002) 
Not a substrate * 
* Not a substrate means that none of dCs is deaminated under the experimental conditions reported. 
+ Not a preferred substrate means that other dCs are also deaminated but at later time points when the 





The dZCC-oligo, which selectively inhibits A3BCTD-DM, was found to be a poor 
substrate for the A3A-mimic and A3GCTD 
8 in comparison to the TCA-oligo and CCC-
oligo (Table 5.5). More evidently, the CCdZ-oligo, which inhibits A3A-mimic and 
A3GCTD 135, was discovered to be a very poor substrate for A3BCTD-DM with a Km ~ 1370 
μM (Table 5.5). Upon inclusion of dZ in the CCC motif, we observed that the A3 enzymes 
still deaminated their preferred dC (observed in Figure 8.3), but had much weaker 
apparent binding affinities Km (Table 5.5). However, when we compared the Km value of 
the dZCC-oligo deaminated by A3A-mimic (Km ~ 520 μM, as it had the lowest Km value 
of the dZ-oligos as a substrate, Table 5.5) to the Ki value for A3BCTD-DM of the same 
oligo (dZCC Ki ~ 19 μM, Table 5.5), we found that this oligonucleotide had a 30 fold 
higher apparent affinity (Km/Ki ~ 30) towards the A3BCTD-DM than to other enzymes. 
Taken together, this would signify that inhibition of the A3BCTD-DM by the dZCC-oligo 
would predominate over the deamination of the preferred dC in this oligonucleotide 
(dZCC-oligo) by the A3A-mimic, as well as the A3GCTD. This conclusion will be valid 
for all other dZ-containing oligos (Table 5.4 and Table 5.5).  
5.4 Conclusions  
Taking advantage of the reported selective deamination of the wild-type A3BCTD and 
wild-type A3A on a dC in a suboptimal substrate containing several cytosines (CCC-
motif) 37, we predicted that selective inhibition of the cancer-associated A3B would be 
achievable. We hypothesised that incorporation of our dZ nucleoside inhibitor in place of 
the preferentially deaminated dC in the CCC-motif would selectively inhibit these A3 
enzymes. To test our hypothesis, we used our active A3BCTD variants, which showed that 
our A3BCTD-DM preferred to deaminate the dC at the 5'-end of the 5'-CCC-oligo (Km ~ 
600 µM) like the wild-type A3BCTD 
37, whereas our A3A-mimic (A3BCTD-AL1) 
deaminated the dC at the 3'-end of the 5'-CCC-oligo (Km ~ 400 µM) like the wild-type 
A3A 37 and A3GCTD 
47-51.  
These observations are consistent with our hypothesis, we found that placement of dZ 
near the 3’-end of the 5'-CCC-oligo selectively inhibited our A3BCTD-DM variant (dZCC-
oligo Ki ~ 19 μM), but not our A3A-mimic or the reported A3GCTD 
135. On the other hand, 
placement of dZ at the 5'-end of the motif specifically inhibited the A3A-mimic (CCdZ-
oligo Ki ~ 12 μM) and a reported A3GCTD (CCdZ-oligo Ki ~ 53 μM) 
135, but not A3BCTD-




the A3BCTD-DM-selective dZCC-oligo inhibitor of (dZCC-oligo, A3A-mimic Km ~ 520 
μM and A3GCTD Km > 1 mM), and the A3BCTD-DM could also deaminate the preferred 
5'-dC in the CCdZ-oligo inhibitor of A3A-mimic and A3GCTD, but with very weak Km 
(CCdZ-oligo, A3BCTD-DM Km ~ 1.37 mM). However, as indicated by the Ki values 
mentioned earlier, these enzymes would bind to these selective inhibitors with a strong 
affinity relative to Km, supporting a scheme where the A3 enzymes would bind to dZ 
rather than to any dC in the oligonucleotide and selective inhibition would overrule. 
Embedding dZ in place of preferentially deaminated dC in the CCC-oligo led to the first 
selective inhibitor of the A3BCTD. The use of more potent inhibitors of cytosine 










6. Evaluation of A3-ssDNA 























6.1  Introduction 
Some of the work reported in this chapter was presented in several conferences listed 
below.  
1) Barzak, F. M., Mohammadzadeh N., Kvach, M. V, Harjes S., Kurup, H. M., Aihara, H., Harris R. 
S., Krause, K. L., Chelico, L., Filichev, V. V., Harjes, E., Jameson G.B. Small-angle X-Ray 
scattering structures of human APOBEC3 bound to single-stranded DNA. Selected poster 
presentation at the Australian Synchrotron User Meeting 2018 held between the 22nd - 23rd 
November 2018 at the Australian Synchrotron, Melbourne, Victoria, Australia. 
 
2) Barzak, F. M., Mohammadzadeh N., Kvach, M. V, Harjes S., Kurup, H. M., Aihara, H., Harris R. 
S., Krause, K. L., Chelico, L., Filichev, V. V., Harjes, E., Jameson G.B. Small-angle X-Ray 
scattering structures of human APOBEC3 bound to single-stranded DNA. Invited oral presentation 
at the Biodiscovery & Biochemistry Conference 2019 held between the 2nd - 4th July 2019 at the 
Victoria University, Wellington, New Zealand. 
 
3) Barzak, F. M., Mohammadzadeh N., Kvach, M. V, Harjes S., Kurup, H. M., Aihara, H., Harris R. 
S., Krause, K. L., Chelico, L., Filichev, V. V., Harjes, E., Jameson G.B. Model structures of human 
APOBEC3 bound to ssDNA-based inhibitors using SAXS. Invited oral presentation at the 24th 
International Analytical Ultracentrifugation Workshop and Symposium held between the 24th - 
29th August 2019 at the University of Canterbury, Christchurch, New Zealand. 
 
Crystal structures have shed some light on single-domain inactive A3 bound to single-
stranded nucleic acid substrates 129, 161, 239; however, so far there has not been any 
experimentally based models and structures of catalytically active A3 bound to ssDNA 
or full-length two-domain enzymes with ssDNA. Several studies, including this study, 
reported that ssDNA substrates bind weakly to inactive A3 catalytic domains (medium-
high µM range) 36, 94, 135, 172. Therefore, in an attempt to enhance the binding affinity and 
prevent deamination complications, we used our recently characterised A3 inhibitors 
containing dZ-modified ssDNA, which had with low µM affinity, to study active A3 
enzymes. Owing to challenges faced during crystallisation, small-angle X-ray scattering 
(SAXS) was used to model the active A3BCTD-ssDNA complex and the two-domain A3-




SAXS operates by registering X-ray scattering pattern intensities of a sample in solution 
on a detector (Figure 6.1) 168. The raw two-dimensional scattering data are processed 
through a number of steps. First, the raw scattering data are reduced (SCATTERBRAIN 
2.82), then the data are plotted as a SAXS profile of integrated intensity versus frame 
number (CHROMIX, ATSAS 2.8.3 suite 75). The frames of interest are averaged and 
buffer subtracted, transforming the data to a 1D-scattering curve where log of the 
scattering intensity is plotted against the scattering vector (log(I) vs q) (PRIMUSQT, 
ATSAS 2.8.3 suite 75) (Figure 6.1) (described in materials and methods 2.6.2).  
Biophysical parameters such as the radius of gyration, maximum dimension, and 
molecular weight of the protein can be derived from the scattering curve to define the 
samples’ morphology in solution.  
6.1.1 Analysis of SAXS data  
Standard SAXS experiments, termed batch mode SAXS, function by exposing the sample 
to monochromatic synchrotron X-rays and then collecting scattering data using an 
automated sample changer 168, 217. This mode is beneficial to screen samples using low 
sample concentrations (between 0.25 mg/mL and ~10 mg/mL), run experiments using a 
range of temperatures (8-45 °C), use smaller sample volumes (40 µL), and retrieve 
samples following the experiment. Batch mode SAXS assumes that samples are 
monodispersed, and background scattering is accounted for by careful buffer matching. 
However, as there is potential of biological macromolecules to aggregate or form higher 
order structures in solution, interpretation of data derived using standard SAXS methods 
maybe hindered. Therefore, the use of SEC-FPLC directly coupled with SAXS (SEC-
SAXS) resolves sample species and buffer matching, while additionally monitoring the 
elution profile by UV detection 218. Furthermore, the use of a co-flow system along with 
SEC-SAXS (SEC-co-flow-SAXS) prevents sample degraded due to radiation damage 
Figure 6.1 Schematic representation of a SAXS experiment and data processing.  
The scattering vector q is defined as q = 4πsinθ/λ, 2θ is the scattering angle, and λ is the wavelength of 





from coating the capillary walls and enhances the signal to noise ratio. In co-flow the 
sample flows in the centre of the cell while a matched buffer encases the sample and 
prevents protein denatured by the intense X-radiation depositing on the cell walls 117.   
During SEC-co-flow-SAXS, the sample’s elution profile is monitored by uv-visible 
spectroscopy at various wavelengths over time, while near-simultaneously collecting 
SAXS data of the sample per frame. However, a slight lag of 1.05 seconds/frame occurs 
between monitoring the elution profile followed by SAXS of the sample; this lag is 
accounted for during analysis. If examining the elution profile shows that the sample 
elutes as a homogeneous species off the SEC column, then the scattering data can be 
transformed into a 1D-scattering curve as described earlier in Figure 6.1 and analysis can 
proceed straightforwardly (Figure 6.2). However, if the sample is partially unresolved 
multiple species, then its scattering data must be first deconvoluted before proceeding 
with further analysis. Simple deconvolution involves using SVD/EFA BioXTAS RAW 
105, where the singular value decomposition (SVD) function defines the number of 
components in the sample (referred to as eigenvalues). Then the evolving factor analysis 
(EFA) method can be used to define the boundaries and extract the scattering curves of 
each component (further described in Figure 8.9). However, for complicated poorly 
resolved samples Gaussian decomposition allows the deconvolution of the data and the 
extraction of the distinct scattering curves of each component (US-SOMO HPLC-SAXS 
module) 31-33. 
Analysis was conducted using programs within the PRIMUSQT ATSAS 2.8.3 suite 75. 
Initially, the 1D-scattering curve is converted into a double logarithmic plot to confirm 
that the sample assessed is homogeneous with a single species, confirmed by the presence 
of a plateau at lower scattering angles (q) values (Figure 6.2E). Plotting low q data using 
the Guinier distribution analysis (log(I) vs q2) through the AUTORG  method (Figure 
6.2A) allows evaluation of the monodispersity of the sample in solution. This also 
provides an initial estimate of the radius of gyration (Rg) and the extrapolated intensity at 
zero scattering angle I(0) describes the overall size of the molecule. The assumption of 
globular shape for the Guinier plot is valid when qRg ≤ 1.3 (denoted q.Rg max) Next, the 
data are converted into a Kratky plot (I*q2 vs q) to assess the shape and fold of the 
molecule (Figure 6.2B). In addition, the Kratky plot provides information regarding the 




An indirect inverse Fourier transformation of the scattering data performed using 
AUTOGNOM results in the pairwise distribution function P(r) curve, which represents 
the distribution of interatomic distances (r) within the molecule. The molecule’s 
maximum diameter (Dmax) can be determined from the P(r) curve as P(r) approaches zero 
at r >> 0 (Figure 6.2C). Furthermore, the Rg and I(0) can be accurately calculated from 
the P(r) curve using all the experimental data, unlike the Guinier analysis, which uses 
only a small subset at low q. The excluded particle volume (also termed Porod volume, 
V) is calculated through the DATPOROD program using I(0) values attained from the 
P(r) plot (Figure 6.2D). The Porod volume can then be used to directly compute the 
molecular weight (MW in Daltons) of the solute (MW  V*0.6) providing valuable 
information about the oligomeric state of the molecule (Figure 6.2). Furthermore, the MW 
can also be calculated from I(0) if the concentration is accurately known using a 
previously described method 178. 
Low-resolution 3D-models can then be computed through ab initio shape restoration 
using the DAMMIF program by applying restraints of biophysical parameters attained 
from the 1D scattering curve. The DAMMIF program first generates several models, 
which are then averaged (DAMAVER) and are further filtered by cut-off volume 
constraints based on derived SAXS analysis parameters (DAMFILT) to produce the 
dummy filled models. The normalised spatial discrepancy (NSD) score quantitatively 
measures the similarities between the generated set of 3D envelope models, where NSD 
Figure 6.2 Schematic of the analysis of SAXS scattering data. 
 




≤ 0.8 is an acceptable variance. These envelope models can be superimposed with atomic 
models to assemble a high-resolution model. Lastly, rigid body modelling is conducted 
using FoXS 74, 226 and CRYSOL 75 by comparing the experimental scattering data to the 
back-calculated 1D-scattering profiles of atomic structures or model structures, to 
validate model. From these programs a fitting parameter termed the Chi2 value (also 
called 2) can be obtained. Chi2 gives a measure of discrepancies between the 
experimental scattering data to the back-calculated 1D-scattering profiles of atomic 
structures; a Chi2 equal to one would indicate a perfect fit.  
6.2 Active A3BCTD-inhibitor ssDNA SAXS model structure 
Until 2016, the structure of the A3BCTD-ssDNA complex was unknown. Structural studies 
were conducted using an inactive A3BCTD-QM-ΔL3-A3Aloop1swap-E255A chimera 
(A3BCTD*) along with a 5mer ssDNA substrate oligonucleotide yielding the first 
visualisation of the A3BCTD*-ssDNA complex (PDB: 5TD5) 
239. Unlike this study 239, our 
study focused on using SAXS to examine an active A3BCTD bound to our ssDNA-based 
inhibitor to visualise the relative complex structure in solution. Using this method we can 
compare our SAXS model structure to the published inactive A3BCTD-ssDNA crystal 
structure (PDB: 5TD5) 239. SAXS experiments were performed using our previously 
described active A3BCTD-AL1 variant (A3BCTD-QM-ΔL3-AL1swap) along with our 
previously characterised dZ-containing oligo (see chapter 4) to prevent cytosine 
deamination in the substrate, enhance binding to the protein, and to examine the formation 
of this complex. This oligonucleotide had 9 base pairs with dZ (see section 2.3.2) as at 
the time 5FdZ had not yet been characterised (Figure 4.9). 
6.2.1 Sample preparation of A3BCTD 
Initial screenings were conducted using batch mode SAXS with varying concentrations 
of A3BCTD-AL1 (1, 2.5, 5, 10 mg/mL) to gain insight of the relative biophysical 
characteristics, especially of reversibly associating dimeric or higher oligomeric species. 
To ensure a homogeneous sample, and reduce background signal noise, SEC-co-flow-
SAXS was exploited to examine the samples in solution. Preliminary analysis of the 
A3BCTD-DM protein resulted in a poor scattering curve as a consequence of a large 
proportion of protein aggregating on the SEC column. Conversely, the A3BCTD-AL1 




Therefore, this variant was selected to study its formation in solution with and without 
dZ-containing ssDNA.  
To assess the protein’s stability, 10 mg/mL of A3BCTD-AL1 was examined using SEC-
FPLC in the previously mentioned 50 mM citrate-phosphate pH 5.5 buffer (termed kinetic 
pH 5.5 buffer in this chapter) and the high salt pH 7.4 buffer (see Table 2.15). As 
demonstrated earlier, the A3BCTD-AL1 variant deaminates target dC within ssDNA more 
efficiently in the mildly acidic pH 5.5 buffer (see Figure 4.7), as this pH influences 
interactions between the protein and ssDNA. However, to maintain the protein’s stability, 
A3BCTD proteins prefer the high salt pH 7.4 buffer (refer to section 3.2.3). Therefore, 
buffer choice was an important consideration to allow both the formation of a strong 
A3BCTD-ssDNA complex and also to prevent protein aggregation during SAXS 
experiments.  
We established that our purified monomeric A3BCTD-AL1 elutes predominantly as a 
single peak in the same manner in both kinetic and high salt buffers as observed in Figure 
6.3. A3BCTD-AL1 peak maximum at around 668 seconds in the high salt pH 7.4 buffer 
(Figure 6.3A), whereas in kinetic pH 5.5 buffer the protein elutes slightly earlier with a 
peak maximum at 650 seconds (Figure 6.3B). These minor differences in retention times 
are attributed to the variations in buffer composition, which may affect the properties of 
the proteins such as the charge of the residues and hydrophobicity, therein influencing the 
separation by SEC-FPLC. However, as there were no obvious signs indicating protein 
aggregation occurring in the kinetic pH 5.5 buffer during SEC-FPLC elution, this buffer 
Figure 6.3 Size exclusion chromatography elution profiles of A3BCTD-AL1 in varying buffers.  
SEC-FPLC performed using (A) A3BCTD-AL1 (10 mg/mL) in high salt pH 7.4 buffer (50 mM Tris-
HCl, pH 7.4, 0.5 M NaCl, and 2 mM β-ME), (B) A3BCTD-AL1 (10 mg/mL) in kinetic pH 5.5 buffer 
(50 mM citrate-phosphate, pH 5.5, 0.2 M NaCl, 2 mM β-ME). Samples were run at 25 °C through a 
SEC column at a flow rate of 0.2 mL/min and monitored using wavelengths of 280 nm (A280). 





was selected for our A3BCTD SAXS experiments. Using the kinetic pH 5.5 buffer will 
drive the formation of the A3BCTD-ssDNA complex as described earlier in Figure 4.7. 
6.2.2 Evaluation of the A3BCTD-AL1 and A3BCTD-AL1/ssDNA complex using SEC-
SAXS  
Scattering data of the A3BCTD-AL1 (5 mg/mL), dZ-oligo, and A3BCTD-AL1 along with 
dZ-oligo at varying ratios were acquired in the kinetic pH 5.5 buffer (containing 10% 
glycerol to prevent radiation damage). In conjunction, UV elution profiles were collected 
to aid with the visualisation of the eluent position off the SEC column. Initial assessment 
of the elution profiles showed that the A3BCTD-AL1 eluted as a single peak with a peak 
maximum at around 648 seconds (Figure 6.4A), whereas the dZ-oligo peak maximum 
was at around 662 seconds (Figure 6.4B). Overlaying the trace Rg values over the elution 
profile revealed that the protein had an average Rg ~ 18.7 Å, while the dZ-oligo had an 
Rg ~ 9.9 Å. Moreover, both samples were monodisperse as indicated by the constant 
plateau of Rg values across the elution peak seen in Figure 6.4A and B.  
Initial screenings were performed to determine the ratio of protein to oligonucleotide 
required to ensure the A3BCTD-AL1-ssDNA complex had formed, as monitored by UV. 
Comparing the elution peak maximum of the A3BCTD-AL1 (blue arrow, Figure 6.4A) to 
the peak maximum of the A3BCTD-AL1 in the presence dZ-oligo at a ratio of one to one 
(protein to ssDNA) (highlighted with blue bar, Figure 6.4C), we found an increase of ~ 
0.3 absorbance units (Au) in the protein peak maximum (blue arrow, Figure 6.4C). This 
increase directly correlated with a decrease of ~ 0.3 Au of the dZ-oligo peak maxima 
(green arrow in Figure 6.4B-C). The change in the absorbance implied that the oligo was 
bound to the A3BCTD-AL1. These observations are consistent, upon binding of the oligo 
to the A3BCTD-AL1, the Rg of the protein increased in size from Rg ~ 18.7 Å (Figure 
6.4A) to Rg ~ 19.5 Å (Figure 6.4C-E), which also caused the protein to elute off the 
column earlier (after ~ 620 seconds, Figure 6.4C-E), further supporting the formation of 





Normally, to check for the presence of DNA along with protein elution we can take the 
maximum A260 value and divide by the maximum A280 value, but due to technical 
difficulty A260 values were not collected for these samples. As mentioned earlier, in the 
presence of dZ-oligo, the protein peak maximum at a ratio of one to one (protein to oligo) 
increases by ~ 0.3 Au (blue arrow, Figure 6.4C), at ratio of one to two it is increased by 
~ 0.4 Au (blue arrow, Figure 6.4D). Whereas, no further increase in peak maximum 
occurs at the one to four ratio (blue arrow, Figure 6.4E), indicating that the A3BCTD-AL1 
protein was saturated with the oligo at a ratio of one to two (protein to oligo) or higher. 
So, for further SAXS experiments using A3BCTD-AL1, a one to two ratio of protein to 
oligo was selected to ensure formation of a complex with dZ-containing ssDNA. 
Figure 6.4 SEC elution profiles of A3BCTD-AL1 in varying molar ratios with dZ-oligonucleotide.  
SEC elution profiles of (A) A3BCTD-AL1 at 5 mg/mL (~ 227 µM), (B) dZ-oligo at 0.68 mg/mL (~ 226 
µM), (C) A3BCTD-AL1 with dZ-oligo at a 1 to 1 ratio, (D) A3BCTD-AL1 with dZ-oligo at a 1 to 2 ratio, 
(E) A3BCTD-AL1 with dZ-oligo at a 1 to 4 ratio. Samples were run at 25 °C through a SEC column at 
a flow rate of 0.2 mL/min in kinetic pH 5.5 buffer (50 mM citrate-phosphate pH 5.5, 0.2 M NaCl, 2 
mM β-ME). Blue bar region and arrow represent A3BCTD-AL1 elution, green bar region and arrow 
represents dZ-oligo elution. Ratio represents molar ratio of protein mixed with ssDNA. 
(A)                                            (C) 
                                                                                    
(D) 
(B)






6.2.3 Model SAXS structures of the active A3BCTD-AL1 and A3BCTD-AL1/dZ-oligo 
complex 
Following SEC-co-flow-SAXS of A3BCTD-AL1, dZ-oligo, and A3BCTD-AL1/dZ-oligo 
(1:2 ratio) samples, the raw scattering data were processed and plotted as SAXS profile 
plots (integrated intensity versus the frame number) along with an Rg trace (see Figure 
6.5A). The dZ-oligo resulted in an Rg ~ 9.5 Å (Figure 6.4B), consistent with having 9 
nucleotides. However, due to its small size and limited resolution of SAXS (Rg > 10 Å) 
further analysis was restricted and not continued for this sample.  
On the other hand, both the A3BCTD-AL1 and A3BCTD-AL1/dZ-oligo SAXS data were 
further investigated. Based, on the steady Rg across the elution profiles (blue bar region, 
Figure 6.4A and D) and scattering profiles of the A3BCTD-AL1 (frames 610-660, Figure 
6.5A) and A3BCTD-AL1/dZ-oligo (frames 570-635, Figure 6.5A) we can conclude that a 
single homogeneous species is present. Therefore, these frames were averaged and 
transformed into 1D-scattering curves as described in section 2.6.2. From the 1D-
scattering curves several biophysical structural parameters were extracted that describe 
the molecules’ configuration in solution (listed in Table 6.1 and displayed in Figure 6.5). 
Assessment of A3BCTD-AL1 and the A3BCTD-AL1/dZ-oligo complex SAXS data using 
the Guinier distribution showed that both samples had a good fit to the linear regression 
at low scattering angles, indicating that the samples were not aggregated and were 
monodispersed (Figure 6.5B i). Moreover, at low q values the double logarithmic plot 
plateaued confirming that the samples were homogeneous (Figure 6.5B ii). Estimation of 
Rg and I(0) values from the Guinier slope agreed well with those calculated by the 
independent P(r) method for both samples (listed in Table 6.1), further confirming the 
quality and relative size of the solutes. The Kratky plot exhibited a bell-shaped peak at 
low q (peak maxima at q ~ 0.1 Å) that then converged to the scattering axis at the higher 
q range (Figure 6.5C), indicating that the molecules were well-folded and globular, with 
not much flexibility. As expected, the Rg, Dmax, and Porod volume increased slightly upon 
formation of the A3BCTD-AL1/dZ-oligo complex in comparison to the ligand-free 
A3BCTD-AL1 (as displayed in Table 6.1). Furthermore, the P(r) plot displayed a 




dZ-containing ssDNA) forms a compact near-spherical shape, consistent with results 
observed using the Kratky plot (Figure 6.5C). 
These parameters were then used to calculate the molecular weight (MW). From the 
Porod volume a MW ~ 21 kDa and from I(0) a MW ~ 23 kDa were calculated for the 
A3BCTD-AL1. The MW estimates were comparable to the known MW of A3BCTD (MW 
~ 22 kDa) 239-240. The A3BCTD-AL1/dZ-oligo sample had slightly larger MWs and 
increase in the overall subunit ratio (summarised in Table 6.1), which further  supports 





Figure 6.5 SEC-SAX analysis of A3BCTD-AL1 and A3BCTD-AL1/dZ-oligo complex.  
SAXS scattering data of A3BCTD-AL1 (red) and A3BCTD-AL1/dZ-oligo (blue) samples were analysed 
using several programs from PRIMUSQT ATSAS 2.8.3 suite 75. (A) SAXS profile plots, (B) 
scattering curves with (i) Guinier plot insert, (ii) double log plot insert, (C) Kratky plot, (D) P(r) 
distribution plot. Experiments conducted injecting into SEC-FPLC 5 mg/mL A3BCTD-AL1 and 
A3BCTD-AL1/dZ-oligo at a 1 to 2 molar ratio in kinetic pH 5.5 buffer. 
 
(A)                                 (B) 
(C)                                    (D) 






Table 6.1 SAXS structural parameters of the A3BCTD-AL1 and A3BCTD-AL1/dZ-oligo complex   
  
Following parameter analysis, envelope models of the A3BCTD-AL1 and the A3BCTD-
AL1/dZ-oligo-oligo complex were generated from the experimental scattering curves 
using the ab initio shape restoration programme (DAMMIF). Using parameter 
information derived from the scattering curves ten ab initio models were generated for 
each sample using P1 symmetry, as these samples were determined to be monomeric. 
The envelope models were filtered (DAMAVER and DAMFILT) into a single model to 
use for atomic modelling. A mean NSD score of 0.559 for the A3BCTD-AL1 envelope and 
of 0.826 for the A3BCTD-AL1/dZ-oligo complex envelope indicated a very good to 
acceptable consistency, respectively, for the generated ensembles (acceptable NSD ≤ 
0.8). Table 6.2 summarises the envelope modelling.  
 
Structural parameters A3BCTD-AL1 A3BCTD-AL1/dZ-oligo 
Guinier analysis   
I(0) (cm-1) 0.00940 ± 0.00005 0.01031 ± 0.00005 
Rg (Å) 18.8 ± 0.2  19.8 ± 0.2 
qmin (Å-1) 0.0106 0.0106 
qRg max  1.3 1.3 
Coefficient of correlation (R2) 0.98 0.99 
P(r) analysis   
I(0) (cm-1) 0.00930 ± 0.00004 0.01020 ± 0.00005 
Rg (Å) 18.7 ± 0.1 19.7 ± 0.1 
Dmax (Å) 57 60 
q range (Å-1) 0.0106 - 0.3539 0.0106 - 0.3539 
Quality estimate 0.87 0.85 
Porod volume (Å3) 35,600 36,700 
MW (Porod Volume*0.6) (Da) (ratio to 
expected subunit 22,000 Da) 
21,360 (0.97) 22,020 (1.00)  
MW (from I(0) 178) (Da) (ratio to expected 
subunit 22,000 Da) 




Table 6.2 SAXS fitting and modelling parameters of the A3BCTD-AL1 and A3BCTD-AL1/dZ-oligo 
complex 
Modelling parameters A3BCTD-AL1 A3BCTD-AL1/dZ-oligo 
Ab intio restoration     
DAMMIF (default parameters, 10 
calculations)  
  
q range (Å-1) for fitting 0.0106 - 0.3539 0.0106 - 0.3539 
Symmetry  1 (none) 1 (none) 
NSD (standard deviation) 0.559 (0.019) 0.862 (0.037) 
Resolution (from SASRES) (Å) 28 ± 2 29 ± 2 
Structure modelling      
PDB structure 5CQI 5TD5* 
q range for modelling (Å-1) 0.0106 - 0.3020 0.0106 - 0.3020 
FoXS, Chi2 1.16 1.51 
CRYSOL, Chi2 0.81 0.86 
Note: 5TD5* modified ssDNA length to 9mer.   
 
The published X-ray crystal structures 5CQI 240 (A3BCTD-QM-ΔL3-E255A) and 5TD5 
239 (inactive A3BCTD-QM-ΔL3-A3ALoop1swap-E255A/5'-TTCAT complex) were 
utilised for manual docking of structures into the experimentally derived SAXS envelope 
models. However, to match the size of our dZ-oligo, four nucleotides were added onto 
the existing 5mer oligonucleotide in the 5TD5 structure (5'-ATTTCATTT) using PyMol 
228 (termed 5TD5*).  
The A3BCTD-AL1 envelope model exhibited a globular shape with a slight concave 
groove (insert in Figure 6.6A). On the other hand, the A3BCTD-AL1/dZ-oligo envelope 
had an additional unoccupied electron density that resembled an arm near and a less 
prominent groove. This empty electron density region was presumed to be part of the dZ-
oligo indicating the location of the active-site. Superimposing our low-resolution dummy 
models with the atomic structures (5CQI or 5TD5* 239-240) resulted in a good visual fit, 
indicating that the derived SAXS envelope models corresponded well to the published 
atomic structures 239-240. Based on the superimposed DNA bound A3BCTD atomic 
structure (5TD5* 239) and the unoccupied electron density observed in the envelope model 
of the A3BCTD-AL1/dZ-oligo sample, we concluded that our dZ-oligo inhibitor bound to 
our A3BCTD-AL1 protein in a similar manner as reported, where the ssDNA binds in a U-




Interestingly, our dZ-oligonucleotide bound to the A3BCTD-AL1 protein, but the 3'-end of 
the oligonucleotide seemed to be loosely attached and was fairly flexible, as indicated by 
the shape of its protrusion from the protein (Figure 6.6), consistent with reports of A3-
ssDNA structures 93, 239. Nevertheless, to validate our generated SAXS models, rigid body 
modelling was performed by comparing back-calculated 1D scattering profiles of the 
atomic structure models (PDB; 5CQI and 5TD5*) to the experimentally derived 
scattering data using FoXS 74, 226 and CRYSOL 75. The scattering data of both samples 
showed a good fit to the X-ray models, as summarised in Table 6.2 and illustrated in 
Figure 6.6.  
In contrast, when we try to fit our ligand-free A3BCTD-AL1 data to the ssDNA-bound 
A3BCTD atomic structure (5TD5*) or our A3BCTD-AL1/dZ-oligo data to the ligand-free 
A3BCTD atomic structure (5CQI) we observe a poor fit (refer to Figure 8.8). Therefore, 
we can conclude that in solution based the SAXS models of A3BCTD-AL1 and A3BCTD-
AL1/dZ- oligo complex are comparable to the X-ray crystal structures (PDB 5CQI and 
5TD5, respectively).  
Figure 6.6 Fitting of A3BCTD-AL1 SAXS profiles to known A3BCTD crystal structures.  
(A) Model fit of A3BCTD-AL1 to 5CQI crystal structure, (B) model fit of A3BCTD-AL1/ dZ-oligo 
complex (injected into SEC-FPLC in a 1 to 2 ratio) to 5TD5* crystal structure.  
(A)                          (B)   
(i)                                   (i)   




6.3 SAXS analysis of the A3BCTD-AL1 homodimer  
6.3.1 Purification of the A3BCTD-AL1 multimer species 
During purification of the active A3BCTD-AL1 protein, two predominant peaks eluted 
from the SEC column (Figure 6.7A). As mentioned previously in section 4.2.2, the peak 
eluting after 90 mL of buffer (termed peak 2) corresponded to the monomeric A3BCTD-
AL1 protein (used in kinetic studies in chapter 4 and SAXS modelling in section 6.2). To 
our surprise another peak (termed peak 1) eluted off the SEC column earlier, following 
70 mL of buffer (Figure 6.7A). Fractions from both these peaks were visualised on a 
reducing SDS-PAGE gel revealing that they had the same molecular weight of ~22 kDa 
(Figure 6.7B), suggesting that both peaks contain the A3BCTD-AL1 protein (non-reducing 
PAGE gel not performed due to time constraint). The protein eluting in peak 1 was 
presumed to be a multimer of A3BCTD-AL1, as it is known that larger proteins elute first.  
Mass spectroscopy analysis noted that the eluted protein from peak 1 corresponded to A3, 
while a previously described in vitro DNA deamination in-gel assay 240 verified that this 
protein was a catalytically active A3BCTD capable of cytosine deamination (refer to Figure 
8.2). The SUMO-A3BCTD-DM with a molecular weight of 38 kDa eluted off the same 
SEC column with a peak maximum located around 77 mL (refer to Figure 4.5). In 
comparison, the A3BCTD-AL1 species from peak 1 eluted with a peak maximum at around 
74 mL (Figure 6.5). Hence, we can propose that the A3BCTD-AL1 protein from peak 1 
would be almost of similar hydrodynamic size (around ~ 44 kDa) as the SUMO fused 
A3BCTD-DM protein. We hypothesise that the A3BCTD-AL1 from peak 1 may exist as a 
homodimer and this species will be further examined using SAXS (referred to as A3BCTD- 




6.3.2 Evaluation of A3BCTD-AL1 dimerisation  
Several studies have described the prospect of multimerisation of the APOBEC proteins 
mediated through surface interactions 13, 23, 233, 276. In this study, the A3BCTD-AL1 protein 
was observed to elute as two species, a monomeric (peak 2) and a putative dimer (peak 
1). In contrast, the other A3BCTD variants used during this research, A3BCTD-QM-ΔL3, 
A3BCTD-QM-ΔL3-E255A, and A3BCTD-DM, all eluted as single peaks and were 
monomeric proteins (see sections 3.2.3 and 4.2.2). As A3BCTD-AL1 adopts some 
characteristics of A3A and mimics its actions 37, it alludes to the notion that this observed 
dimerisation may be caused by the incorporation of the A3A loop 1 into A3BCTD. Previous 
reports have suggested that A3A exists as both a monomer and a dimer in vitro 23, 129; 
however, the significance of A3 dimerisation on the function and stability of the enzymes 
remains unclear. Therefore, examination of our A3BCTD-AL1 putative dimer in solution 
may shed some light on its assembly and action.  
6.3.2.1 SEC-FPLC assessment of the A3BCTD-AL1 putative dimer 
The presence of surface-exposed cysteine residues, Cys239 and Cys354, in A3BCTD-AL1 
raises the possibility of a disulfide-bridged homodimeric species forming under oxidising 
conditions (see section 6.3.1, where the reducing SDS-PAGE showed that the putative 
dimer travelled in a similar manner as the monomeric A3BCTD-AL1 species). Initially, the 
A3BCTD-AL1 putative dimer was refined through SEC-FPLC in reducing conditions. 
However, this larger species remained intact, signifying that under non-denaturing 
Figure 6.7 SEC-FPLC purification of the A3BCTD-AL1 multimers.  
SEC-FPLC of A3BCTD-AL1 sample run through a SEC column at a flow rate of 0.5 mL/min in high 
salt pH 7.4 buffer (50 mM Tris-HCl, pH 7.4, 0.5 M NaCl, and 2 mM β-ME) at 25 °C. (A) SEC elution 
profile displaying the elution of the two forms of A3BCTD-AL1, peak 1 and peak 2. (B) 16% Tricine 










conditions of SEC-FPLC (Figure 6.8A) (as contrasted with SDS-PAGE, Figure 6.7B) this 
conformation is stable and the disulfide bridge must be buried and inaccessible to the 
reducing agent.  
To determine if the A3BCTD-AL1 is in equilibrium between the two multimeric states 
(putative dimeric and monomeric forms), the dissociation behaviour of the A3BCTD-AL1 
putative dimer was examined. First, the A3BCTD-AL1 putative dimer was concentrated to 
approximately 5 mg/mL, then examined using SEC-FPLC in both the standard high salt 
pH 7.4 buffer and kinetic pH 5.5 buffer. In both buffers the protein behaved in a similar 
manner, so for simplification results are presented for the high salt pH 7.4 buffer. The 
concentrated A3BCTD-AL1 putative dimer sample eluted off the SEC column as two 
peaks. The majority of the sample ~ 93 % eluted off the column after 70 mL of buffer 
(peak 1) corresponding to the A3BCTD-AL1 putative dimeric form, whereas a very minor 
peak of ~ 7 %, which correlated to the monomeric A3BCTD-AL1 species, was also visible 
(peak 2, Figure 6.8A). In parallel, when the monomeric A3BCTD-AL1 sample (10 mg/mL) 
was concentrated we observed a similar elution effect. Here, the majority eluted as a 
monomer (~ 96 %), while a very small percentage ~ 4 % eluted as the larger dimeric 
species (see small peak at 580 seconds, Figure 6.3). These findings suggested that an 
equilibrium between the putative dimeric and monomeric A3BCTD-AL1 species, and vice 
versa, is unlikely.  
To further explore this idea, the A3BCTD putative dimer was additionally studied under 
dilute concentrations (0.5, 1.25, and 2.5 mg/mL in high salt pH 7.4 buffer) to determine 
if the degree of dissociation of putative dimer changes as a function of concentration. 
Inspection of the elution profiles illustrated that for all the concentrations tested, the 
A3BCTD-AL1 putative dimer resulted in the same relative amount of monomeric A3BCTD-
AL1 (7-8%, observed at peak maximum around 710 seconds, Figure 6.8B), comparable 
with previous observations shown in Figure 6.8A. As the assembly and disassembly of 
the A3BCTD-AL1 putative dimer is not triggered by a concentration impact, and this 
putative dimer’s stability is maintained in solution, it can be concluded that self-





6.3.2.2 Interface assessment of A3BCTD-AL1 dimer  
Assessment of the potential binding interface region between two A3BCTD subunits was 
investigated using the PRISM 2.0 webserver 9, 264. This server uses a prediction-based 
algorithm with known interacting protein complexes as the template interface dataset. 
The target protein’s surface is first structurally aligned to template interfaces, then hotspot 
binding regions on the target protein are identified. Using this information, the proteins 
are modelled onto the selected template using docking methods, then rigorous refinement 
is conducted to predict the interface complex of the target proteins. The favourability of 
a given binding reaction is described by Gibbs free energy (ΔG), where ΔG values lower 
than zero are favourable. The more negative ΔG, the more favourable is the formation of 
a dimerisation interface. 
Under the notion that loop 1 from A3A may influence dimerisation of A3BCTD-AL1  
(discussed earlier in section 6.3.2.1), we compared the dimerisation potential of our 
A3BCTD-AL1 (A3BCTD-QM-ΔL3-AL1swap) and A3BCTD-QM-ΔL3 variants using 
PRISM 2.0 webserver 9, 264 as they only differed by a change of loop 1. We found that the 
generated A3BCTD-AL1 interface models had much lower ΔG values (ΔG ~ -38 and -18 
kcal/mol, see Table 8.8 Table 8.9) in comparison to the interface models of our A3BCTD-
QM-ΔL3 variant (ΔG ~ -13 and -3 kcal/mol, Table 8.6 Table 8.7). This indicated that our 
A3BCTD-AL1 construct had a much greater dimerisation potential than our A3BCTD-QM-
ΔL3 construct. As A3BCTD-AL1 only differed by loop 1 from A3A from our A3BCTD-
Figure 6.8 Purification of the A3BCTD-AL1 putative dimer using SEC-FPLC.  
Analysis of the A3BCTD-AL1 putative dimer using SEC-FPLC. (A) SEC elution profile of 5 mg/mL 
A3BCTD-AL1 putative dimer, (B) SEC elution profiles of the A3BCTD-AL1 putative dimer at varying 
concentrations 0.5 - 2.5 mg/mL. SEC-FPLC was conducted at a flow rate of 0.5 mL/min through the 











QM-ΔL3 construct, we can conclude that the presence of the A3A loop 1 directly 
influences dimerisation. The PRISM 2.0 results are in line with experimental 
observations, where only the A3BCTD-AL1 variant resulted in the elution of a larger 
putative dimeric species (Figure 6.7).  
Two potential dimerisation models of A3BCTD-AL1 (termed model 1 and model 2) were 
predicted. The interface of each model was predicted to be largely formed through 
electrostatic interactions that accordingly stabilise the structural arrangement of a dimeric 
molecule (refer to Table 8.8 and Table 8.9). The interface of model 2 was noticeably less 
favourable (ΔG ~ -18  kcal/mol) than that of the model 1 interface (ΔG ~ -38 kcal/mol) 
and was predicted to associate through loops 3 and 5, which forms part of the active-site 
cavity (described in section 1.6.4). As the surface of the active site is highly positively 
charged due to a histidine and a stretch of arginines, the interactions between residues 
forming this interface maybe weaker and less stable due to electrostatic repulsion (Figure 
6.9B). On the other hand, the interface of model 1 was predicted to be more favourable 
(ΔG ~ -38 kcal/mol), occurring through interactions slightly away from the active site 
(Figure 6.9A). Self-association between residues in β1, α1, α2, and loop 1 of the two 
molecules influences the arrangement of the interface (Figure 6.9).  Moreover, this 
interface places in close proximity a pair of cysteines (Cys239 on beta sheet 2 (β2)) that 
potentially further stabilise the interface by forming a disulfide bond (see Table 8.8 and 
Figure 6.9A).   
Assessment of these models using an alternate webserver PISA 131-132 indicated that both 
of these interfaces form through weak interactions such as hydrogen bonds and salt 
bridges (ΔG < 0) (see Table 8.10 and Table 8.11). So, the predicted disulfide bond of 
model 1 is essential to structural stability. These results indicate that the interface of 
model 1 is more likely than that of model 2 interface to form the A3BCTD-AL1 dimer, but 





Moreover, the A3BCTD-AL1 interface models formed interactions between residues 
within α2 and loop 1 in model 1 (Table 8.8 and Figure 6.9A) or α2, loop 3, and loop 5 in 
model 2 (Table 8.9 and Figure 6.9B). As discussed in section 1.6.4, several residues in 
the α2-helix and the aforementioned loops are essential in facilitating substrate binding 
and deamination of the target dC. Therefore, dimerisation through these regions may 
hinder substrate accessibility into the active site, consistent with a reduction of dC 
deamination in comparison to the monomeric A3BCTD-AL1 observed in Figure 8.2 
(further discussed in section 6.3.4). 
6.3.3 SEC-SAXS experiments on the A3BCTD-AL1 putative dimer 
To examine the hydrodynamic size and relative structure of the A3BCTD-AL1 putative 
dimer, SEC-co-flow-SAXS experiments using 2.5 mg/mL of this protein in kinetic pH 
5.5 buffer were performed (slight aggregates formed and the SEC diluted the 
concentration, so the new calculated concentration based on the absorbance ~ 1.3 
mg/mL). Initially, the Rg trace was overlaid onto the SAXS profile plot indicating that 
Figure 6.9 Models of the dimerisation interface of A3BCTD-AL1.  
Predicted interface models between two A3BCTD-AL1 molecules using PRISM webserver. A3BCTD-
AL1 molecule A (green, dimerisation interface in blue) and A3BCTD-AL1 molecule B (cyan, 
dimerisation interface in red) with Zn2+ (yellow sphere) in active-site. (A) & (C) Model 1 interface 
with a calculated ΔG ~ -38.12 kcal/mol, (B) & (D) Model 2 interface with a calculated ΔG ~ -18.6 
kcal/mol. Models represented as cartoons in  (A) & (B) have the chains and loops involved in the 
dimerisation interface labelled;, in (C) & (D) residues (in stick format) involved in the dimerisation 
interface are shown.  
(A)                         (B)   




across the sample peak an approximate Rg ~ 24 Å can be estimated (frames 540 – 615, 
Figure 6.10A). This revealed that this protein was in fact larger than the A3BCTD-AL1 
monomer (Rg ~18 Å, Figure 6.5). Guinier distribution analysis of the scattering data 
showed signs of slight sample aggregation at very low scattering angles (q < 0.0165 Å-1). 
Therefore, minor ameliorations were conducted (removing the first few points) to derive 
a linear dependency of the low q data in the Guinier plot (Figure 6.10B insert).  
The Kratky plot showed that the sample was a well-folded globular protein. This plot 
displayed a bell-shaped curve at low q, but at higher scattering angles (q > 0.2 Å-1) we 
see an upward turn of data implicating that there may be some flexibility in the putative 
dimer. Interestingly, the peak maximum of Kratky plot of the A3BCTD-AL1 putative 
dimer was around q ~ 0.07 Å, see Figure 6.10C, in contrast the monomeric A3BCTD-AL1 
Kratky plot that had a peak maximum around q ~ 0.10 Å as displayed in Figure 6.5C, 
further implying that the protein being studied here was hydrodynamically larger in size. 
This observation was also consistent for the P(r) plot, which displayed a histogram curve 
   (A)                                       (B) 
   (C)                                   (D) 
(i) 
Figure 6.10 SEC-SAXS analysis of A3BCTD-AL1 putative dimer.  
SAXS analysis of the A3BCTD-AL1 putative dimer scattering data was conducted using several 
programs from PRIMUSQT ATSAS 2.8.3 suite 75. (A) SAXS profile plot, (B) scattering curve (i) with 
the Guinier plot insert, (C) Kratky plot, (D) P(r) distribution plot. Experiments were conducted using 






that was slightly skewed (Figure 6.5D) consistent with standard compact dimers. Both 
the Guinier and P(r) calculations resulted in very similar Rg and I(0) values, listed in 
Table 6.3. The Rg, Dmax, and Porod volume of the A3BCTD-AL1 putative dimer were also 
indicative of a bigger molecule (Table 6.3) as compared to the structural parameters 
derived for the monomeric A3BCTD-AL1 (Table 6.1 and Figure 6.5). Finally, calculation 
of the MW using the Porod volume yields a MW of ~44 kDa similar to the MW derived 
from I(0) of ~46 kDa. This MW was roughly twice the size of the monomeric A3BCTD-
AL1, verifying that the species eluting in peak 1 observed in Figure 6.7A was in fact a 
dimeric form of A3BCTD-AL1.  
Table 6.3 SAXS structural parameters of the A3BCTD-AL1 putative dimer 
 
Next, space-filled envelope models were generated from the scattering profile 
(DAMMIF) using P2 symmetry as the state of the protein was a dimer. These models 
were averaged resulting in a model with an acceptable NSD score of 0.816 (Table 6.4). 
The generated envelope model were first fitted with two A3BCTD-AL1 monomer crystal 
structures (PDB: 5CQI 240). However, the relative orientations of the two A3BCTD-AL1 
molecules were difficult to determine.  
Structural parameters A3BCTD-AL1 putative dimer 
Guinier analysis  
I(0) (cm-1) 0.00480 ± 0.00004 
Rg (Å) 24.2 ± 0.8  
qmin (Å-1) 0.0165 
qRg max  1.3 
Coefficient of correlation (R2) 0.96 
P(r) analysis  
I(0) (cm-1) 0.00480 ± 0.00001 
Rg (Å) 24.5 ± 0.6 
Dmax (Å) 77.9 
q range (Å-1) 0.0165 - 0.3450 
Quality estimate 0.88 
Porod volume (Å3) 72,900 
MW (Porod Volume*0.6) (Da) (ratio to expected subunit 
22,000 Da) 
43,740 (1.99)  




Therefore, the simulated interface models described earlier in Figure 6.9 were used. The 
interface models were compared to the A3BCTD-AL1 dimer scattering data using rigid 
body modelling (FoXS 74, 226 and CRYSOL 75) as described in section 6.1.1. We found 
that model 1 resulted in very good visual fits to the data (see Figure 6.11A); in contrast 
model 2 had slightly less optimal visual fits, especially in the mid-q region 0.1 – 0.2 Å-1 
(Figure 6.11B). This suggested that model 1 was the most plausible solution. 
Furthermore, the interface model 1 was predicted to form in the most favourable 
conformation (as indicated by ΔG ~ -38 kcal/mol, Figure 6.9A), which further supports 
these observed results. Chi2 values for both models did not discriminate, as the Chi2 
values are dominated by the exponentially more intense low q <0.1 Å-1 data (Figure 6.11A 
and B).  
 
 
Figure 6.11 Fitting A3BCTD-AL1 dimer scattering data to the simulated atomic interface models.  
Rigid body modelling of the A3BCTD-AL1 dimer to (A) interface model 1 or (B) interface model 2 
using FoXS and CRYSOL . (C) model 1 interface structure fitted to the A3BCTD-AL1 dimer envelope.  
Averaged envelope model of  A3BCTD-AL1 dimer derived using P2 symmetry (DAMMIF, 





(A)                                                   (B)   





          (C) 
  
  




Table 6.4 SAXS fitting and modelling parameters of the A3BCTD-AL1 dimer 
Modelling parameters A3BCTD-AL1 dimer 
Ab intio restoration    
DAMMIF (default parameters, 10 calculations)   
q range (Å-1) for fitting 0.00165 - 0.345 
Symmetry  P2 
NSD (standard deviation) 0.816 (0.110) 
Resolution (from SASRES) (Å) 41 ± 3 
Structure modelling     
Interface dimer model 1  
FoXS, Chi2 0.93 
CRYSOL, Chi2 0.45 
Interface dimer model 2  
FoXS, Chi2 0.80 
CRYSOL, Chi2 0.32 
 
Moreover, model 1 interface was found to be organised in a similar manner to a 
previously reported crystal structure of an A3A homodimer (PBD 4XXO 23). In this 
structure a dimerisation groove was formed through the N-terminus slightly away from 
the active-site, leading to binding of the two A3 molecules 23, in a manner similar to our 
predicted interface model 1 (Figure 6.12B). Formation of this interface between the two 
A3A molecules were reported to occur through interactions with metal ions, salt bridges, 
and hydrophobic interactions. Four main residues (His11, Lys30, His16, and His56) were 
identified to be necessary for the formation of this interface (displayed in Figure 6.12A). 
One important interaction in the A3A homodimer was between a pair of His56 that were 
bridged by a Zn2+ ion, interestingly the A3A His56 is isosteric with Cys239 of A3BCTD-
AL1. Furthermore, interactions occurred between residues in loop 1, α1, α2, and β2 




Therefore, from this we can presume that our derived in-solution A3BCTD-AL1 dimer may 
in fact resemble the model 1 interface. Superimposing the generated envelope model with 
our interface dimer model 1 structure we can see that it fits well (Figure 6.11A and C). 
This model gives a starting point to look at the association of subunits of two-domain A3 
enzymes. 
6.3.4 A3BCTD-AL1 dimer complex with ssDNA   
The A3BCTD-AL1 dimeric form was identified to be catalytically active, with behaviour 
intermediate between the A3BCTD-QM-ΔL3-AL1swap and A3BCTD-QM-ΔL3 (see Figure 
8.2). Therefore, to understand how ssDNA binds to the A3BCTD-AL1 dimer in order to 
permit catalysis, the relative structure of this dimer in complex with dZ-oligo (to prevent 
complications of activity) was explored using SEC-co-flow-SAXS. Data were collected 
for the A3BCTD-AL1 dimer at 2.5 mg/mL in kinetic pH 5.5 buffer with and without dZ-
oligo (slight aggregates formed and the SEC diluted the concentration, adjusted ~ 1.3 
mg/mL as described in section 6.2.1). However, in these experiments we used a higher 
concentration of the dZ-oligo at a 1 to 10 ratio (protein to oligo) to ensure that the 
A3BCTD-AL1 dimer was saturated with ssDNA and drive the formation of a protein-
ssDNA complex. The initial inspection of the UV elution profile (Figure 6.13C) and the 
SAXS profile plot (Figure 6.13B) showed that the Rg values were not constant across the 
profiles, signalling that the sample was not homogeneous. Only the peak corresponding 
to the dZ-oligo had a constant Rg value of ~10 Å, as expected (711-750 sec, Figure 6.13B 
& C, frame numbers 668 – 698 Figure 6.14).  
(A)                                 (B)   
Figure 6.12 Dimerisation interface of A3A and A3BCTD-AL1. 
(A) A3A homodimer (PDB 4xxo 23) (grey) labelled with residues that are important in forming the 
dimerisation interface. A3A molecule A dimerisation residues labelled in blue  and A3A molecule B 
dimerisation residues labelled in orange (B) Comparison of the A3A homodimer (PDB 4xxo 23) (grey) 
to our dimer interface model 1 of A3BCTD-AL1 (molecule A in green and molecule B in cyan). Zn2+ 





Next, we compared the A3BCTD-AL1 dimer/dZ-oligo elution and SAXS profiles (Figure 
6.13C & Figure 6.14A) to the profiles of the ligand-free A3BCTD-AL1 dimer (Figure 
6.13A & Figure 6.14A). We found that upon the presence of the dZ-oligo the intensity of 
the peak corresponding to the A3BCTD-AL1 dimer decreases significantly (elution profile 
550 – 640 sec, Figure 6.13C, SAXS profile frames 520 – 610, Figure 6.14A). 
Interestingly, upon the decrease of the A3BCTD-AL1 dimer peak we noticed the 
appearance of a peak coinciding with the relative elution position and size (Rg ~ 18-19 
Å) of the monomeric A3BCTD-AL1 species (elution profile shoulder peak 650 – 700 sec 
insert Figure 6.13C, and SAXS profile frames ~ 613 – 653 Figure 6.14A).  
The increase of this monomeric species was intriguing. The three peaks visualised in 
Figure 6.14B reflected that the A3BCTD-AL1/dZ-oligo sample contained three scattering 
species, which were postulated to be a A3BCTD-AL1 dimer species, an A3BCTD-AL1 
monomeric species, and the unbound dZ-oligo (termed species 1-3, respectively). From 
(A)                                       (B) 
  
              (C)               
  
Figure 6.13 SEC elution profiles of A3BCTD-AL1 dimer and A3BCTD-AL1 dimer/dZ-oligo.  
SEC-FPLC performed using (A) 2.5 mg/mL (~ 56 µM) of A3BCTD-AL1 dimer, (B) 1.7 mg/mL (~ 566 
µM) of dZ-oligo, and (C) A3BCTD-AL1 dimer with dZ-oligo at a 1 to 10 ratio, closeup shown in the 
insert. Samples were run at 25 °C through a SEC column at a flow rate of 0.2 mL/min in kinetic pH 





the UV elution profile we observed that the peak maximum associated with the unbound 
dZ-oligo decreases slightly by ~5-fold (Figure 6.13C) in comparison to the control 
oligonucleotide elution profile in Figure 6.13B. This decrease suggested that a protein-
ssDNA complex may have formed. However, it was unclear from the elution profile 
which A3BCTD-AL1 species was in complex with the ssDNA (Figure 6.13C). To analyse 
each species the scattering curves had to first be generated, but as components of each 
peak overlapped slightly the boundaries of each scattering species had to be defined using 
deconvolution analysis SVD/EFA (BioXTAS RAW 105 (described in section 6.1.1 and 
Figure 8.9). SVD analysis was first performed resulting in an eigenvalue of three (see 
Figure 8.9), corresponding to the presence of three distinct scattering species in the 
sample, as previously presumed from the Rg pattern in the elution and SAXS profiles 
(Figure 6.13C and Figure 6.14A). Then, EFA was used to define the boundaries of each 
species (Figure 6.14B) and their respective 1D-scattering curves were generated.  
 
Figure 6.14 Deconvolution of SAXS data of the A3BCTD-AL1 dimer/dZ-oligo.  
(A) Comparison of the SAXS profiles of the A3BCTD-AL1 dimer (green) and A3BCTD-AL1 dimer with 
dZ-oligo at a 1 to 10 ratio (orange) overlaid with Rg trace values. (B) EFA analysis using BioXTAS 
RAW indicating the distinct scattering species 1-3. 










Analysis of these scattering curves was performed as described in section 6.1.1 using the 
PRIMUSQT ATSAS 2.8.3 suite. The scattering curve of species 3, which corresponds to 
the unbound dZ-oligo was not further analysed due to limitations of SAXS resolution (> 
10 Å). So, focus was placed on the analysis of species 1 and 2. First, the double log plot 
indicated that both species were homogeneous as the data at low q plateaued (Figure 
6.15B). The Kratky plots reinforced that species 1 was larger than species 2, and based 
on the peak maximum position we can justify that species 1 was fundamentally the 
dimeric A3BCTD-AL1 (q ~ 0.07 Å
-1), while species 2 was the A3BCTD-AL1 monomer (q 
~ 0.1 Å-1) (Figure 6.15C) as observed earlier in sections 6.2.3 and 6.3.3), and supported 
by the calculated MW (see Table 6.5) 
 
 
   (A)                            (B) 
   (C)                            (D) 
Figure 6.15 SAXS analysis of the A3BCTD-AL1-dimer/dZ-oligo deconvoluted species.  
Analysis of the scattering data of the deconvoluted A3BCTD-AL1 dimer/dZ-oligo species was 
conducted using several programs from the PRIMUSQT ATSAS 2.8.3 suite 75. (A) 1D-scattering 
curves of each species with a Guinier plot insert, (B) double log plot, (C) Kratky plot, (D) P(r) 
distribution plot. Experiments were conducted using 2.5 mg/mL of A3BCTD-AL1-dimer with dZ-oligo 







Table 6.5 SAXS structural parameters of the A3BCTD-AL1 dimer/dZ-oligo sample 
 
The molecular weights of these species were only calculated from the Porod volume, not 
from I(0) 178 (listed in Table 6.5), as the concentration of each species was difficult 
estimate due to their overlap during elution. The Guinier distribution analysis showed that 
the scattering profile of species 1 had a reasonably good linear fit, after eliminating the 
first several lowest q data points (Figure 6.15A insert), with estimated Rg and I(0) values 
(listed in Table 6.5) in good agreement with values calculated from the P(r) plot (as 
described in section 6.3.3). However, analysis performed using the low q data range for 
species 2 required significant amendments (removing the first 15 points), giving a 
suboptimal fit to the linear regression, with compromised precision and accuracy (Figure 
6.15A insert). The P(r) plot for species 2 gave Rg ~ 20 Å and Dmax ~ 60 Å and the Porod 
plot gave MW ~ 23 kDa (listed in Table 6.5). These parameters are consistent with a 
monomeric A3BCTD-AL1 in complex with ssDNA (as noted earlier in Table 6.1). 
However, as the scattering data of species 2 were particularly noisy (Figure 6.15A) due 
to its low concentration (see Figure 6.13C and Figure 6.14), calculation of its structural 
parameters are less precise than those for species 1 (see Table 6.5) 
Structural parameters Species 1               
(A3BCTD-AL1 dimer) 
Species 2               
(A3BCTD-AL1 
monomer/dZ-oligo)  
Guinier analysis   
I(0) (cm-1) 0.0036 ± 0.0001 0.00110 ± 0.00005 
Rg (Å) 24.8 ± 1.5  20.0 ± 1.5  
qmin (Å-1) 0.01795 0.0231 
qRg max  1.3 1.3 
Coefficient of correlation (R2) 0.98 0.86 
P(r) analysis   
I(0) (cm-1) 0.00352 ± 0.00007 0.00110 ± 0.00005 
Rg (Å) 25.1 ± 0.5 20.1 ± 0.8 
Dmax (Å) 78.2 60.1 
q range (Å-1) 0.01795 - 0.2756 0.0231 - 0.2317 
Quality estimate 0.89 0.85 
Porod volume (Å3) 74,000 38,400 
MW (Porod Volume*0.6) (Da) (ratio to 
expected subunit 22,000 Da) 




The values of Rg, Dmax, and MW (from Porod volume) of species 1 (listed in Table 6.5) 
are similar to those obtained for the ligand-free A3BCTD-AL1 dimer (Table 6.3). This 
suggested that in the presence of the oligonucleotide the A3BCTD-AL1 dimer did not form 
a complex with the ssDNA. To verify this notion, the A260/A280 ratio of the ligand-free 
A3BCTD-AL1 dimer was compared to the ratio of the A3BCTD-AL1 dimer/dZ-oligo 
sample to assess the presence of DNA in the eluted protein sample. Using this method, 
we observed that the ratio remained relatively unchanged in the region where species 1 
elutes off the SEC column (see Figure 6.16). This implied that the A3BCTD-AL1 dimer 
(species 1) was in fact not bound to the oligonucleotide. Interestingly, as shown in Figure 
6.16, in the region where species 2 elutes the A260/A280 ratio of the A3BCTD-AL1 
dimer/dZ-oligo sample (1.335 at 680 s) is significantly larger than the ratio of the ligand-
free A3BCTD-dimer sample (0.811 at 680 s).  
These results justify earlier observations that this monomeric A3BCTD-AL1 is in complex 
with the dZ-oligo. As our dimeric A3BCTD-AL1 (species 1) does not bind ssDNA in 
solution we can presume that it is not associated with the observed catalytic activity 
(Figure 8.2). So, we can conclude that the trace of monomeric A3BCTD-AL1 (species 2) 
that is always present would be mediating the observed activity. From these observations, 
we can propose that the catalytic activity of the enzyme could be regulated through 
Figure 6.16 Ratio of A260/A280 to assess the presence of DNA during elution of A3BCTD-AL1 
dimer/dZ-oligo sample.  
A260/A280 ratio taken of the A3BCTD-AL1 dimer (blue) and the A3BCTD-AL1 dimer/dZ-oligo (green) 
samples. Overlaid with the A280 elution profile of the A3BCTD-AL1 dimer/dZ-oligo sample (red) to 






dimerisation as suggested by earlier studies 22-23, 27, 79, 118, 233. However, whether 
dimerisation of A3 enzymes would occur in this manner within the cell remains unknown.  
Table 6.6 SAXS fitting and modelling parameters of the A3BCTD-AL1 dimer/dZ-oligo sample. 
 
Next, space-filled envelope models were produced from the scattering profiles of species 
1 using P2 symmetry and species 2 using P1 symmetry (DAMMIF). However, as 
expected the high noise ratio of the data generated envelope models that were largely 
variable resulting in high NSD scores > 0.9 for the averaged models (for satisfactory 
models NSD ≤ 0.8); see Table 6.6. Therefore, the derived envelope models do not give 
an accurate representation of the SAXS model of each species (see Figure 8.11).  
Modelling parameters Species 1               
(A3BCTD-AL1 dimer) 
Species 2               
(A3BCTD-AL1 
monomer/dZ-oligo) 
Ab intio restoration     
DAMMIF (default parameters, 10 
calculations)  
  
q range (Å-1) for fitting 0.01795 - 0.2756 0.0231 - 0.2317 
Symmetry  P2 P1 
NSD (standard deviation) 0.993 (0.081) 1.006 (0.044) 
Resolution (from SASRES) (Å) 28 ± 2 29 ± 2 
Structure modelling      
5TD5*     
FoXS, Chi2 2.46 0.30 
CRYSOL, Chi2 1.73 0.28 
Interface dimer model 1   
FoXS, Chi2 1.03 0.42 
CRYSOL, Chi2 1.41 0.33 
Interface dimer model 2   
FoXS, Chi2 1.26 0.42 




So, rigid body modelling was performed (FoXS and CRYSOL) to provide better insights 
into the structures of each species by comparing their experimentally derived scattering 
data to the simulated dimer models described earlier (section 6.3.2.2 and 6.3.3) and the 
atomic A3BCTD/dZ-oligo structure (5TD5* mentioned earlier 6.2.3 
239) (Table 6.6). Using 
this method, we found that monomeric A3BCTD-AL1/dZ-oligo (species 2) scattering data 
had a nice visual fit to the A3BCTD-ssDNA structure (5TD5*), particularly in low q range 
of 0-0.15 Å-1 (Figure 6.17B i). In contrast, this species had less then optimal visual fits to 
the A3BCTD-AL1 dimer interface models (Figure 6.17B ii-iii), as anticipated. However, 
the Chi2 values did not differentiate between the models as Chi2 is dominated by the 
exponentially more intense low q data (< 0.1 Å-1). On the other hand, our A3BCTD-AL1 
dimeric species data (species 1) resulted in a very poor fit to the monomeric A3BCTD-
ssDNA structure (5TD5*), as expected (see Figure 6.17A i and Table 6.6 which reports 
high Chi2 values). Better fits, however, were obtained against the dimer interface models, 
especially at low q regions (0.01-0.12 Å-1, Figure 6.17A ii-iii).  
However, at  q > 0.15 Å-1, this dimeric species did not seem to fit so nicely to these models 
as previously observed for our ligand-free A3BCTD-AL1 dimer (Table 6.2). The 
discrepancy is attributed to errors in deconvoluting noisy data, rather than to some 
Figure 6.17 Fitting A3BCTD-AL1 dimer/dZ-oligo species 1 and 2 scattering data to models 
structures.  
Rigid body modelling of the A3BCTD-AL1 dimer/dZ-oligo (A) species 1 and (B) species 2, against the 
(i) 5TD5* crystal structure (A3BCTD-9mer), (ii) model 1 dimer interface (iii) model 2 dimer interface 
using FoXS and CRYSOL.  
(A) 
 (i)                                           (ii)                       (iii)   
(B) 




interaction of the A3BCTD-AL1 dimer with the dZ-oligo, as such interaction is not 
supported by the A260/A280 ratio. 
6.4 SAXS models of the double domain A3 protein  
Structures of inactive single A3 domains in complex with substrate ssDNA have been 
reported 239, but structures of double-domain A3 bound to ssDNA remain unknown due 
to difficulties in crystallisation. Therefore, to understand how one domain is positioned 
relative to the other and how ssDNA binds to these domains in solution, SEC-SAXS was 
utilised. We examined active two-domain A3 structures in the absence and presence of 
our ssDNA-based inhibitor to prevent substrate deamination during the experiment.  
6.4.1 Selection of the double domain A3G 
Initially, A3B constructs, cloned into a pcDNA3.1(-)/MycHis expression vector 
(Invitrogen) (obtained from Harris and Aihara labs, University of Minnesota), were 
transfected into HEK293T mammalian cells and purified as described 239-240. However, 
expression levels and solubility of the full-length recombinant A3B protein were poor. 
Therefore, the closely related A3G enzyme was used to model two-domain A3 structures 
(obtained from Prof. Linda Chelico, University of Saskatchewan). Both A3G and A3B 
are subcategorised into the same phylogenetic class based on the same domain 
configuration (N'-Z2/Z1-C') (see section 1.6.1) and share an overall sequence identity of 
approximately ~56 % (refer to Figure 8.10).  
6.4.2 The double domain A3G  
A catalytically active full-length wild type A3G protein (termed A3Gfl-Wt) was assessed 
at 2.5 mg/mL in A3G kinetic pH 6 buffer to favour DNA binding (slight aggregates 
formed and SEC caused a dilution so a new concentration ~ 1.3 mg/mL was calculated 
based on the absorbance). Inspection of the UV elution profile and SAXS profile of the 
A3Gfl-Wt showed that the sample was not well resolved, resulting in a large peak made 
up of several overlapping peaks (Figure 6.18A and B). Moreover, superimposing the Rg 
trace values over the elution and SAXS profiles we see a large variability in the Rg values 
from ~30 to !50 Å across this peak, indicating that multiple scattering species were 
present in the sample (Figure 6.18A and B). Therefore, before continuing to parameter 
analysis, the SAXS data had to first be analysed by SVD and EFA (SVD/EFA BioXTAS 
RAW 105) to elucidate the number and boundaries of the scattering components (see 




in the sample (EFA 1; frames 353-578, EFA 2; 463-668, EFA 3; 563-718). However, as 
the boundaries were significantly overlapped it was difficult to isolate the data of each 
scattering species (Figure 6.18C).  
Therefore, Gaussian decomposition analysis (US‑SOMO) was performed by Dr. Timothy 
Ryan (SAXS/WAXS beamline scientist, Australian Synchrotron) by fitting Gaussian 
functions to produce decomposed 1D-scattering curves of distinct components (Figure 
6.18D). The derived scattering curves had a high noise-to-signal ratio as a consequence 
of deconvolution and the low concentration of each species. Although the data were fitted 
with five Gaussians, only Gaussians 2 and 3 (termed A3G_species A and B) produced 
decent scattering curves (Gaussian 2, frames 414-483, and Gaussian 3, frames 459-541) 
with higher intensities than the other Gaussians indicating their significance in the overall 
scattering pattern of the sample. Therefore, these two curves were analysed using 
PRIMUSQT (ATSAS 2.8.3 suite) to identity the species present.  
Figure 6.18 Deconvolution of the SAXS data of the A3Gfl-Wt.  
SEC-SAXS analysis of A3Gfl-Wt. (A) SEC elution profile collected with A280 and (B) SAXS profile 
superimposed with Rg trace values. (C) EFA analysis using BioXTAS RAW (D) Gaussian 
decomposition analysis using US‑SOMO. Experiments were conducted at 25 °C using 2.5 mg/mL 
A3Gfl-Wt in A3G pH 6.0 kinetic buffer (50 mM phosphate pH 6.0, 200 mM NaCl, 2mM β-ME, 5% 
glycerol, 200 µM Na2-EDTA). 
   (A)                                   (B) 




Initial analysis of the derived scattering curves revealed that the A3G scattering species 
were homogeneous, illustrated by the plateau of low q values in the double log graph 
(Figure 6.19B).  Guinier distribution analysis of A3G_species A using data in the low q 
range resulted in an unsatisfactory fit to the linear regression, which compromised 
estimation of the Rg and I(0) (Figure 6.19B insert). From the P(r) plot, A3G_species A 
was estimated to have an  Rg ~ 60 Å and Dmax ~ 160 Å. However, as the scattering data 
of this species had a low signal-to-noise ratio, accurate derivation of the structural 
parameters for this species was difficult (Figure 6.19A and B).  
Comparison of the Kratky plots of the derived scattering species showed that the position 
of the peak maximum of the A3G_species A (at q ~0.025 Å-1) was half that of the 
A3G_species B (q ~ 0.05 Å-1) (Figure 6.19C), indicating that the A3G_species A was 
about double the size of the A3G_species B. This was also observed in the elution pattern, 
as bigger particles elute off the SEC column earlier than smaller ones, A3G_species A 
elutes before A3G_species B (Figure 6.18A). Finally, A3G_species B was perceived to 
Figure 6.19 SAXS analysis of A3Gfl-Wt deconvoluted species.  
Analysis of the scattering data of the deconvoluted A3Gfl-Wt species was conducted using several 
programs from the PRIMUSQT ATSAS 2.8.3 suite 75. (A) 1D-scattering curves of the species (B) 
Double log plot with insert Guinier plot (C) Kratky plot. (D) P(r) distribution plot. Experiments were 
conducted using 2.5 mg/mL of A3Gfl-Wt in A3G pH 6.0 kinetic buffer. 
   (A)                                           (B) 




be much more prominent than the larger A3G_species A, as displayed by better signal to 
noise (Figure 6.18B).  
We then focused, on the more prominent A3G_species B, for which we found a sensible 
fit of the Guinier plot indicating a monodispersed sample (see Figure 6.19B insert). Both 
the Rg and I(0) derived from the Guinier and the P(r) plots were very similar, confirming 
the relative size of the species as listed in Table 6.7. The Kratky plot showed a nice bell-
shaped curve with a peak maximum q ~ 0.05 Å-1; however, the plot at high q did not 
completely return to the baseline suggesting that the structure may contain flexible 
regions (Figure 6.19C). Noticeably, the estimated size of Rg and Dmax of our A3G_species 
B (Rg ~ 42 Å, Dmax ~ 141 Å, Table 6.7) was found to be similar to a previously reported 
A3G elongated dimer SAXS model 276. However, our molecular weight was estimated to 
be ~ 208 kDa (derived from Porod volume, not from I(0) 178 as each species overlapped 
discussed in section 0), which was double the size of this previously reported A3G 
elongated dimer ~100 kDa 276. This suggested that our A3G species is not a dimer, but 
may exist as a compact tetramer under our conditions, where four two-domain A3G 
molecules oligomerise together.  
Table 6.7 SAXS structural parameters of the A3Gfl_Wt sample 
  Structural parameters A3G_species B                              
(A3G tetramer) 
Guinier analysis  
I(0) (cm-1) 0.0044 ± 0.0001 
Rg (Å) 41.5 ± 1.5  
qmin (Å-1) 0.01245 
qRg max  1.3 
Coefficient of correlation (R2) 0.95 
P(r) analysis  
I(0) (cm-1) 0.0044 ± 0.0001 
Rg (Å) 42.0 ± 1.0 
Dmax (Å) 145.9 
q range (Å-1) 0.01245 - 0.34030 
Quality estimate 0.85 
Porod volume (Å3) 346,000 







Therefore, ab initio shape restoration (DAMMIF, ATSAS 2.8.3 suite 75) was performed 
with a P4 symmetry constraint based on the parameter calculations indicating a tetrameric 
structure. The averaged low-resolution dummy model had an acceptable NSD value of 
0.645 indicating that the models were in good agreement (see Table 6.8). Modelling the 
molecular envelope without symmetry gave a similar NSD ~ 0.695.  
Table 6.8 SAXS fitting and modelling parameters of the A3Gfl-Wt sample 
Modelling parameters A3G_species B 
Ab initio restoration    
DAMMIF (default parameters, 10 calculations)   
q range (Å-1) for fitting 0.01245 - 0.34030 
Symmetry  P4 
NSD (standard deviation) 0.645 (0.180) 
Resolution (from SASRES) (Å) 33 ± 3 
 
The envelope model exhibited an elongated shape (Figure 6.20A), consistent with 
observations from the Kratky plot (Figure 6.19C). Initially, we attempted to superimpose 
the derived A3G space-filled model with four of our A3BCTD-AL1 dimer envelopes to 
determine their relative fit, resulting in a generally good fit (Figure 6.20B). However, due 
to the large surface area of the A3G tetramer space-filled model we were not able to 
accurately determine the position of these envelopes, so we cannot build a model structure 
using this approach. Nevertheless, docking the four A3BCTD-AL1 dimer envelopes onto 
this A3G tetramer model we saw that they were tightly attached to one another, consistent 
with notation of being a compact tetramer.  
Figure 6.20 Ab initio shape restoration of A3G tetramer.  
(A) Envelope models generated using DAMMIF (ATSAS 2.8.3 suite) 75 under P4 symmetry of A3G 
tetramer and further refined using DAMAVER and DAMFILT (ATSAS 2.8.3 suite) 75, (B) A3G 
tetramer envelope model (orange) docked with four A3BCTD-AL1 dimer envelopes. 




Until now, double-domain A3 structures remained unknown, but crystal structures of 
A3G dimers (derived from the Rhesus macaque) have been published earlier this year 
(January 2020) (PDB; 6p40, 6p3x, 6p3z, and 6p3y) 286. Using these atomic A3G dimer 
structures, interface analysis can be performed using PRISM 2.0 webserver 9, 264 in a 
similar manner as described in section 6.3.2.2 to generate A3G tetramer models, which 
can then be compared to our A3G scattering data. However, this work remains to be 
concluded. Nevertheless, from our SEC-SAXS experiments we can conclude that the 
ligand-free double-domain A3G exists in multiple states in solution that are yet to be 
structurally elucidated. 
6.4.3 SAXS model of two-domain A3 in complex with ssDNA 
6.4.3.1 SAXS model of a CCdZ30-40mer ssDNA 
Several aspects contributed in the design and use of a 40mer dZ-containing 
oligonucleotide, to model the double-domain A3G-ssDNA complex using SAXS. As 
mentioned earlier in chapter 5, A3G has an intrinsic preference towards deamination of 
dC near the 3'-end of a CCC-motif (Km ~ 570 µM for A3GCTD on 5'-ATTCCCAATT 94). 
Incorporation of dZ in this position was reported to lead to significant inhibition of the 
A3GCTD activity (CCdZ) 
136. Contrary to A3BCTD-AL1 (5FdZ-oligo ~ 2 µM, dZ ~ 8 µM, 
section 4.4.2), 5FdZ-containing ssDNA (5'-ATTCC5FdZAATT, Ki ~ 71 ± 14 µM) did 
not show a marked improvement in the inhibition of A3G over dZ-containing ssDNA (5'-
ATTCCdZAATT, Ki ~ 53 ± 10 µM). Therefore, we decided to incorporate dZ into the 
CCC-motif to prevent deamination complications by the catalytically active A3G and to 
enhance the binding affinity of the ssDNA to the protein. 
Moreover, it was reported that 20mer oligonucleotides had higher binding affinities to 
single domain A3 enzymes than shorter oligonucleotide sequences 135. Therefore, a 40mer 
oligonucleotide was thought to better accommodate binding to two-domain A3 enzymes. 
Studies conducted by Dr Stefan Harjes demonstrated that extending the 10mer CCdZ- or 
CC5FdZ-oligos by a poly T30 tail at the 3'-end decreased the deamination rates of the 
active A3G in comparison to the 10mer oligonucleotides, consistent with an increased 
affinity for the longer oligonucleotide (illustrated in Figure 6.21). Placement of the CCdZ 
or CC5FdZ-motifs near the 5'-end of the 40mer ssDNA (CCdZT30-oligo and CC5FdZT30-
oligo, Figure 6.21) led to significant inhibition of the full-length A3G activity, whereas 




Figure 6.21) did not greatly reduce the enzymatic activity. This implied that the specificity 
of these oligonucleotides to inhibit the two-domain A3G must be spatially oriented 
towards the CTD (5'-CCdZT30 or 5'-CC5FdZT30). These observation were also reported 
by Chelico et al 48  
Furthermore, Harjes et al reported that the inhibition of the A3GCTD was comparable to 
the overall inhibition of the two-domain A3G 136, signifying that inhibition of the catalytic 
activity of the two-domain A3G was attributed to inhibition of the CTD rather than the 
NTD, which regardless lacks deamination activity 187. Taken together, the specificity of 
modified-ssDNA to bind to double-domain A3 relies on the CTD and the ssDNA’s 
orientation. Therefore, to study the structure of the double-domain A3G in complex with 
ssDNA, a 40mer CCdZT30-oligo (5'-ATTCCdZAATTT30, poly T30 tail at the 3'-end) was 
selected to ensure binding to the CTD and inhibition of the catalytically active A3G.  
Figure 6.21 Qualitative screen of modified-oligos on the inhibition of A3Gfl-Wt catalysed 
deamination of the preferred dC substrate in 5'-ATTCCCAATT. 
Plot of the initial speed of deamination of 500 μM 5'- ATTCCCAATT (target dC underlined) by the 
A3Gfl-Wt in the absence or presence of 50 μM CCdZ- or CC5FdZ-containing oligos. Experiments 
were performed using the 1H-NMR-based inhibition assay (see section 2.5.3) in a pH 6.0 buffer (100 
mM NaCl, 50 mM sodium phosphate buffer, pH 6.0, 10 % D2O, 1 mM citrate, 50 μM DSS) at 298 K. 
Experiments with 10mer oligonucleotides were repeated multiple times and the mean values were 
plotted with error bars reported as SD, whereas single experiments were performed on 40mer 





Initially, the CCdZT30-oligo (termed CCdZ-40mer) was examined using SEC-co-flow-
SAXS to understand its dynamic structure in solution and to aid in modelling the A3G-
ssDNA complex. The CCdZ-40mer oligo eluted off the SEC column as a single 
monodisperse species (Figure 6.24B), with a steady Rg ~32 Å displayed across the peak 
in both the elution and SAXS profiles (see Figure 6.22A and Figure 6.24B). The double 
log plot resulted in a plateau at low q values, indicating that the sample was homogenous 
(see insert Figure 6.22B ii), which was further verified by a good fit to the linear 
regression in the Guinier plot (insert Figure 6.22B i).  
Estimation of the Rg and I(0) values from the Guinier slope agreed well with values 
obtained by the independent P(r) method, further confirming the quality and relative size 
of the oligonucleotide listed in Table 6.9. From these parameters the estimated MW ~12-
13 kDa of the oligonucleotide was found to be comparable to the expected MW ~12 kDa 
(Table 6.9). The Kratky profile indicated that the oligonucleotide adopted a highly 
flexible extended conformation, as values at q > 0.1 Å-1 did not return back to the baseline 
(Figure 6.22C). This was additionally supported by the P(r) plot, which was significantly 
Figure 6.22 SEC-SAXS analysis of the CCdZ-40mer oligo.  
SAXS analysis of the scattering data of the CCdZ-40mer oligo conducted using several programs 
from the PRIMUSQT ATSAS 2.8.3 suite 75. (A) SAXS profile with Rg trace values superimposed 
over profile, (B) scattering curve with inserts of the (i) Guinier plot and (ii) double log plot, (C) 
Kratky plot. (D), P(r) distribution plot. Experiments preformed using 0.68 mg/mL (~ 56 µM) of 
CCdZ-40mer ssDNA in A3G pH 6 kinetic buffer.  
   (A)                         (B) 
   (C)                                 (D) 







skewed to the right in comparison to the standard symmetrical bell-shaped histogram 
(Figure 6.22D).  
Table 6.9 SAXS structural parameters of the CCdZ-40mer oligo sample 
  Structural parameters CCdZ-40mer oligo  
Guinier analysis  
I(0) (cm-1) 0.00530 ± 0.00012 
Rg (Å) 32.0 ± 1.0  
qmin (Å-1) 0.0165 
qRg max  1.3 
Coefficient of correlation (R2) 0.97  
P(r) analysis  
I(0) (cm-1) 0.005260 ± 0.000008 
Rg (Å) 32.2 ± 0.3 
Dmax (Å) 118.0 
q range (Å-1) 0.0165 - 0.2975 
Quality estimate 0.78 
Porod volume (Å3) 20,700 
MW (Porod Volume*0.6) (Da) (ratio to expected subunit 
12,084 Da) 
12,420 (1.03) 
MW (from I(0) 178) (Da) (ratio to expected subunit 12,084 Da) 13,150 (1.09) 
 
Reconstruction of the scattering profile using 3D envelope modelling (NSD ~ 0.875) 
demonstrated, remarkably, that we can visualise the grooves within the oligonucleotide. 
The envelope model mimics a dumbbell, which is consistent with the shape of the P(r) 
curve (observed in Figure 6.22D), as described in literature 209. This model illustrates that 
the oligonucleotide is made up of four helical turns, consistent with the number of base 
pairs in the 40mer ssDNA (ten base pairs is equivalent to one helical turn). Interestingly, 
we observe that the CCdZ-40mer oligo forms a kink in the middle of the sequence (Figure 
6.23B i). This may be due to the adenosine near the modification, which may influence 




Based on the envelope model, the CCdZ-40mer oligo adopts the standard B-form DNA 
structure, even though it is single stranded, under our conditions in solution, which is a 
less compact helical structure in comparison to the standard compact A-form (Figure 
6.23B). Therefore, the averaged envelope model was superimposed with a B-form 40mer 
ssDNA structure (designed using the make na server http://structure.usc.edu/make-
na/server.html), and modelled with a kink, which gave a nice visual fit (Figure 6.23B ii). 
To validate this model, rigid body modelling was performed by comparing back-
calculated 1D scattering profiles of the designed B-form DNA structure to the 
experimentally derived CCdZ-40mer scattering data using both FoXS 74, 226 and CRYSOL 
75. The scattering data showed a good visual fit to the B-DNA model, especially in the q 
regions between 0.02 – 0.2 Å-1 as illustrated in Figure 6.23 and summarised in Table 6.10. 
Therefore, the in-solution SAXS-based model of the CCdZ-40mer oligo is comparable to 












Figure 6.23 Fitting CCdZ-40mer ssDNA experimental data. 
(A) Rigid body modelling of CCdZ-40mer oligo data to a B-form 40mer oligo model structure using 
FoXS and CRYSOL (B) (i) Averaged envelope model of  CCdZ-40mer oligo using P1 symmetry 
using DAMMIF and refined with DAMAVER and DAMFILT (ATSAS 2.8.3 suite) 75. (ii) Envelope 




Table 6.10 SAXS fitting and modelling parameters of the CCdZ-40mer ssDNA sample 
Modelling parameters CCdZ-40mer oligo  
Ab intio restoration    
DAMMIF (default parameters, 10 calculations)   
q range (Å-1) for fitting 0.0165 - 0.2975 
Symmetry  P1 
NSD (standard deviation) 0.875 (0.052) 
Resolution (from SASRES) (Å) 36 ± 3 
Structure modelling     
40mer ssDNA B-form model  
FoXS, Chi2 0.74 
CRYSOL, Chi2 0.43 
 
6.4.3.2 SAXS model of the active two-domain A3G in the presence of dZ-containing 
ssDNA 
To elucidate a model for the two-domain A3 in complex with ssDNA, SEC-SAXS 
experiments were performed on A3Gfl-Wt in the presence of CCdZ-40mer oligo 
(described earlier 6.4.3.1) in A3G kinetic pH 6.0 buffer. However, we observed that the 
sample was not homogeneous and the eluents were not well resolved, similar to the 
ligand-free A3Gfl-Wt sample (see section 6.4.2). Focusing on the elution profiles, the Rg 
trace was observed to be variable across the protein elution peaks, denoting that multiple 
A3G species were present in the sample (Rg ~ 30 - 54 Å across 460 - 590 sec, Figure 
6.24C), as detailed earlier in section 6.4.2. However, Rg remains constant over the region 
where the oligo elutes (Rg ~ 33 Å, from 597 – 645 seconds, Figure 6.24C). However, 
when we compared the absorbance maximum of the eluted ssDNA peak from this sample 
(A280 ~ 1.02, Figure 6.24C) to that of ssDNA control sample (A280 ~ 1.53, Figure 6.24B), 
we found that the absorbance significantly decreased by ~ 30 %. This decrease was 
reciprocated by an increase in the overall absorbance of the eluted protein fractions, 
establishing that a protein-DNA complex had formed. However, as the A3Gfl-Wt protein 
existed in multiple conformation under our conditions (detailed earlier in section 6.4.2), 
it was unclear from the elution profile which A3G form was in complex with the 
oligonucleotide (further discussed later in Figure 6.27). Therefore, Gaussian 




(frame numbers 385 - 650, Figure 6.25A), to extract the scattering curves for each A3G 
component from the A3Gfl-Wt/CCdZ-40mer sample.  
Initially, SVD and EFA analyses were conducted using SVD/EFA BioXTAS RAW 105 to 
establish the number and boundaries of each scattering species, as described earlier in 
section 6.1.1. SVD estimated that there were four components in this region (refer to 
Figure 8.13). EFA analysis integrated the boundaries of each species (EFA 1: 385-526, 
EFA 2: 446-559, EFA 3: 485-583, EFA 4: 477-590, Figure 6.25B). Plotting these as 
individual peaks we found that the components in EFA 2, 3, and 4 were major contributors 
to the scattering pattern, while EFA 1 was barely present (Figure 6.25B). To further 
isolate the 1D-scattering curves of each component Gaussian decomposition analysis 
(US‑SOMO) were performed by Dr. Timothy Ryan (SAXS/WAXS beamline scientist, 
Australian Synchrotron) as described earlier in section 6.4.2. Four Gaussian functions 
were fitted to the data (Figure 6.25C), then converted into four 1D-scattering curves of 
each component (termed species 1-4).  
Figure 6.24 SEC elution profiles of A3Gfl-Wt with and without ssDNA.  
SEC-FPLC performed using (A) A3Gfl-Wt at 2.5 mg/mL (~ 56 µM), (B) 0.68 mg/mL (~ 56 µM) of 
CCdZ-40mer oligo and, (C) A3Gfl-Wt with CCdZ-40mer ssDNA at a 1 to 2 ratio. Samples were run 
at 25 °C through a SEC column at a flow rate of 0.2 mL/min in A3G pH 6 kinetic buffer (50 mM 
phosphate pH 6.0, 200 mM NaCl, 2 mM β-ME, 5% glycerol, 200 µM Na2-EDTA). 
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Initially, we established using the double log plot  that all the derived scattering curves 
contained only one scattering species (Figure 6.26B), as explained in section 6.1.1. The 
Kratky plots of species 1-3 presented characteristic bell-shaped peaks at low q implying 
that the proteins were globular, though the structures also had flexible regions as indicated 
by high q data not completely returning to baseline (Figure 6.26C). These results were 
again consistent with the skewed shape of the P(r) curve from a standard bell-shaped 
curve, implying these components had elongated shapes (Figure 6.26D). Interestingly, 
the Kratky plot of species 4 had a broader peak that downturned at low q, which is typical 
of a multidomain structure with a flexible linker (Figure 6.26C). However, due to the low 
abundance of species 1 as indicated by its low signal intensity (Figure 6.25B) no accurate  
parameters could be derived for this species (see Figure 6.26B insert). Nevertheless, the 
Kratky plot of species 1 indicated that it was twice as big as species 2, based on the peak 
maximum positions as described earlier in section 6.4.2. Therefore, we focused on 
deriving structural parameters for species 2-4, as listed in Table 6.11.  
Figure 6.25 Deconvolution of SAXS data of the A3Gfl-Wt/CCdZ 40mer sample.  
SEC-SAXS analysis of A3Gfl-Wt/CCdZ-40mer sample (A) SAXS profile with Rg trace values 
superimposed over profile. (B) EFA analysis using BioXTAS RAW (C) Gaussian decomposition 
analysis using US‑SOMO. Experiment conducted using 2.5 mg/mL A3Gfl-Wt in a 1 to 2 ratio with 
CCdZ-40mer oligo in A3G pH 6.0 kinetic buffer at 25 °C. 
 
 
   (A)                                (B) 




Table 6.11 SAXS structural parameters of the A3Gfl_Wt in presence of CCdZ-40mer oligo  
  Structural parameters Species 2 Species 3 Species 4 
Guinier analysis    
I(0) (cm-1) 0.00812 ± 0.00018 0.00492 ± 0.00093 0.00261 ± 0.00092 
Rg (Å) 47.0 ± 1.4  33.6 ± 1.2  29.8 ± 1.7  
qmin (Å-1) 0.0139 0.0183 0.0183 
qRg max  1.3 1.3 1.3 
Coefficient of correlation (R2) 0.98  0.45  0.57  
P(r) analysis    
I(0) (cm-1) 0.00834 ± 0.00012 0.00496 ± 0.00069 0.00244 ± 0.00044 
Rg (Å) 48.4 ± 0.6 32.7 ± 0.5 30.4 ± 0.4 
Dmax (Å) 162.1 100.1 92.9 
q range (Å-1) 0.0139 - 0.3052 0.0183 - 0.3052 0.0183 - 0.3052 
Quality estimate 0.89 0.80 0.79 
Porod volume (Å3) 379,000 117,000 62,700 
MW (Porod Volume*0.6) (Da) 
(ratio to expected subunit 46,408 
Da) 
227,400 (4.9) 70,200 (1.5) 37,620 (0.8) 
Figure 6.26 SEC-SAXS analysis of A3Gfl-W/CCdZ-40mer deconvoluted species. 
Analysis of the scattering data of the A3Gfl-Wt/CCdZ-40mer deconvoluted species was conducted 
using several programs from the PRIMUSQT ATSAS 2.8.3 suite 75. (A) 1D-scattering curves of each 
species (B), double log plot with insert of a Guinier plot, (C) Kratky plot. (D) P(r) distribution plot. 
Experiments were conducted using 2.5 mg/mL of A3Gfl-Wt in A3G pH 6.0 kinetic buffer. 
 
 
   (A)                                       (B) 




6.4.3.2.1 Analysis of species 2 from A3Gfl-Wt/CCdZ-40mer SEC-SAXS 
Based on the estimated MW, we deduced that species 2 corresponded to an A3G tetramer 
made up of four two-domain subunits (Table 6.11). We noted, that the size (MW, Rg, 
Dmax, Table 6.11) of this species  was slightly larger (estimate of 4.9 subunits) than the 
ligand-free A3G-tetramer species (estimate of 4.4 subunits, Table 6.7), indicating that this 
component was in complex with an oligonucleotide.  To verify this notation, the A260/A280 
ratio of the A3Gfl-Wt sample was compared to the A3Gfl-Wt/CCdZ-40mer sample, as 
described earlier in section 6.3.4. Interestingly, the A260/A280 ratio of the A3Gfl-
Wt/CCdZ-40mer sample appeared to be larger than the ratio of  the ligand-free protein 
across the entire elution profile as displayed in Figure 6.27, illustrating that the our A3G 
species 2 (A3G tetramer), and all other species (1, 3, and 4) elute along with DNA. This 
signified that each of these species forms a complex with the CCdZ-40mer oligo.  
Figure 6.27 Ratio of A260/A280 to assess the presence of DNA during the elution of the A3Gfl-
Wt/CCdZ-40mer sample.  
A260/A280 ratio of the A3Gfl-Wt (blue) and A3Gfl-Wt/CCdZ-40mer (green) samples. Overlaid with the 
A280 elution profile of the A3Gfl-Wt/CCdZ-40mer sample (red) to display the boundaries of each 




Based on differences between the MW of species 2 (MW ~ 227 kDa, Table 6.11) and the 
ligand-free A3G tetramer (MW ~ 203 kDa, Table 6.7), we can deduce that two 
oligonucleotides (24 kDa ~ two 12 kDa CCdZ-40mer oligos, Table 6.9) form a complex 
with the A3G tetrameric species 2. To help elucidate the 3D structure of this species, ab 
initio shape reconstruction (DAMMIF) was performed using P4 symmetry as this sample 
was determined to be tetrameric. A mean NSD score of 0.578 for the averaged envelope 
model was derived, which indicated very good consistency for the ensemble (acceptable 
NSD ≤ 0.8) (Table 8.12). The envelope model was globular and resembled a cross as 
illustrated in Figure 6.28A. Superimposing this model with the envelope model of the 
previously identified ligand-free A3G-tetramer, we find that the ligand-free envelope has 
a rather nice fit to this model. However, two noticeable areas either side of the docked 
ligand-free A3G tetramer model appeared to be unoccupied as visualised in Figure 6.28B. 
These empty regions indicate the binding of two oligonucleotides, confirming earlier 
interpretations, whereby the A3G tetramer (species 2) complexes with two CCdZ-40mer 
oligonucleotides in solution, under our conditions. 
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Figure 6.28 Envelope models of the A3G tetramer with and without CCdZ-40mer oligo.  
(A) Envelope model of the A3G tetramer/CCdZ-40mer oligo (purple) generated under P4 symmetry 
(DAMMIF, ATSAS 2.8.3 suite) 12, with Dmax ~ 162 Å and Rg ~ 47 Å. (B) A3G tetramer/CCdZ-40mer 





Interestingly, upon binding of the oligonucleotides to the A3G tetramer we see that the 
protein seems to elongate slightly in comparison to the ligand-free form (Figure 6.28B), 
which was consistent with a 17 Å increase in Dmax (Table 6.11). The action of binding 
these ssDNAs to the tetrameric protein may cause structural rearrangements in the A3G 
tetramer leading to the observed elongation of the molecule. However, as we do not have 
high-resolution A3G tetrameric structures we cannot conclude this theory. 
6.4.3.2.2 Analysis of species 3 and 4 from A3Gfl-Wt/CCdZ-40mer SEC-SAXS 
Estimation of the MWs of species 3 and 4 from the Porod volumes seemed to be 
underestimated and inaccurate (Table 6.11), due to a low signal-to-noise ratio following 
deconvolution of the scattering data. Furthermore, calculating MWs using the I(0) method 
178 was difficult as estimation of protein concentration estimates of each species presented 
large inaccuracies (peak overlaps). Nevertheless, based on the peak maxima position of 
the Kratky plots, we can estimate the oligomeric state of these species. By comparison, 
our DNA bound A3G tetramer species 2 (q ~0.036 Å-1) was determined to be ~ 1.7 times 
larger than species 3 (q ~0.061 Å-1), and ~ 2.6 times larger than species 4 (q ~0.092 Å-1) 
(Figure 6.26C).  
As the DNA bound A3G tetramer (species 2) was estimated to be made up of 4.9 subunits 
(four A3G two-domain subunits and two oligos) (Table 6.11), using this information we 
estimated the number of subunits in species 3 and 4 (number of subunits in species 
2/estimated difference of size). Species 3 was calculated to be composed of approximately 
2.9 subunits (4.9/1.7), whereas species 4 was estimated to be comprised of ~ 1.9 subunits. 
As shown earlier in Figure 6.27, both species 3 and 4 were indicated to complex with our 
CCdZ-40mer oligo. Therefore, based on these annotations we can conclude that species 
3 corresponds to an A3G dimer in complex with CCdZ-40mer, whereas species 4 may in 
fact be an A3G monomer (single double-domain) in complex with DNA. However, 
whether one or more oligonucleotides is bound to these species is difficult to conclude 
from these data. 
To endorse these claims, rigid body modelling was performed by comparing the 
experimentally derived scattering data of species 3 and 4 to back-calculated 1D scattering 
profiles of the reported A3G dimer atomic structures (PDB; 6p40, 6p3z, 6p3x, and 6p3y) 
286 using FoXS 74, 226 and CRYSOL 75. As anticipated, species 3 had an overall better fit 




Chi2, Figure 6.29B) as listed in Table 8.13, further supporting our model that species 3 
was an in fact an A3G dimer. We observed that species 3 had a slightly better visual fit 
against the A3G dimeric structure 6p40, especially at low q regions (0 -0.1 Å-1, Figure 
6.29A), in contrast to the other A3G dimer structures. However, this was not clearly 
indicated by its Chi2 scores < 1, suggesting that Chi2 values of the other A3G dimer 
structures (PDB, 6p3z, 6p3x, and 6p3y) result in better fits (see Table 8.13). Moreover, 
at  q > 0.12 Å-1 the scattering data of species 3 did not fit nicely to the structural models 
(Figure 6.29A), consistent with the additional scattering of our CCdZ-40mer oligo, which 
was bound to our A3G tetramer (species 3). 
On this basis, envelope models were generated using a P2 symmetry for species 3, and 
P1 symmetry for species 4 (DAMMIF) as described in section 6.1.1, to visualise the low-
resolution model of each species. Using this method, the averaged envelope model for 
species 3 resulted in a mean NSD score of 0.937 (acceptable NSD ≤ 0.8), indicating that 
the model was not an accurate representation of this species (see model in Figure 8.14A). 
Therefore, no further modelling was continued for this component. However, a very good 
mean NSD score of 0.559 was obtained for the envelope model of species 4, which 
indicated consistency of this ensemble. Docking half of the atomic A3G dimer structure 
as an A3G full-length monomer (A3G two-domain structures all similar so used PDB, 
Figure 6.29 Rigid body modelling of A3Gfl-Wt/CCdZ-40mer species 3 (A3G dimer) and species 
4 (A3G monomer) scattering data to known A3Gfl dimer crystal structures. 
Rigid body modelling of the A3G dimer/CCdZ-40mer (species 3) and (B) A3G monomer/CCdZ-
40mer (species 4) to A3Gfl dimer PDB structures (6p40, 6p3x, 6p3y, and 6p3z 286) using FoXS and 
CRYSOL.  
 




6p3z) into the envelope model of species 4, we observed that this structure fits only into 
part of the envelope model leaving a large region of electron density unoccupied on one 
side of the envelope (Figure 6.30A insert). This was consistent with a poor fit of the 
species 4 scattering data to the A3G-full length structure, as illustrated by the high Chi2 
scores and fit in Figure 6.30A. The unoccupied region indicated the binding location of 
the CCdZ-40mer ssDNA, and suggested that a single oligonucleotide binds to the two-
domain A3G monomer (Figure 6.30A insert).  
Therefore, we manually superimposed our 40mer B-form ssDNA (displayed in Figure 
8.15C) into this vacant space and positioned it into the active-site in several ways. Using 
this method, we derived several models that were then assessed against the scattering data 
of species 4 using rigid body modelling (see Figure 8.15). We first noted that the presence 
of our oligonucleotide within the structure significantly improved the overall fit of species 
4 scattering data (Figure 6.30B), in contrast to the ligand-free structure (Figure 6.30A). 
Overall, our generated atomic models had an okay fit to the scattering data (Figure 8.14), 
noting that model 4 resulted in a better overall fit (as indicated by the Chi2 scores, Figure 
8.14D).  
However, in all our models (see Figure 8.15) the oligonucleotide appeared to be largely 
bound to only one of the domains with less contact to the other domain. From these 
models, we propose that the oligonucleotide was bound to the CTD and was not 
specifically associating with the NTD. From these observations we can envisage that our 
model may resemble the in-solution structure of an active two-domain A3G in complex 
with a ssDNA inhibitor. As described earlier in section 6.4.3.1, inhibition of the two-
domain A3G was reported to be attributed to the specificity of the dZ/5FdZ-containing 
oligos to bind to the catalytic CTD rather than the NTD. Based on these data reported by 
Dr. Stefan Harjes (see Figure 6.21), it is reasonable to conclude that the fit of our SAXS 
model supports inhibition. whereby dZ would be bound in the active site of the CTD 
(Figure 6.30B), in a similar manner as structures of the previously reported inactive 




Interestingly, our model showed that the long poly-T tail at the 3'-end of the 
oligonucleotide remained fairly flexible. Several studies indicated that the presence of the 
NTD enhances the deamination efficacy in two-domain A3 over the CTD alone, 
suggesting its importance in binding ssDNA 24, 78, 88, 91, 187, 189, 247. Based on these 
observations, we expected to observe that the 3'-end long tail of the oligonucleotide would 
be associated with the NTD, supporting the ~2-fold increase in the inhibition of the 
enzyme by the long CCdZT30-oligo versus the short 10mer CCdZ-oligo (Figure 6.21, 
noting that 40mer oligonucleotides were assessed with only a single experiment). 
However, from our SAXS data, we found that the long tail had limited interactions with 
the NTD and it looped away from the protein (Figure 6.30B). This suggested that in-
solution binding of the ssDNA to the NTD may be dynamic and loosely fixed, while 
binding of the oligonucleotide into the CTD is more specific. To validate these 
observations further refinement with molecular dynamics and elucidation with higher 
resolution structures would be advantageous to understand these mechanisms. However, 
Figure 6.30 Fitting SAXS profile of A3G/CCdZ-40mer species 4 to model structure 4.  
(A) Fit of 6p3z monomer to SAXS data for species 4 (B) Fit of 6pz3 monomer plus model for CCdZ-
40mer to SAXS data for species 4.  Inserts show the models docked in the molecular envelopes 
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the structural parameters and models obtained from SEC-SAXS provide a platform for 
further structural studies using chemically modified oligonucleotide inhibitors.    
6.5 Conclusions 
Here, we report the first SAXS models of catalytically active A3s in complex with dZ-
containing ssDNA inhibitors. Initially, we studied the catalytically active A3BCTD-AL1 
in the presence of a dZ-containing oligo. Our model indicated that dZ-containing ssDNA 
was bound to the A3BCTD-AL1, while the 3'-end of the oligonucleotide remained rather 
flexible (Figure 6.6). This low-resolution model was found to be comparable to the 
previously reported inactive substrate-bound A3BCTD crystal structure (PDB, 5TD5 
239) 
(Figure 6.6). This result further suggests that our dZ-containing inhibitor binds into the 
active-site of A3BCTD in a similar manner to the dC substrate oligonucleotide, as 
supported by our inhibition mechanism (described in section 3.4.2).  
Under our conditions, the ligand-free A3BCTD-AL1 was detected to elute from the SEC 
column as two species, the monomeric A3BCTD-AL1 form and a secondary larger 
multimer. Using SEC-SAXS, we were able to elucidate that this secondary eluting species 
was in fact an A3BCTD-AL1 homodimer in solution. A model structure that was generated 
was in support of a dimer interface that was formed through several weak interactions, 
but stability was largely attributed to a covalent disulfide bond. Interestingly, this 
interface seemed to mimic a previously reported A3A dimer (PDB, 4xxo 23), which was 
not surprising as our A3BCTD-AL1 variant contained a loop from A3A (A3A loop 1) that 
was involved in the formation of this interface. However, examination of our A3BCTD-
AL1 dimer in the presence of the dZ-oligo inhibitor, revealed that contrary to its observed 
catalytic activity (Figure 8.2) the dimer was in fact not bound to the oligonucleotide 
(Figure 6.16), seemingly at odds with observed catalytic activity of this species, described 
earlier 22-23, 27, 79, 118, 233. However, we always observed a small amount of monomeric 
A3BCTD-AL1 with the dimeric species. The observed catalytic activity is ascribed to this 
monomer species, noting the presence of the redox-active citrate in the citrate-phosphate 
buffer used.  
Under our conditions, ligand-free two-domain A3G eluted from the SEC column in 
multiple oligomeric states but was largely found to exist as higher molecular weight 
(HMW) species, consistent with published studies 48, 50, 55. Lower molecular weight 




(Figure 6.18A and D). These various multimeric states may aid with the stability of two-
domain A3 proteins in regulating their catalytic activity 23, 48, 50, 55, 150, 276. In particular, 
using derived SAXS parameters we identified that an A3G tetramer was the most 
prominent eluting species. This species formed from four two-domain A3G molecules 
oligomerising together in a compact formation (MW ~ 200 kDa), potentially through 
surface associations like our reported A3BCTD-AL1 dimer (discussed in section 6.3.2.2), 
though this remains unclear.  
In the presence of the CCdZ-40mer ssDNA, several LMW A3G conformations (a dimer 
and monomer species) became much more prominent, while the higher HMW formations 
decreased slightly (see Figure 6.18 and Figure 6.25). This suggested that the higher order 
multimeric species may be converted into these smaller configurations due to interactions 
with the ssDNA, as all our eluted A3G species were identified to be in complex with 
ssDNA, as indicated upon examination of the A260/A280 ratio. From this we propose that 
the binding of the negatively charged ssDNA to the larger A3G conformations may 
displace the interface interactions between the A3G molecules.  
The previously identified ligand-free A3G tetramer was determined to be capable of 
forming a complex with two CCdZ-40mer oligonucleotides. However, a model structure 
was difficult to elucidate as the formation of the binding interfaces between the A3G 
molecules was unknown. Two LMW A3G conformations were also detected. An A3G 
dimer was identified as its scattering data had a passable fit to the reported A3G dimer 
crystal structures 286, although this dimer formed a complex with ssDNA. However, due 
to its low concentration a SAXS model could not be elucidated. An A3G monomer 
complexed with a CCdZ-40mer oligonucleotide was discovered, revealing the first full-
length catalytically active A3 model structure in complex with a ssDNA inhibitor. Our 
model showed that the modified-oligonucleotide was largely anchored into the CTD, 
consistent with the observed inhibition of the enzyme’s activity and higher binding 
affinity for dZ (Figure 6.21). In solution the long poly-T tail seemed to be flexible and 
had a limited interaction with the NTD. Interestingly, this observation deviated from 
earlier studies 24, 78, 88, 91, 187, 189, 247, which implied that the ssDNA was bound to NTD 
enhancing the deamination efficiency of full-length A3, in comparison to CTD alone. 
However, based on the A3G inhibition assays reported by Harjes, it is notable to mention 
that the inhibition of the full-length A3G enzyme by our dZ/5FdZ-containing 




seemed consistent with our derived A3Gfl-Wt/CCdZ-40mer bound SAXS model, where 
the modified oligonucleotide has a higher affinity towards the CTD active site. Based on 
these observations, we propose that the ssDNA may initially bind to the domains of A3 
in an allosteric manner. DNA binding to the NTD causes a conformational change in the 
CTD which helps position the dZ close to the CTD active-site. Upon, specific binding of 
the dZ into the CTD active site, the dZ is converted into a transition state of deamination 
where it remains bound. The nucleotides flanking the target dZ stack on top of one another 
to stabilise the overall conformation, as observed in the single domain A3-ssDNA 
complex structures 239. These SAXS structural parameters and models may help enlighten 






























































7.1 Summary of findings 
Cancer recurrence, metastases, and drug resistance are some of the consequences of the 
mutagenic action of the A3B. Therefore, the selective inhibition of A3B may prevent 
rapid cancer evolution, while retaining the other A3 family members involved in the 
innate immunity. Until now, no selective A3B inhibitors have been described. In this 
research, we present a novel approach to inhibit the A3B’s catalytic activity using 
chemically modified ssDNA containing cytosine analogue nucleosides that mimic the 
transition state of deamination. Here, we report the first selective ssDNA-based A3B 
inhibitor. Furthermore, we illustrate the first SAXS models of active A3BCTD and two-
domain A3 in complex with our modified-ssDNA inhibitor, which will help further 
structural studies.  
Coherent with our rationale, incorporating cytosine analogue nucleosides in place of the 
target dC in the A3s’ preferred ssDNA sequences led to the inhibition of the catalytic 
activity of our A3BCTD enzyme, as well as A3A, A3GCTD, and a full-length A3G as 
reported us and our collaborators 136. These are the first substrate-like ssDNA A3 
competitive inhibitors that utilise the preference of A3s to bind and deaminate cytosines 
in ssDNA 15, 26, 48. The CDA prefers to target free dC or cytosine analogues over ones 
incorporated in ssDNA 289, so our ssDNA-based inhibitors would not interfere with 
CDA’s functions. By embedding dZ and 5FdZ into the A3B’s preferred deamination 
sequence motif (5'-TC) in a short ssDNA, we illustrated that the A3BCTD catalytic activity 
was inhibited with low micromolar inhibition constants (see Table 4.1). In particular, the 
dZ-containing ssDNA had an ~30-fold inhibition potency against A3BCTD, whereas the 
5FdZ-containing oligonucleotides had a higher potency close to 100-fold. This trend was 
also observed for the closely related A3A 136 and CDA against zebularine and 5-
fluorozebularine 6. These results indicate that the structure of the cytosine analogues dZ 
and 5FdZ determine the inhibitory potential against the A3 enzymes. Notably, the N3 of 
cytosine analogue was required to be protonated by the conserved catalytic glutamate in 
the A3s’ active site to facilitate the inhibitory mechanism. This protonation authorises the 
nucleophilic attack of C4 of the cytosine analogue by an activated Zn2+--coordinated 
water molecule that is necessary for the formation of a tetrahedral transition-state 
analogue of cytosine deamination (Figure 3.10). This is consistent with zebularine 
inhibition CDA 77. As indicated when the A3BCTD catalytic glutamate was mutated to 




Most A3s (except A3G) have the same intrinsic preference of deaminating a cytosine 
preceded by thymidine, our modified substrate-like inhibitors based on a 5'-TC motif 
would not be selective towards the actions of A3B alone, as noted in the inhibition of the 
A3A 136. The A3A and A3B were reported to deaminate different target dC within the 
suboptimal CCC-motif 37. A3A (and A3G) prefers to target the dC at the 3'-end followed 
by a purine (dA or dG) 37, 41, 122-123, 207, 252 (5'-CCC, where underlined is the preferred dC), 
whereas A3B prefers the dC at the 5'-end flanked by a thymidine 36-37 (5'-CCC-motif, 
where underlined is the preferred dC). We exploited this differential target pattern, to 
obtain a selective A3B inhibitor. We noted that nucleotides adjacent to our cytosine 
analogue (dZ) in the CCC-motif influenced the specificity of the inhibitor. Utilising these 
observations, placement of dZ in place of the A3B’s preferred dC in this motif (5'-dZCC) 
led to the first selective substrate-like inhibitor of A3B with a low micromolar inhibition 
constant (Table 5.4). This selective inhibitor had a similar inhibition efficiency of ~30-
fold as our preferred non-selective dZ-containing inhibitor (in the 5'-TC motif), further 
supporting that the structure of the cytosine analogue defines the inhibitory potential. 
However, to date the cellular effects of our inhibitors are unknown and would need to be 
evaluated.  
When this research began in 2015 there were no reported structures of the A3B; therefore, 
we attempted to determine its structure to better enlighten drug design. Using solution-
state NMR experiments we aimed to elucidate the structure of a single domain A3BCTD. 
However, during our study the ligand-free A3BCTD structures 
37, 240 and an inactive 
A3BCTD-ssDNA structure 
37, 239 were solved. Nevertheless, we were able to assign the 
resonances of a ligand-free weakly active A3BCTD-QM-ΔL3 and made use of the 
assignment by establishing the experimental conditions of chemical shift perturbation 
assays. Although the substrate-bound A3BCTD structure has been established 
37, 239, we 
can use our chemical shift perturbation experiments to study the binding location of small-
molecules and ssDNA-based inhibitors to A3BCTD. We decided to utilise SAXS to 
examine the relative structure and structural features of our active A3BCTD-AL1 with our 
dZ-modified ssDNA inhibitor. We obtained the first low-resolution SAXS models of a 
catalytically active A3BCTD in complex with the dZ-containing ssDNA inhibitor. We 
determined that the ssDNA-based inhibitor binds to the active A3BCTD in a similar manner 




239. This further supports’ our proposed competitive inhibition mechanism of dZ-
containing DNA (refer to Figure 3.10).  
Moreover, our A3BCTD-AL1 also eluted as a larger oligomeric species. Using a 
combination interface modelling and SAXS we confirmed that this species was an 
A3BCTD-AL1 dimer in solution that was formed through several weak interactions and 
stabilised through a disulfide bond. It was apparent that this construct dimerised as a result 
of the loop 1 from the A3A, likely coincidentally similar to a previously reported A3A 
crystallographic dimer (PDB, 4xxo 23). As described in several studies 22-23, 27, 79, 118, 233, 
the potential of oligomerisation of A3 enzymes may regulate the catalytic activity of the 
enzymes. Oligomerisation of our construct may allow added stability and inactivate the 
catalytic activity. We can deduce that dimerisation may mimic a regulatory mechanism 
of the A3A enzyme; however, whether this occurs in the cell remains unknown. 
To model the structure of two-domain A3 enzymes, the full-length two-domain A3G was 
used. In solution the ligand-free full-length A3G eluted off the SEC column in several 
conformational states, but largely as high molecular weight (HMW) oligomers, consistent 
with several studies 48, 50, 55. These HMW A3G species are reported to be formed through 
non-specific interactions with RNA leading to their inactivation 23, 48, 50, 55, 150, 276, but these 
species can be reversed to active low molecular weight (LMW) A3G forms upon 
treatment with RNase A 48, 55. In our study, the A3G tetramer, made up of four two-
domain A3G subunits, was predominant species in solution. However, we could not 
determine the interface and whether our A3G tetramer was bound through RNA. Upon 
the addition of dZ-containing ssDNA, our A3G tetramer forms a complex with two 
ssDNA molecules, and triggers disassembly into LMW A3G conformations (A3G dimer 
and monomer), rather than by the treatment with RNase as indicated in previous studies 
48, 55. We predict that the RNA may bind non-specifically near the active-site of the two-
domain A3 causing oligomerisation and hindrance of the enzyme’s catalytic activity. 
However, upon binding of ssDNA to HMW conformations the enzyme dismantles into 
the active LMW states, supporting a catalytic regulatory mechanism. Higher resolution 
structures would help elucidate this structure and understand the mechanism of 
regulation. Notably, we report the first SAXS model structure of the two-domain A3G in 
complex with a ssDNA inhibitor, which has been largely unknown. From our in-solution 
model, we can deduce that the ssDNA-inhibitor binds into the CTD, whereby dZ binds 




the oligonucleotide remained flexible with limited interactions with the NTD (Figure 
6.21), inconsistent with studies implying that the NTD is required in binding ssDNA to 
enhance deamination at the CTD 24, 78, 88, 91, 187, 189, 247. This suggests that the mechanism 
of ssDNA binding to two-domain A3 must be highly dynamic and needs to be modelled. 
Overall, this work provides a platform for the development of selective A3B-inhibitors 
and further structural studies with modified ssDNA inhibitors. We aim to develop highly 
potent selective A3B ssDNA-based inhibitors and evaluate them in cellular studies and 
ultimately to be utilised as possible conjuvants in anti-cancer treatments. 
7.2 Future directions  
7.2.1 Structural studies 
Using the reported full-length A3G dimer structures 286, we can use these structures to 
determine the interface between two molecules (PRISM 2.0 webserver 9, 264) and build 
low resolution models of our ligand-free A3G tetramer. This would advance our 
understanding of the interactions that drive oligomerisation of A3G and other A3 
enzymes, as indicated in the literature 22-23, 27, 79, 118, 233. 
Using our A3BCTD-QM-ΔL3 variant assignment, we can use chemical shift perturbation 
experiments to further examine the interactions between the A3BCTD and our ssDNA-
based inhibitors to better understand the binding mechanism. In addition, X-ray 
crystallography can be utilised to determine the structures of the active A3BCTD and the 
multiple forms of two-domain A3 structures in complex with our ssDNA-based 
inhibitors. 
7.2.2 Evaluation of ssDNA-based inhibitors using wild-type A3 enzymes  
In our experiments, we used A3BCTD constructs that provided the starting point in the 
development of ssDNA-based inhibitors. We noted that the inhibition effect of our 
ssDNA-based inhibitors on the full-length two domain A3G was similar to the inhibition 
of the single catalytic domain A3GCTD 
136, as deaminase activity is largely attributed to 
the CTD. This indicates that the two-domain A3B would equally be inhibited in a similar 
manner as that detected for the A3BCTD. However, to verify this presumption we would 




7.2.3 A3B inhibitors with enhanced potencies  
Future work will focus on optimisations of our substrate-like ssDNA inhibitors. The use 
of more potent CDA cytosine analogue nucleoside inhibitors 6, 45, 277 incorporated into the 
A3B preferred ssDNA sequences, in principle will enhance the inhibition potential of 
these oligonucleotides. Furthermore, as noted in our study, nucleotides flanking the target 
dZ influence the binding specificity of the A3 enzymes, as these enzymes have different 
electrostatic and hydrophobic distribution around the active site. Therefore, modifications 
of these flanking regions by placement of large aromatic moieties may improve inhibitory 
potential, perhaps by acting as molecular caps closing the ssDNA binding site and 
stabilising the complex by removing water molecules. Moreover, as indicated by our 
SAXS models and inhibition mechanism, our modified-ssDNA inhibitors appear to bind 
to the A3BCTD in a similar manner as substrate ssDNA 
239 (PDB, 5CQI), which conforms 
in a U-shape. Therefore, our linear modified-ssDNAs must undergo several 
conformational changes to stabilise this form and position the cytosine analogue 
nucleoside into the active-site of the enzyme. So, by pre-shaping our modified-ssDNA 
inhibitors in this U-shaped conformation we assume that the binding affinity to the 
enzyme will be improved, thereby boosting the inhibition potential of these inhibitors. 
Evaluation of ssDNA with more potent transition-state analogues of cytosine deamination 
are expected to increase inhibition to the level required for the cellular studies. These 
inhibitors can then be used as evaluated with existing anticancer therapies in cancer cells, 






























Figure 8.1 Cleavage of SUMO fusion tag from His-SUMO-A3BCTD-DM using SUMO protease.  
Cleavage process as described in section 2.2.5.1. Tricine 16% SDS PAGE gel, Lane 1; SeeBlue Plus2 
Pre-stained protein standard ladder, Lane 2; SUMO-A3BCTD-DM, Lane 3; His6-SUMO-A3BCTD-DM 
treated with SUMO protease at 1:5 ratio, Lane 4; A3BCTD-DM eluted off IMAC column.   
Figure 8.2 In vitro deaminase activity assay of the A3BCTD variants.  
An established in vitro DNA deamination in-gel based assay 240 was performed using a final 
concentration of 5 µM of our purified A3B variants along with 800 nM of a fluorescein tagged 
oligonucleotide (TC 3' 6-FAM) as described in section 2.5.1. The wild type full-length A3B (A3B-
Wt-Fl) protein was used as a control of catalytic activity.  














Figure 8.3 Deamination speed of the A3 enzymes on the preferred dC in dZ containing CCC-
motifs. 
Deamination speed measured using 1H-NMR at 298 K of (A) A3A-mimic (50 nM) as a function of 
dZCC-oligo substrate concentration in 50 mM citrate-phosphate buffer at pH 5.5, (B) A3BCTD-DM (2 
µM) as a function of CCdZ-oligo substrate concentration 50 mM citrate-phosphate buffer at pH 7.5. 
Initial speed of deamination obtained at varying substrate concentrations (2 – 2500 µM) (i) Plot of the 
speed of deamination as a function of substrate concentration, (ii) Lineweaver-Burk plot of the inverse 
speed of deamination as a function of inverse substrate concentration. In all NMR assays, buffers 
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Figure 8.4 Non-linear regression analysis of A3BCTD-AL1 and A3BCTD-DM cytosine deamination of 
5'-ATTTCATTT.   
Non-linear regression analysis of the rate of cytosine deamination of the 5'-TCA-oligo at various substrate 
concentration by (A) A3BCTD-AL1 or (B) A3BCTD-DM. (i) Plot of initial rate of deamination as a function 
of substrate concentration fitted with a non-linear regression model to derive Km and kcat parameters, (ii) 
predicted values from model from each observation plotted against the observed data (iii) residuals 
calculated from the model for each observation. The derived parameters are tabulated in Table 8.3. I 
acknowledge Prof. Geoffrey B. Jameson for conducting non-linear regression analysis on derived data 









Figure 8.5 Non-linear regression analysis of the inhibition of A3BCTD-AL1 and A3BCTD-DM cytosine 
deamination by dZ- and 5FdZ-containing oligos.   
Non-linear regression analysis of the rate of cytosine deamination of the 5'-TCA-oligo by A3BCTD-
variants in the presence dZ- and 5FdZ-containing oligos. (A) A3BCTD-AL1 in the presence of dZ-oligo, 
(B) A3BCTD-DM in the presence of dZ-oligo, and (C) A3BCTD-AL1 in the presence of 5FdZ-oligo. (i) Plot 
of initial rate of deamination as a function of inhibitor concentration fitted with a non-linear regression 
model to derive Ki, (ii) predicted values from model from each observation plotted against the observed 
data (iii) residuals calculated from the model for each observation. The derived parameters are tabulated 
in Table 8.4. I acknowledge Prof. Geoffrey B. Jameson for conducting non-linear regression analysis on 
derived data using excel XLSAT addon program. 
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Figure 8.6 Non-linear regression analysis of A3A-mimic, A3BCTD-DM, A3GCTD-Wt on the 
deamination of their selective dC.  
Non-linear regression analysis of the rate of cytosine deamination of by (A) A3A-mimic deamination of 
dC near the 3'-end in the 5'-CCC-oligo, (B) A3BCTD-DM deamination of dC near the 5'-end in the 5'-
CCC-oligo, (C) A3A-mimic deamination of dC near the 3'-end in the 5'-dZCC-oligo, (D) A3BCTD-DM 
deamination of dC near the 5'-end in the 5'-CCdZ-oligo, (E) A3GCTD-Wt deamination of dC near the 3'-
end in the 5'-dZCC-oligo. (i) Plot of initial rate of deamination as a function of substrate concentration 
fitted with a non-linear regression model to derive Km and kcat parameters, (ii) predicted values from 
model from each observation plotted against the observed data (iii) residuals calculated from the model 
for each observation. The derived parameters are tabulated in Table 8.3. I acknowledge Prof. Geoffrey B. 
Jameson for conducting non-linear regression analysis on derived data using excel XLSAT addon 
program. 
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Figure 8.8 Fitting of A3BCTD-AL1 and A3BCTD-AL1-dZ-oligo SAXS profiles to A3BCTD-DNA 
(5TD5*) and A3BCTD (5CQI) crystal structures, respectively.  
Model fit of 5TD5* to A3BCTD-AL1 scattering data (left), fit of 5CQI to A3BCTD-AL1-dZ oligo (1 to 2 
ratio) scattering data. 
   (A)                                 (B) 
(A) 
 
(i)                         (ii)    (iii) 
(B) 
(i)                         (ii)    (iii) 
Figure 8.7 Non-linear regression analysis of the inhibition of A3A-mimic and A3BCTD-DM cytosine 
deamination by selective dZ-containing oligos.   
Non-linear regression analysis of the rate of cytosine deamination of the 5'-TCA-oligo by A3BCTD-
variants in the presence selective dZ-containing oligos. (A) A3A-mimic dC deamination of the TCA-
oligo in the presence of the CCdZ-oligo, (B) A3BCTD-DM dC deamination of the TCA-oligo in the 
presence of the dZCC-oligo. (i) Plot of initial rate of deamination as a function of inhibitor concentration 
fitted with a non-linear regression model to derive Ki, (ii) predicted values from model from each 
observation plotted against the observed data (iii) residuals calculated from the model for each 
observation. The derived parameters are tabulated in Table 8.4. I acknowledge Prof. Geoffrey B. Jameson 





Figure 8.10 Comparison between the amino acid sequence of A3B and A3G.  
* represents the same amino acid 
Figure 8.9 Singular value decomposition (SVD) of A3BCTD-AL1 dimer with dZ-oligo sample. 
SAXS profile assessed using SVD/EFA BioXTAS RAW 105. Top panel represents SVD showing the 
Eigen value on the index represents number of eigenvalues equivalent to number of components in 
scattering sample. Top panel represents SVD showing an eigenvalue of three. Bottom panel displays 
the autocorrelation between the singular vectors (blue and red lines). indicating that the singular 







Figure 8.12 Singular value decomposition (SVD) of A3Gfl-Wt sample.  
SAXS profile assessed using SVD/EFA BioXTAS RAW 105, index represents number of eigenvalues 
equivalent to number of components in scattering sample. Top panel represents SVD showing an 
eigenvalue of three. Bottom panel displays the autocorrelation between the singular vectors (blue and 
red lines). indicating that the singular values are not so variable. 
 
(A)                                  (B) 
Figure 8.11 Envelope models of A3BCTD-AL1 dimer/dZ-oligo scattering species.  
(A) Average dummy-model of species 1, an A3BCTD-AL1 dimer, generated using P2 symmetry with 
an NSD of 0.993, (B) Average dummy-model of species 2, an A3BCTD-AL1 monomer, generated 
using P1 symmetry with an NSD of 1.006. For each species ten models were generated using 






Figure 8.13 Singular value decomposition (SVD) of A3Gfl-Wt with CCdZ-40mer oligo sample.  
SAXS profile assessed using SVD/EFA BioXTAS RAW 105. Top panel represents SVD showing the 
Eigen value on the index represents number of eigen values equivalent to number of components in 
scattering sample. Top panel represents SVD showing an Eigen value of four. Bottom panel displays 
the autocorrelation between the singular vectors (blue and red lines). indicating that the singular 
values are not too variable. 
45 ° 
Figure 8.14 A3Gfl with 40mer ssDNA species 3 (A3G dimer) envelope model.  
Average dummy-model generated using P2 symmetry with an NSD of 0.937. For each species ten 
models were generated using DAMMIF, then filtered using DAMAVER and DAMFILT (ATSAS 
















Figure 8.15 Rigid body modelling of A3G monomer with CCdZ-40mer (species 4) scattering 
data to envelope generated hypothetical models. 
Fitting DNA bound A3G monomer models (inserts) (A) model 1, (B) model 2, (C) model 3, (D) 
model 4 into A3G monomer 40mer ssDNA scattering data. 
(A)                   (B)   













Equation 8.3 Calculation of uncertainties for Km and kcat using error propagation method. 
Errors of linear regression fit to measured data were calculated using LINEST function in Excel 
(termed σa and σb in equation). Uncertainties of Km and kcat (termed σKm and σkcat in equation) 
calculated using error-propagation method by using partial derivatives. I acknowledge the assistance 
of Prof. Geoffrey B. Jameson in deriving equations for error propagation.  
Equation 8.4 Calculation of uncertainty for Ki using error propagation method. 
Errors of linear regression fit to measured data were calculated using LINEST function in Excel 
(termed σa and σb in equation). Uncertainty of Ki (termed σKi in equation) calculated using error-
propagation method by using partial derivatives. I acknowledge the assistance of Prof. Geoffrey B. 





8.3 Supplementary tables 































1 7 GLU CA C 55.488 0.3 1 
2 7 GLU H H 7.721 0.02 1 
3 7 GLU HA H 3.87 0.02 1 
4 7 GLU N N 118.399 0.3 1 
5 8 ILE CA C 53.919 0.3 1 
6 8 ILE H H 7.992 0.02 1 
7 8 ILE N N 122.086 0.3 1 
8 9 LEU H H 8.428 0.02 1 
9 9 LEU N N 120.968 0.3 1 
10 11 TYR CA C 59.942 0.3 1 
11 11 TYR H H 8.201 0.02 1 
12 11 TYR N N 122.284 0.3 1 
13 12 LEU CA C 53.974 0.3 1 
14 12 LEU H H 8.125 0.02 1 
15 12 LEU N N 126.184 0.3 1 
16 13 MET CA C 54.84 0.3 1 
17 13 MET H H 8.051 0.02 1 
18 13 MET HA H 4.522 0.02 1 
19 13 MET N N 120.868 0.3 1 
20 14 ASP CA C 56.483 0.3 1 
21 14 ASP H H 8.031 0.02 1 
22 14 ASP HA H 3.829 0.02 1 
23 14 ASP N N 120.568 0.3 1 
24 16 ASP CA C 56.083 0.3 1 
25 16 ASP H H 8.409 0.02 1 
26 16 ASP HA H 4.158 0.02 1 
27 16 ASP N N 117.476 0.3 1 
28 17 THR CA C 65.49 0.3 1 
29 17 THR H H 7.931 0.02 1 
30 17 THR N N 120.047 0.3 1 
31 18 PHE CA C 61.626 0.3 1 
32 18 PHE H H 7.935 0.02 1 
33 18 PHE N N 121.935 0.3 1 
34 19 THR CA C 65.599 0.3 1 
35 19 THR H H 9.156 0.02 1 
36 19 THR HA H 4.685 0.02 1 
37 19 THR N N 116.152 0.3 1 
38 20 SER CA C 59.857 0.3 1 
39 20 SER H H 8.051 0.02 1 
40 20 SER HA H 4.062 0.02 1 
41 20 SER N N 113.364 0.3 1 
42 21 ASN CA C 54.987 0.3 1 
43 21 ASN H H 7.226 0.02 1 
44 21 ASN HA H 4.171 0.02 1 
45 21 ASN N N 114.551 0.3 1 
46 23 ASN CA C 53.547 0.3 1 
47 23 ASN H H 5.882 0.02 1 
48 23 ASN HA H 4.529 0.02 1 
49 23 ASN N N 114.573 0.3 1 
50 24 ASN CA C 50.591 0.3 1 
51 24 ASN H H 6.833 0.02 1 
52 24 ASN HA H 4.433 0.02 1 
53 24 ASN N N 123.512 0.3 1 



























55 27 LEU H H 8.46 0.02 1 
56 27 LEU HA H 4.125 0.02 1 
57 27 LEU N N 118.772 0.3 1 
58 28 VAL CA C 61.519 0.3 1 
59 28 VAL H H 7.006 0.02 1 
60 28 VAL HA H 4.174 0.02 1 
61 28 VAL N N 120.103 0.3 1 
62 29 LEU CA C 54.25 0.3 1 
63 29 LEU H H 8.2 0.02 1 
64 29 LEU N N 127.47 0.3 1 
65 30 ARG CA C 52.676 0.3 1 
66 30 ARG H H 8.548 0.02 1 
67 30 ARG HA H 4.736 0.02 1 
68 30 ARG N N 126.729 0.3 1 
69 31 ARG CA C 58.763 0.3 1 
70 31 ARG H H 7.898 0.02 1 
71 31 ARG N N 123.848 0.3 1 
72 35 TYR CA C 56.67 0.3 1 
73 35 TYR H H 8.362 0.02 1 
74 35 TYR N N 126.124 0.3 1 
75 36 LEU CA C 53.22 0.3 1 
76 36 LEU H H 9.131 0.02 1 
77 36 LEU HA H 4.782 0.02 1 
78 36 LEU N N 126.345 0.3 1 
79 37 CYS CA C 56.179 0.3 1 
80 37 CYS H H 9.618 0.02 1 
81 37 CYS HA H 5.006 0.02 1 
82 37 CYS N N 126.063 0.3 1 
83 38 TYR CA C 53.481 0.3 1 
84 38 TYR H H 8.955 0.02 1 
85 38 TYR HA H 4.038 0.02 1 
86 38 TYR N N 121.133 0.3 1 
87 39 GLU CA C 53.926 0.3 1 
88 39 GLU H H 8.623 0.02 1 
89 39 GLU HA H 3.657 0.02 1 
90 39 GLU N N 113.776 0.3 1 
91 40 VAL CA C 60.811 0.3 1 
92 40 VAL H H 8.623 0.02 1 
93 40 VAL N N 120.972 0.3 1 
94 41 GLU CA C 52.837 0.3 1 
95 41 GLU H H 9.157 0.02 1 
96 41 GLU HA H 5.666 0.02 1 
97 41 GLU N N 124.882 0.3 1 
98 42 ARG CA C 54.171 0.3 1 
99 42 ARG H H 9.154 0.02 1 
100 42 ARG HA H 5.365 0.02 1 
101 42 ARG N N 124.609 0.3 1 
102 43 LEU CA C 51.88 0.3 1 
103 43 LEU H H 8.47 0.02 1 
104 43 LEU HA H 4.3 0.02 1 
105 43 LEU N N 124.654 0.3 1 
106 44 ASP CA C 53.555 0.3 1 
107 44 ASP H H 8.015 0.02 1 
108 44 ASP N N 127.028 0.3 1 
109 45 ASN CA C 54.839 0.3 1 



























111 45 ASN N N 121.739 0.3 1 
112 46 GLY CA C 44.449 0.3 1 
113 46 GLY H H 8.79 0.02 1 
114 46 GLY HA2 H 3.997 0.02 1 
115 46 GLY N N 111.175 0.3 1 
116 47 THR CA C 59.9 0.3 1 
117 47 THR H H 7.739 0.02 1 
118 47 THR HA H 4.524 0.02 1 
119 47 THR N N 116.314 0.3 1 
120 48 SER CA C 56.455 0.3 1 
121 48 SER H H 8.546 0.02 1 
122 48 SER N N 119.457 0.3 1 
123 49 VAL CA C 60.317 0.3 1 
124 49 VAL H H 9.02 0.02 1 
125 49 VAL HA H 5.218 0.02 1 
126 49 VAL N N 125.331 0.3 1 
127 50 LYS CA C 56.374 0.3 1 
128 50 LYS H H 8.766 0.02 1 
129 50 LYS HA H 4.285 0.02 1 
130 50 LYS N N 127.436 0.3 1 
131 51 MET CA C 53.734 0.3 1 
132 51 MET H H 8.526 0.02 1 
133 51 MET HA H 5.147 0.02 1 
134 51 MET N N 124.674 0.3 1 
135 52 ASP CA C 54.302 0.3 1 
136 52 ASP H H 8.381 0.02 1 
137 52 ASP HA H 3.886 0.02 1 
138 52 ASP N N 123.71 0.3 1 
139 53 GLN CA C 55.809 0.3 1 
140 53 GLN H H 9.134 0.02 1 
141 53 GLN N N 116.73 0.3 1 
142 54 HIS CA C 53.021 0.3 1 
143 54 HIS H H 7.899 0.02 1 
144 54 HIS N N 121.953 0.3 1 
145 55 MET CA C 53.385 0.3 1 
146 55 MET H H 7.384 0.02 1 
147 55 MET HA H 4.411 0.02 1 
148 55 MET N N 115.913 0.3 1 
149 56 GLY CA C 44.418 0.3 1 
150 56 GLY H H 7.319 0.02 1 
151 56 GLY HA2 H 3.688 0.02 1 
152 56 GLY N N 107.419 0.3 1 
153 57 PHE CA C 54.24 0.3 1 
154 57 PHE H H 8.223 0.02 1 
155 57 PHE HA H 4.126 0.02 1 
156 57 PHE N N 114.088 0.3 1 
157 58 LEU CA C 52.528 0.3 1 
158 58 LEU H H 9.438 0.02 1 
159 58 LEU HA H 5.159 0.02 1 
160 58 LEU N N 121.131 0.3 1 
161 59 CYS CA C 53.85 0.3 1 
162 59 CYS H H 7.71 0.02 1 
163 59 CYS HA H 4.159 0.02 1 
164 59 CYS N N 115.179 0.3 1 
165 60 ASN CA C 53.128 0.3 1 



























167 60 ASN HA H 3.776 0.02 1 
168 60 ASN N N 119.48 0.3 1 
169 66 ALA CA C 52.904 0.3 1 
170 66 ALA H H 8.253 0.02 1 
171 66 ALA N N 121.152 0.3 1 
172 67 GLU CA C 60.087 0.3 1 
173 67 GLU H H 12.31 0.02 1 
174 67 GLU HA H 2.977 0.02 1 
175 67 GLU N N 119.146 0.3 1 
176 68 LEU CA C 55.48 0.3 1 
177 68 LEU H H 6.873 0.02 1 
178 68 LEU HA H 3.585 0.02 1 
179 68 LEU N N 115.435 0.3 1 
180 69 ARG CA C 58.07 0.3 1 
181 69 ARG H H 7.589 0.02 1 
182 69 ARG N N 118.09 0.3 1 
183 70 PHE CA C 60.754 0.3 1 
184 70 PHE H H 8.284 0.02 1 
185 70 PHE HA H 3.561 0.02 1 
186 70 PHE N N 120.74 0.3 1 
187 71 LEU CA C 57.067 0.3 1 
188 71 LEU H H 7.565 0.02 1 
189 71 LEU HA H 3.558 0.02 1 
190 71 LEU N N 119.178 0.3 1 
191 72 ASP CA C 55.193 0.3 1 
192 72 ASP H H 8.119 0.02 1 
193 72 ASP HA H 4.043 0.02 1 
194 72 ASP N N 118.19 0.3 1 
195 73 LEU CA C 53.743 0.3 1 
196 73 LEU H H 7.213 0.02 1 
197 73 LEU HA H 4.217 0.02 1 
198 73 LEU N N 117.908 0.3 1 
199 74 VAL CA C 67.398 0.3 1 
200 74 VAL H H 7.117 0.02 1 
201 74 VAL HA H 3.223 0.02 1 
202 74 VAL N N 120.217 0.3 1 
203 75 PRO CA C 64.05 0.3 1 
204 75 PRO HA H 3.975 0.02 1 
205 76 SER CA C 59.417 0.3 1 
206 76 SER H H 7.79 0.02 1 
207 76 SER HA H 4.314 0.02 1 
208 76 SER N N 112.727 0.3 1 
209 77 LEU CA C 54.387 0.3 1 
210 77 LEU H H 7.871 0.02 1 
211 77 LEU HA H 3.874 0.02 1 
212 77 LEU N N 120.741 0.3 1 
213 78 GLN CA C 54.923 0.3 1 
214 78 GLN H H 7.407 0.02 1 
215 78 GLN HA H 3.808 0.02 1 
216 78 GLN N N 111.22 0.3 1 
217 79 LEU CA C 53.556 0.3 1 
218 79 LEU H H 8.667 0.02 1 
219 79 LEU HA H 3.719 0.02 1 
220 79 LEU N N 118.405 0.3 1 
221 80 ASP CA C 50.058 0.3 1 



























223 80 ASP HA H 4.883 0.02 1 
224 80 ASP N N 125.951 0.3 1 
225 82 ALA CA C 51.096 0.3 1 
226 82 ALA H H 8.43 0.02 1 
227 82 ALA HA H 4.418 0.02 1 
228 82 ALA N N 121.109 0.3 1 
229 83 GLN CA C 52.505 0.3 1 
230 83 GLN H H 8.091 0.02 1 
231 83 GLN HA H 3.77 0.02 1 
232 83 GLN N N 119.862 0.3 1 
233 84 ILE CA C 58.673 0.3 1 
234 84 ILE H H 8.019 0.02 1 
235 84 ILE HA H 4.273 0.02 1 
236 84 ILE N N 118.119 0.3 1 
237 85 TYR CA C 54.967 0.3 1 
238 85 TYR H H 8.803 0.02 1 
239 85 TYR HA H 5.361 0.02 1 
240 85 TYR N N 122.093 0.3 1 
241 86 ARG CA C 53.324 0.3 1 
242 86 ARG H H 9.327 0.02 1 
243 86 ARG HA H 5.243 0.02 1 
244 86 ARG N N 121.357 0.3 1 
245 87 VAL CA C 59.669 0.3 1 
246 87 VAL H H 9.594 0.02 1 
247 87 VAL HA H 4.924 0.02 1 
248 87 VAL N N 131.988 0.3 1 
249 88 THR CA C 60.903 0.3 1 
250 88 THR H H 9.037 0.02 1 
251 88 THR HA H 5.264 0.02 1 
252 88 THR N N 124.077 0.3 1 
253 89 TRP CA C 50.845 0.3 1 
254 89 TRP H H 8.782 0.02 1 
255 89 TRP HA H 3.934 0.02 1 
256 89 TRP N N 124.495 0.3 1 
257 90 PHE CA C 55.581 0.3 1 
258 90 PHE H H 9.55 0.02 1 
259 90 PHE N N 123.849 0.3 1 
260 91 ILE CA C 57.163 0.3 1 
261 91 ILE H H 9.617 0.02 1 
262 91 ILE HA H 4.099 0.02 1 
263 91 ILE N N 124.412 0.3 1 
264 92 SER CA C 56.938 0.3 1 
265 92 SER H H 9.027 0.02 1 
266 92 SER HA H 5.816 0.02 1 
267 92 SER N N 124.175 0.3 1 
268 93 TRP CA C 53.565 0.3 1 
269 93 TRP H H 6.608 0.02 1 
270 93 TRP N N 116.806 0.3 1 
271 94 SER CA C 57.036 0.3 1 
272 94 SER H H 8.4 0.02 1 
273 94 SER HA H 4.278 0.02 1 
274 94 SER N N 114.978 0.3 1 
275 97 PHE CA C 57.454 0.3 1 
276 97 PHE H H 9.208 0.02 1 
277 97 PHE N N 114.701 0.3 1 



























279 98 SER H H 10.833 0.02 1 
280 98 SER HA H 3.713 0.02 1 
281 98 SER N N 119.431 0.3 1 
282 99 TRP CA C 58.178 0.3 1 
283 99 TRP H H 7.904 0.02 1 
284 99 TRP HA H 3.776 0.02 1 
285 99 TRP N N 118.466 0.3 1 
286 100 GLY CA C 44.939 0.3 1 
287 100 GLY H H 7.377 0.02 1 
288 100 GLY HA2 H 3.693 0.02 1 
289 100 GLY N N 105.865 0.3 1 
290 101 CYS CA C 65.868 0.3 1 
291 101 CYS H H 7.344 0.02 1 
292 101 CYS HA H 3.859 0.02 1 
293 101 CYS N N 120.612 0.3 1 
294 102 ALA CA C 55.648 0.3 1 
295 102 ALA H H 8.719 0.02 1 
296 102 ALA HA H 3.865 0.02 1 
297 102 ALA N N 119.725 0.3 1 
298 103 GLY CA C 45.712 0.3 1 
299 103 GLY H H 8.514 0.02 1 
300 103 GLY HA2 H 3.744 0.02 1 
301 103 GLY N N 103.563 0.3 1 
302 104 GLU CA C 58.268 0.3 1 
303 104 GLU H H 7.899 0.02 1 
304 104 GLU HA H 4.266 0.02 1 
305 104 GLU N N 122.828 0.3 1 
306 105 VAL CA C 65.964 0.3 1 
307 105 VAL H H 8.894 0.02 1 
308 105 VAL HA H 3.699 0.02 1 
309 105 VAL N N 121.866 0.3 1 
310 106 ARG CA C 59.471 0.3 1 
311 106 ARG H H 8.567 0.02 1 
312 106 ARG HA H 3.786 0.02 1 
313 106 ARG N N 120.463 0.3 1 
314 107 ALA CA C 54.029 0.3 1 
315 107 ALA H H 7.764 0.02 1 
316 107 ALA HA H 4.134 0.02 1 
317 107 ALA N N 120.481 0.3 1 
318 108 PHE CA C 59.933 0.3 1 
319 108 PHE H H 8.093 0.02 1 
320 108 PHE HA H 4.337 0.02 1 
321 108 PHE N N 118.785 0.3 1 
322 109 LEU CA C 56.159 0.3 1 
323 109 LEU H H 8.595 0.02 1 
324 109 LEU HA H 3.8 0.02 1 
325 109 LEU N N 120.572 0.3 1 
326 110 GLN CA C 55.701 0.3 1 
327 110 GLN H H 8.082 0.02 1 
328 110 GLN HA H 4.023 0.02 1 
329 110 GLN N N 117.411 0.3 1 
330 111 GLU CA C 54.17 0.3 1 
331 111 GLU H H 7.336 0.02 1 
332 111 GLU HA H 4.322 0.02 1 
333 111 GLU N N 115.244 0.3 1 



























335 112 ASN H H 7.561 0.02 1 
336 112 ASN HA H 5.065 0.02 1 
337 112 ASN N N 119.718 0.3 1 
338 113 THR CA C 62.741 0.3 1 
339 113 THR H H 8.01 0.02 1 
340 113 THR HA H 4.317 0.02 1 
341 113 THR N N 111.086 0.3 1 
342 114 HIS CA C 55.367 0.3 1 
343 114 HIS H H 8.436 0.02 1 
344 114 HIS HA H 4.289 0.02 1 
345 114 HIS N N 121.13 0.3 1 
346 115 VAL CA C 60.602 0.3 1 
347 115 VAL H H 7.273 0.02 1 
348 115 VAL HA H 4.526 0.02 1 
349 115 VAL N N 119.869 0.3 1 
350 116 ARG CA C 52.095 0.3 1 
351 116 ARG H H 8.729 0.02 1 
352 116 ARG HA H 4.81 0.02 1 
353 116 ARG N N 125.494 0.3 1 
354 117 LEU CA C 52.214 0.3 1 
355 117 LEU H H 8.663 0.02 1 
356 117 LEU HA H 5.16 0.02 1 
357 117 LEU N N 120.076 0.3 1 
358 118 ARG CA C 53.466 0.3 1 
359 118 ARG H H 8.974 0.02 1 
360 118 ARG HA H 4.751 0.02 1 
361 118 ARG N N 126.936 0.3 1 
362 119 ILE CA C 59.937 0.3 1 
363 119 ILE H H 8.946 0.02 1 
364 119 ILE HA H 4.442 0.02 1 
365 119 ILE N N 123.491 0.3 1 
366 120 LYS CA C 53.021 0.3 1 
367 120 LYS H H 9.12 0.02 1 
368 120 LYS N N 128.843 0.3 1 
369 121 ALA CA C 47.982 0.3 1 
370 121 ALA H H 9.041 0.02 1 
371 121 ALA HA H 5.67 0.02 1 
372 121 ALA N N 124.831 0.3 1 
373 122 ALA CA C 54.491 0.3 1 
374 122 ALA H H 9.019 0.02 1 
375 122 ALA HA H 5.973 0.02 1 
376 122 ALA N N 125.972 0.3 1 
377 123 ARG CA C 53.499 0.3 1 
378 123 ARG H H 6.779 0.02 1 
379 123 ARG N N 108.045 0.3 1 
380 125 TYR CA C 55.356 0.3 1 
381 125 TYR H H 8.785 0.02 1 
382 125 TYR HA H 5.335 0.02 1 
383 125 TYR N N 130.143 0.3 1 
384 126 ASP CA C 53.234 0.3 1 
385 126 ASP H H 7.98 0.02 1 
386 126 ASP HA H 3.667 0.02 1 
387 126 ASP N N 123.662 0.3 1 
388 127 TYR CA C 58.15 0.3 1 
389 127 TYR H H 6.226 0.02 1 



























391 127 TYR N N 115.919 0.3 1 
392 128 ASP CA C 49.091 0.3 1 
393 128 ASP H H 6.897 0.02 1 
394 128 ASP N N 117.348 0.3 1 
395 129 PRO CA C 63.084 0.3 1 
396 129 PRO HA H 4.103 0.02 1 
397 130 LEU CA C 53.092 0.3 1 
398 130 LEU H H 8.395 0.02 1 
399 130 LEU HA H 4.698 0.02 1 
400 130 LEU N N 120.168 0.3 1 
401 131 TYR CA C 59.984 0.3 1 
402 131 TYR H H 7.956 0.02 1 
403 131 TYR HA H 4.061 0.02 1 
404 131 TYR N N 117.484 0.3 1 
405 132 LYS CA C 59.01 0.3 1 
406 132 LYS H H 7.461 0.02 1 
407 132 LYS N N 121.876 0.3 1 
408 133 GLU CA C 59.291 0.3 1 
409 133 GLU H H 8.716 0.02 1 
410 133 GLU N N 121.833 0.3 1 
411 134 ALA CA C 54.173 0.3 1 
412 134 ALA H H 7.723 0.02 1 
413 134 ALA HA H 3.846 0.02 1 
414 134 ALA N N 119.672 0.3 1 
415 135 LEU CA C 57.172 0.3 1 
416 135 LEU H H 7.211 0.02 1 
417 135 LEU N N 116.268 0.3 1 
418 136 GLN CA C 58.139 0.3 1 
419 136 GLN H H 8.349 0.02 1 
420 136 GLN HA H 3.719 0.02 1 
421 136 GLN N N 117.393 0.3 1 
422 137 MET CA C 58.155 0.3 1 
423 137 MET H H 8.187 0.02 1 
424 137 MET HA H 3.917 0.02 1 
425 137 MET N N 118.442 0.3 1 
426 138 LEU CA C 56.955 0.3 1 
427 138 LEU H H 7.928 0.02 1 
428 138 LEU HA H 4.335 0.02 1 
429 138 LEU N N 118.846 0.3 1 
430 139 ARG CA C 57.716 0.3 1 
431 139 ARG H H 8.004 0.02 1 
432 139 ARG HA H 4.426 0.02 1 
433 139 ARG N N 121.137 0.3 1 
434 140 ASP CA C 56.076 0.3 1 
435 140 ASP H H 8.816 0.02 1 
436 140 ASP HA H 4.429 0.02 1 
437 140 ASP N N 122.344 0.3 1 
438 141 ALA CA C 50.807 0.3 1 
439 141 ALA H H 7.708 0.02 1 
440 141 ALA HA H 4.418 0.02 1 
441 141 ALA N N 119.974 0.3 1 
442 142 GLY CA C 43.433 0.3 1 
443 142 GLY H H 7.926 0.02 1 
444 142 GLY HA2 H 3.722 0.02 1 
445 142 GLY N N 104.888 0.3 1 



























447 143 ALA H H 8.031 0.02 1 
448 143 ALA HA H 4.689 0.02 1 
449 143 ALA N N 124.036 0.3 1 
450 144 GLN CA C 53.671 0.3 1 
451 144 GLN H H 8.1 0.02 1 
452 144 GLN HA H 4.439 0.02 1 
453 144 GLN N N 121.862 0.3 1 
454 145 VAL CA C 59.951 0.3 1 
455 145 VAL H H 9.01 0.02 1 
456 145 VAL HA H 4.752 0.02 1 
457 145 VAL N N 129.096 0.3 1 
458 146 SER CA C 56.265 0.3 1 
459 146 SER H H 9.235 0.02 1 
460 146 SER HA H 5.179 0.02 1 
461 146 SER N N 120.374 0.3 1 
462 149 THR CA C 58.56 0.3 1 
463 149 THR H H 8.473 0.02 1 
464 149 THR N N 117.515 0.3 1 
465 150 TYR CA C 62.747 0.3 1 
466 150 TYR H H 9.687 0.02 1 
467 150 TYR N N 121.557 0.3 1 
468 151 ASP CA C 56.036 0.3 1 
469 151 ASP H H 8.654 0.02 1 
470 151 ASP HA H 5.435 0.02 1 
471 151 ASP N N 115.195 0.3 1 
472 155 TYR CA C 60.273 0.3 1 
473 155 TYR H H 8.013 0.02 1 
474 155 TYR N N 121.106 0.3 1 
475 156 CYS CA C 63.256 0.3 1 
476 156 CYS H H 7.973 0.02 1 
477 156 CYS HA H 3.789 0.02 1 
478 156 CYS N N 118.677 0.3 1 
479 157 TRP CA C 58.296 0.3 1 
480 157 TRP H H 7.911 0.02 1 
481 157 TRP HA H 3.764 0.02 1 
482 157 TRP N N 122.741 0.3 1 
483 158 ASP CA C 54.888 0.3 1 
484 158 ASP H H 8.038 0.02 1 
485 158 ASP HA H 5.995 0.02 1 
486 158 ASP N N 113.827 0.3 1 
487 159 THR CA C 64.329 0.3 1 
488 159 THR H H 7.443 0.02 1 
489 159 THR HA H 5.439 0.02 1 
490 159 THR N N 115.142 0.3 1 
491 160 PHE CA C 57.29 0.3 1 
492 160 PHE H H 8.215 0.02 1 
493 160 PHE HA H 4.475 0.02 1 
494 160 PHE N N 114.292 0.3 1 
495 161 VAL CA C 59.495 0.3 1 
496 161 VAL H H 6.519 0.02 1 
497 161 VAL HA H 4.025 0.02 1 
498 161 VAL N N 117.838 0.3 1 
499 162 TYR CA C 54.861 0.3 1 
500 162 TYR H H 8.769 0.02 1 
501 162 TYR HA H 4.753 0.02 1 



























503 163 ARG CA C 56.904 0.3 1 
504 163 ARG H H 8.428 0.02 1 
505 163 ARG HA H 4.1 0.02 1 
506 163 ARG N N 127.444 0.3 1 
507 165 GLY CA C 44.824 0.3 1 
508 165 GLY H H 11.556 0.02 1 
509 165 GLY HA2 H 3.702 0.02 1 
510 165 GLY N N 111.911 0.3 1 
511 166 CYS CA C 54.18 0.3 1 
512 166 CYS H H 7.916 0.02 1 
513 166 CYS HA H 4.716 0.02 1 
514 166 CYS N N 123.647 0.3 1 
515 168 PHE CA C 56.234 0.3 1 
516 168 PHE H H 9.134 0.02 1 
517 168 PHE HA H 6.488 0.02 1 
518 168 PHE N N 121.572 0.3 1 
519 169 GLN CA C 49.506 0.3 1 
520 169 GLN H H 7.184 0.02 1 
521 169 GLN HA H 4.317 0.02 1 
522 169 GLN N N 128.787 0.3 1 
523 171 TRP CA C 53.634 0.3 1 
524 171 TRP H H 5.542 0.02 1 
525 171 TRP HA H 4.633 0.02 1 
526 171 TRP N N 117.476 0.3 1 
527 172 ASP CA C 52.154 0.3 1 
528 172 ASP H H 9.245 0.02 1 
529 172 ASP HA H 5.079 0.02 1 
530 172 ASP N N 125.428 0.3 1 
531 174 LEU CA C 59.641 0.3 1 
532 174 LEU H H 6.878 0.02 1 
533 174 LEU HA H 4.346 0.02 1 
534 174 LEU N N 119.89 0.3 1 
535 175 GLU CA C 59.19 0.3 1 
536 175 GLU H H 9.377 0.02 1 
537 175 GLU HA H 3.723 0.02 1 
538 175 GLU N N 119.587 0.3 1 
539 176 GLU CA C 59.094 0.3 1 
540 176 GLU H H 8.28 0.02 1 
541 176 GLU HA H 5.195 0.02 1 
542 176 GLU N N 122.831 0.3 1 
543 177 HIS CA C 57.678 0.3 1 
544 177 HIS H H 8.812 0.02 1 
545 177 HIS HA H 4.212 0.02 1 
546 177 HIS N N 120.669 0.3 1 
547 178 SER CA C 61.272 0.3 1 
548 178 SER H H 8.476 0.02 1 
549 178 SER N N 115.134 0.3 1 
550 179 GLN CA C 58.067 0.3 1 
551 179 GLN H H 8.53 0.02 1 
552 179 GLN N N 121.487 0.3 1 
553 180 ALA CA C 54.124 0.3 1 
554 180 ALA H H 8.293 0.02 1 
555 180 ALA HA H 4.284 0.02 1 
556 180 ALA N N 124.243 0.3 1 
557 182 SER CA C 61.46 0.3 1 



























559 182 SER HA H 4.039 0.02 1 
560 182 SER N N 116.856 0.3 1 
561 183 GLY CA C 46.182 0.3 1 
562 183 GLY H H 8.18 0.02 1 
563 183 GLY HA2 H 4.147 0.02 1 
564 183 GLY N N 109.656 0.3 1 
565 184 ARG CA C 58.273 0.3 1 
566 184 ARG H H 7.738 0.02 1 
567 184 ARG HA H 4.237 0.02 1 
568 184 ARG N N 122.994 0.3 1 
569 185 LEU CA C 56.989 0.3 1 
570 185 LEU H H 8.736 0.02 1 
571 185 LEU HA H 4.238 0.02 1 
572 185 LEU N N 119.765 0.3 1 
573 186 ARG CA C 58.676 0.3 1 
574 186 ARG H H 8.331 0.02 1 
575 186 ARG HA H 4.135 0.02 1 
576 186 ARG N N 118.311 0.3 1 
577 187 ALA CA C 53.493 0.3 1 
578 187 ALA H H 7.355 0.02 1 
579 187 ALA HA H 4.29 0.02 1 
580 187 ALA N N 119.351 0.3 1 
581 188 ILE CA C 63.627 0.3 1 
582 188 ILE H H 7.87 0.02 1 
583 188 ILE HA H 4.421 0.02 1 
584 188 ILE N N 119.106 0.3 1 
585 189 LEU CA C 54.295 0.3 1 
586 189 LEU H H 8.164 0.02 1 
587 189 LEU HA H 4.108 0.02 1 













Table 8.3 Kinetic parameters of A3 variants analysed using linear and non-linear regression methods 
(I acknowledge Prof. Geoffrey B. Jameson for conducting non-linear regression analysis) 
Enzyme Oligonucleotide Parameters Linear analysis  Non-linear 
A3BCTD-AL1 TCA-oligo Km (μM) 197 ± 30  146  ± 34 
  
Vmax (μM/s) 0.014 ± 0.002 0.013 ± 0.001 
A3BCTD-DM TCA-oligo Km (μM) 317 ± 55  438 ± 105 
  
Vmax (μM/s) 0.017 ± 0.003 0.021 ± 0.003 
A3A-mimic CCC-oligo Km (μM) 440 ± 80 629 ± 211 
(A3BCTD-AL1) 
 
Vmax (μM/s) 0.019 ± 0.003 0.025 ± 0.005 
A3BCTD-DM CCC-oligo Km (μM) 590 ± 90 646 ± 120 
  
Vmax (μM/s) 0.017 ± 0.003 0.019 ± 0.002 
A3A-mimic dZCC-oligo Km (μM) 520 ± 90 784 ± 210 
(A3BCTD-AL1) 
 
Vmax (μM/s) 0.022 ± 0.005 0.030 ± 0.005 
A3BCTD-DM CCdZ-oligo Km (μM) 1370 ± 270 1072 ± 296 
  
Vmax (μM/s) 0.020 ± 0.004 0.018 ± 0.002 
A3GCTD-Wt dZCC-oligo Km (μM) 15805 ± 1305 1174 ± 415 
  
Vmax (μM/s) 0.088 ± 0.087 0.082 ± 0.014 
 
Table 8.4 Inhibition constants and parameters of A3 variants analysed using linear and non-linear 
regression methods (I acknowledge Prof. Geoffrey B. Jameson for conducting non-linear regression 
analysis) 
Enzyme Oligonucleotide Parameters Linear analysis  Non-linear 
A3BCTD-AL1 dZ-oligo Ki (μM) 7.5 ± 1.7  8.0 ± 1.5  
  
Vmax (μM/s) 0.0095 ± 0.0009 0.0143 ± 0.0010 
A3BCTD-DM dZ-oligo Ki (μM) 11.4 ± 2.6 8.6 ± 1.2  
  
Vmax (μM/s) 0.0063 ± 0.0004  0.0133 ± 0.0005  
A3BCTD-AL1 5FdZ-oligo Ki (μM) 2.1 ± 0.8 4.6 ± 1.1 
  
Vmax (μM/s) 0.016 ± 0.007 0.015 ± 0.0016 
A3A-mimic CCdZ-oligo Ki (μM) 12.3 ± 1.8 11.7 ± 2.9  
(A3BCTD-AL1) 
 
Vmax (μM/s) 0.0057 ± 0.0034  0.0088 ± 0.0006  
A3BCTD-DM dZCC-oligo Ki (μM) 18.5 ± 5.5 22.2 ± 2.3  
  




Table 8.5 1H-NMR signal location of H-5 doublets of dC and dU in ssDNAs and their J-coupling 
Oligonucleotide 1H Signal Chemical shifts (ppm) J-coupling (Hz) 
A9C-oligo H-5 dC 5.84 7.50 
A9U-oligo H-5 dU 5.665 7.65 
A9C-oligo H-4 dT 7.41 7.72 
9merC--oligo  H-5 dC 5.90 7.55 
9merU-oligo H-5 dU 5.72 7.63 
CCU-oligo H-5 dU 5.673 8.49 
CUC-oligo H-5 dU 5.748 8.43 
UCC-oligo H-5 dU 5.775 8.5 
 
Table 8.6 Interface residue contacts of A3BCTD-QM-ΔL3 (5CQI, PDB) interface A (ΔG = -12.65 
kcal/mol) (PRISM 9) 
Number A3BCTD_A Residue contact A3BCTD _B 
1 pdb1_A_TYR_350 →  pdb2_B_ASP_194 
2 pdb1_A_TYR_215 → pdb2_B_TYR_191 
3 pdb1_A_SER_264 →  pdb2_B_SER_264 
4 pdb1_A_SER_264 → pdb2_B_VAL_262 
5 pdb1_A_PRO_263 → pdb2_B_PRO_263 
6 pdb1_A_SER_264 →  pdb2_B_ASP_260 
7 pdb1_A_SER_264 → pdb2_B_LEU_261 
8 pdb1_A_GLN_233 → pdb2_B_GLU_241 
9 pdb1_A_ASP_232 →  pdb2_B_GLU_241 
10 pdb1_A_LEU_261 → pdb2_B_SER_264 
11 pdb1_A_TYR_191 → pdb2_B_PHE_348 
12 pdb1_A_ASP_260 →  pdb2_B_GLN_266 
13 pdb1_A_GLN_266 → pdb2_B_ASP_260 
14 pdb1_A_MET_193 →  pdb2_B_TYR_191 
15 pdb1_A_SER_264 → pdb2_B_PRO_263 
16 pdb1_A_ASP_194 →  pdb2_B_TYR_350 
17 pdb1_A_GLN_233 → pdb2_B_ARG_257 
18 pdb1_A_LEU_192 → pdb2_B_TYR_191 
19 pdb1_A_TYR_191 →  pdb2_B_TYR_191 
20 pdb1_A_TYR_191 → pdb2_B_MET_193 
21 pdb1_A_TYR_191 → pdb2_B_LEU_192 






Table 8.7 Interface residue contacts of A3BCTD-QM-ΔL3 (5CQI, PDB) interface B (ΔG = -2.94 
kcal/mol) (PRISM 9) 
Number A3BCTD_A Residue contact A3BCTD _B 
1 pdb1_A_GLY_251 →  pdb2_B_TYR_191 
2 pdb1_A_GLN_213 → pdb2_B_ASP_194 
3 pdb1_A_HIS_253 →  pdb2_B_TYR_350 
4 pdb1_A_ARG_212 → pdb2_B_PRO_195 
5 pdb1_A_ARG_212 → pdb2_B_ASP_194 
6 pdb1_A_ARG_212 →  pdb2_B_THR_197 
7 pdb1_A_ARG_212 → pdb2_B_ASP_196 
8 pdb1_A_SER_250 → pdb2_B_MET_193 
9 pdb1_A_GLY_251 →  pdb2_B_LEU_192 
10 pdb1_A_GLU_241 → pdb2_B_PHE_237 
11 pdb1_A_TYR_191 → pdb2_B_SER_250 
12 pdb1_A_SER_250 →  pdb2_B_PHE_237 
13 pdb1_A_GLY_251 → pdb2_B_TYR_350 
14 pdb1_A_TRP_287 →  pdb2_B_TYR_350 
15 pdb1_A_TRP_287 → pdb2_B_GLN_352 
 
Table 8.8 Interface residue contacts of A3BCTD-AL1 interface model 1 (ΔG = -38.13 kcal/mol) (PRISM 
9)   
Number A3BCTD-AL1_A Residue contact A3BCTD-AL1_B 
1 pdb1_A_ASP_260 →  pdb2_B_TYR_350 
2 pdb1_A_CYS_239 → pdb2_B_CYS_239 
3 pdb1_A_LYS_213 → pdb2_B_LYS_213 
4 pdb1_A_TYR_191 →  pdb2_B_ARG_257 
5 pdb1_A_GLU_241 → pdb2_B_TYR_215 
6 pdb1_A_ASP_196 → pdb2_B_SER_250 
7 pdb1_A_ARG_257 →  pdb2_B_THR_197 
8 pdb1_A_THR_197 → pdb2_B_GLU_241 
9 pdb1_A_ASP_260 → pdb2_B_ASP_194 
10 pdb1_A_ARG_257 →  pdb2_B_MET_193 
11 pdb1_A_TYR_215 → pdb2_B_SER_250 
12 pdb1_A_MET_193 → pdb2_B_ARG_257 
13 pdb1_A_TYR_191 →  pdb2_B_LEU_261 
14 pdb1_A_PHE_237 → pdb2_B_GLU_241 
15 pdb1_A_MET_235 → pdb2_B_TYR_191 
16 pdb1_A_TYR_218 →  pdb2_B_TYR_191 
17 pdb1_A_LEU_261 → pdb2_B_TYR_191 
18 pdb1_A_LEU_265 → pdb2_B_TYR_191 
19 pdb1_A_ARG_257 →  pdb2_B_PHE_237 
20 pdb1_A_TYR_215 → pdb2_B_GLU_241 
21 pdb1_A_MET_193 → pdb2_B_GLU_241 
22 pdb1_A_THR_197 →  pdb2_B_SER_250 
23 pdb1_A_GLU_241 → pdb2_B_THR_197 




Number A3BCTD-AL1_A Residue contact A3BCTD-AL1_B 
25 pdb1_A_ASP_194 →  pdb2_B_ARG_257 
26 pdb1_A_SER_250 → pdb2_B_LYS_213 
27 pdb1_A_ASP_194 → pdb2_B_ARG_252 
28 pdb1_A_ARG_257 →  pdb2_B_ASP_194 
29 pdb1_A_SER_264 → pdb2_B_ARG_190 
30 pdb1_A_SER_264 → pdb2_B_TYR_191 
31 pdb1_A_SER_264 →  pdb2_B_LEU_192 
32 pdb1_A_TYR_191 → pdb2_B_LEU_238 
33 pdb1_A_PRO_263 → pdb2_B_TYR_350 
34 pdb1_A_ASN_201 →  pdb2_B_SER_250 
35 pdb1_A_ARG_252 → pdb2_B_ASP_196 
36 pdb1_A_HIS_234 → pdb2_B_TYR_191 
 
Table 8.9 Interface residue contacts of A3BCTD-AL1 interface model 2 (ΔG = -18.6 kcal/mol) (PRISM 
9) 
Number A3BCTD-AL1_A Residue contact A3BCTD-AL1_B 
1 pdb1_A_GLY_291 →  pdb2_B_GLY_288 
2 pdb1_A_GLU_299 → pdb2_B_ARG_252 
3 pdb1_A_GLU_299 → pdb2_B_GLY_251 
4 pdb1_A_GLU_299 →  pdb2_B_SER_250 
5 pdb1_A_GLY_291 → pdb2_B_SER_286 
6 pdb1_A_GLY_291 → pdb2_B_TRP_287 
7 pdb1_A_TRP_287 →  pdb2_B_ALA_295 
8 pdb1_A_ALA_295 → pdb2_B_TRP_287 
9 pdb1_A_MET_325 → pdb2_B_SER_286 
10 pdb1_A_ASP_260 →  pdb2_B_ARG_252 
11 pdb1_A_GLU_292 → pdb2_B_LEU_256 
12 pdb1_A_GLU_292 → pdb2_B_ARG_252 
13 pdb1_A_PHE_296 →  pdb2_B_SER_250 
14 pdb1_A_PHE_296 → pdb2_B_GLY_251 
15 pdb1_A_ALA_295 → pdb2_B_HIS_253 
16 pdb1_A_SER_250 →  pdb2_B_GLU_299 
17 pdb1_A_PRO_263 → pdb2_B_SER_250 
18 pdb1_A_PHE_285 → pdb2_B_PHE_285 
19 pdb1_A_GLU_299 →  pdb2_B_GLU_241 
20 pdb1_A_GLU_299 → pdb2_B_ASN_240 
21 pdb1_A_ASN_300 → pdb2_B_SER_250 
22 pdb1_A_ASN_300 → pdb2_B_GLY_251 
23 pdb1_A_GLU_292 →  pdb2_B_TRP_287 
24 pdb1_A_ASP_260 → pdb2_B_ASP_260 
25 pdb1_A_LEU_256 → pdb2_B_GLU_292 
26 pdb1_A_LEU_259 →  pdb2_B_ARG_252 





Table 8.10 Model 1 dimer interface assessment using PISA 132 (ΔG = -2.00 kcal/mol, interface area = 
1034.4 Å2) 
Number A3BCTD-AL1_A Residue contact A3BCTD-AL1_B 
1 ARG 257  H-bond →  THR 197 
2 THR 197  H-bond → GLU 241 
3 SER 264  H-bond →  ARG 190 
4 GLU 241  H-bond → CYS 239 
5 ASP 194  H-bond →  ARG 252 
6 ASP 196  H-bond → ARG 252 
7 LEU 192  H-bond →  ARG 257 
8 ARG 252  Salt-bridge → ASP 196 
9 ASP 194  Salt-bridge → ARG 252 
10 ASP 196  Salt-bridge → ARG 252 
 
Table 8.11 Model 2 dimer interface assessment PISA 132 (ΔG = -4.00 kcal/mol, interface area = 725.8 
Å2)  
Number A3BCTD-AL1_A Residue contact A3BCTD-AL1_B 
1 GLU 292  H-bond →  ARG 252 
2 GLU 299  H-bond → SER 250 
3 ASP 260  Salt-bridge → ARG 252 
4 GLU 292  Salt-bridge →  ARG 252 
 
Table 8.12 SAXS ab intio modelling parameters of the A3Gfl_Wt along with CCdZ-40mer oligo  
Modelling parameters A3G_species 2 A3G_species 3 A3G_species 4 
Ab intio restoration      
DAMMIF (default parameters, 10 
calculations)  
   
q range (Å-1) for fitting 0.0139 - 0.3052 0.0183 - 0.3052 0.0183 - 0.3052 
Symmetry  P4 P2 P1 
NSD (standard deviation) 0.578 (0.066) 0.937 (0.126) 0.559 (0.049) 





Table 8.13 SAXS fitting and modelling parameters of the A3Gfl_Wt along with CCdZ-40mer oligo 
to reported A3G dimer crystal structures 
Modelling parameters A3G_species 3 A3G_species 4 
Structure modelling      
PDB, 6p40   
     FoXS, Chi2 0.50 4.93 
     CRYSOL, Chi2 0.34 2.39 
PDB, 6p3x   
     FoXS, Chi2 1.22 5.87 
     CRYSOL, Chi2 0.71 2.86 
PDB, 6p3y   
     FoXS, Chi2 1.27 5.95 
     CRYSOL, Chi2 0.72 2.89 
PDB, 6p3z   
     FoXS, Chi2 1.28 5.95 
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